CN111492243A - 用于新颖抗原结合模块的特异性测试的car-t细胞测定法 - Google Patents
用于新颖抗原结合模块的特异性测试的car-t细胞测定法 Download PDFInfo
- Publication number
- CN111492243A CN111492243A CN201880081668.XA CN201880081668A CN111492243A CN 111492243 A CN111492243 A CN 111492243A CN 201880081668 A CN201880081668 A CN 201880081668A CN 111492243 A CN111492243 A CN 111492243A
- Authority
- CN
- China
- Prior art keywords
- ser
- gly
- leu
- val
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000027455 binding Effects 0.000 title claims abstract description 336
- 239000000427 antigen Substances 0.000 title claims abstract description 331
- 108091007433 antigens Proteins 0.000 title claims abstract description 329
- 102000036639 antigens Human genes 0.000 title claims abstract description 329
- 238000003556 assay Methods 0.000 title abstract description 55
- 238000012360 testing method Methods 0.000 title abstract description 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 157
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 29
- 210000004027 cell Anatomy 0.000 claims description 316
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 151
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 102
- 230000011664 signaling Effects 0.000 claims description 98
- 238000000034 method Methods 0.000 claims description 95
- 230000014509 gene expression Effects 0.000 claims description 87
- 108700008625 Reporter Genes Proteins 0.000 claims description 80
- 230000004913 activation Effects 0.000 claims description 49
- 238000004873 anchoring Methods 0.000 claims description 44
- 108091027981 Response element Proteins 0.000 claims description 42
- 102000005962 receptors Human genes 0.000 claims description 42
- 108020003175 receptors Proteins 0.000 claims description 42
- 239000013598 vector Substances 0.000 claims description 37
- 241000282414 Homo sapiens Species 0.000 claims description 33
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 28
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 28
- 102000040430 polynucleotide Human genes 0.000 claims description 24
- 108091033319 polynucleotide Proteins 0.000 claims description 24
- 239000002157 polynucleotide Substances 0.000 claims description 24
- 230000004068 intracellular signaling Effects 0.000 claims description 16
- 230000006044 T cell activation Effects 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 11
- 230000003213 activating effect Effects 0.000 claims description 10
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 8
- 102000034287 fluorescent proteins Human genes 0.000 claims description 8
- 108091006047 fluorescent proteins Proteins 0.000 claims description 8
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 7
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 6
- 238000002823 phage display Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 102000006830 Luminescent Proteins Human genes 0.000 claims description 4
- 108010047357 Luminescent Proteins Proteins 0.000 claims description 4
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 1
- 238000004113 cell culture Methods 0.000 abstract description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 82
- 229920001184 polypeptide Polymers 0.000 description 74
- 125000003275 alpha amino acid group Chemical group 0.000 description 52
- 108090000623 proteins and genes Proteins 0.000 description 51
- 108020004414 DNA Proteins 0.000 description 48
- 230000004936 stimulating effect Effects 0.000 description 39
- 150000007523 nucleic acids Chemical class 0.000 description 38
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 34
- 108010017391 lysylvaline Proteins 0.000 description 33
- 102000039446 nucleic acids Human genes 0.000 description 33
- 108020004707 nucleic acids Proteins 0.000 description 33
- 108091028043 Nucleic acid sequence Proteins 0.000 description 32
- 150000001413 amino acids Chemical class 0.000 description 32
- 239000012634 fragment Substances 0.000 description 31
- 102000004169 proteins and genes Human genes 0.000 description 31
- 108010078144 glutaminyl-glycine Proteins 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- 230000037361 pathway Effects 0.000 description 24
- 108010037850 glycylvaline Proteins 0.000 description 23
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 22
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 22
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 22
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 21
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 21
- 239000013604 expression vector Substances 0.000 description 21
- 230000004927 fusion Effects 0.000 description 21
- 210000004881 tumor cell Anatomy 0.000 description 21
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 20
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 20
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 239000002953 phosphate buffered saline Substances 0.000 description 20
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 19
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 19
- 230000000139 costimulatory effect Effects 0.000 description 19
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 18
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 17
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 17
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 17
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 16
- 241000880493 Leptailurus serval Species 0.000 description 16
- FPCGZYMRFFIYIH-CIUDSAMLSA-N Ser-Lys-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O FPCGZYMRFFIYIH-CIUDSAMLSA-N 0.000 description 16
- 108010050848 glycylleucine Proteins 0.000 description 16
- 108010018006 histidylserine Proteins 0.000 description 16
- 108010073969 valyllysine Proteins 0.000 description 16
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 15
- KYIIALJHAOIAHF-KKUMJFAQSA-N Leu-Leu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 KYIIALJHAOIAHF-KKUMJFAQSA-N 0.000 description 15
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 15
- HBOABDXGTMMDSE-GUBZILKMSA-N Ser-Arg-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O HBOABDXGTMMDSE-GUBZILKMSA-N 0.000 description 15
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 15
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 15
- 108010092854 aspartyllysine Proteins 0.000 description 15
- 238000011534 incubation Methods 0.000 description 15
- 238000004020 luminiscence type Methods 0.000 description 15
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 14
- MIFFFXHMAHFACR-KATARQTJSA-N Lys-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN MIFFFXHMAHFACR-KATARQTJSA-N 0.000 description 14
- QLFAPXUXEBAWEK-NHCYSSNCSA-N Lys-Val-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O QLFAPXUXEBAWEK-NHCYSSNCSA-N 0.000 description 14
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 14
- SGAOHNPSEPVAFP-ZDLURKLDSA-N Thr-Ser-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SGAOHNPSEPVAFP-ZDLURKLDSA-N 0.000 description 14
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 14
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 14
- 108010089804 glycyl-threonine Proteins 0.000 description 14
- 108010057821 leucylproline Proteins 0.000 description 14
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 13
- ZFBBMCKQSNJZSN-AUTRQRHGSA-N Gln-Val-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZFBBMCKQSNJZSN-AUTRQRHGSA-N 0.000 description 13
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 13
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 13
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 13
- 108091023040 Transcription factor Proteins 0.000 description 13
- 108010008355 arginyl-glutamine Proteins 0.000 description 13
- 108010047857 aspartylglycine Proteins 0.000 description 13
- ISJWBVIYRBAXEB-CIUDSAMLSA-N Arg-Ser-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O ISJWBVIYRBAXEB-CIUDSAMLSA-N 0.000 description 12
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 12
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 12
- NNCSJUBVFBDDLC-YUMQZZPRSA-N Gly-Leu-Ser Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O NNCSJUBVFBDDLC-YUMQZZPRSA-N 0.000 description 12
- 108010065920 Insulin Lispro Proteins 0.000 description 12
- MVJRBCJCRYGCKV-GVXVVHGQSA-N Leu-Val-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O MVJRBCJCRYGCKV-GVXVVHGQSA-N 0.000 description 12
- UWKNTTJNVSYXPC-CIUDSAMLSA-N Lys-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN UWKNTTJNVSYXPC-CIUDSAMLSA-N 0.000 description 12
- SJDQOYTYNGZZJX-SRVKXCTJSA-N Met-Glu-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O SJDQOYTYNGZZJX-SRVKXCTJSA-N 0.000 description 12
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 12
- JMVQDLDPDBXAAX-YUMQZZPRSA-N Pro-Gly-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 JMVQDLDPDBXAAX-YUMQZZPRSA-N 0.000 description 12
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 12
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 12
- HNDMFDBQXYZSRM-IHRRRGAJSA-N Ser-Val-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HNDMFDBQXYZSRM-IHRRRGAJSA-N 0.000 description 12
- NJEMRSFGDNECGF-GCJQMDKQSA-N Thr-Ala-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O NJEMRSFGDNECGF-GCJQMDKQSA-N 0.000 description 12
- JQTYTBPCSOAZHI-FXQIFTODSA-N Val-Ser-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N JQTYTBPCSOAZHI-FXQIFTODSA-N 0.000 description 12
- WUFHZIRMAZZWRS-OSUNSFLBSA-N Val-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N WUFHZIRMAZZWRS-OSUNSFLBSA-N 0.000 description 12
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 12
- 108010051242 phenylalanylserine Proteins 0.000 description 12
- 108010033670 threonyl-aspartyl-tyrosine Proteins 0.000 description 12
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 description 11
- KUDREHRZRIVKHS-UWJYBYFXSA-N Ala-Asp-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KUDREHRZRIVKHS-UWJYBYFXSA-N 0.000 description 11
- MDNAVFBZPROEHO-UHFFFAOYSA-N Ala-Lys-Val Natural products CC(C)C(C(O)=O)NC(=O)C(NC(=O)C(C)N)CCCCN MDNAVFBZPROEHO-UHFFFAOYSA-N 0.000 description 11
- XYOVHPDDWCEUDY-CIUDSAMLSA-N Asn-Ala-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O XYOVHPDDWCEUDY-CIUDSAMLSA-N 0.000 description 11
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 11
- IULKWYSYZSURJK-AVGNSLFASA-N Gln-Leu-Lys Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O IULKWYSYZSURJK-AVGNSLFASA-N 0.000 description 11
- CLROYXHHUZELFX-FXQIFTODSA-N Glu-Gln-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O CLROYXHHUZELFX-FXQIFTODSA-N 0.000 description 11
- XHVONGZZVUUORG-WEDXCCLWSA-N Gly-Thr-Lys Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN XHVONGZZVUUORG-WEDXCCLWSA-N 0.000 description 11
- QQFSKBMCAKWHLG-UHFFFAOYSA-N Ile-Phe-Pro-Pro Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(NC(=O)C(N)C(C)CC)CC1=CC=CC=C1 QQFSKBMCAKWHLG-UHFFFAOYSA-N 0.000 description 11
- DBVWMYGBVFCRBE-CIUDSAMLSA-N Leu-Asn-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O DBVWMYGBVFCRBE-CIUDSAMLSA-N 0.000 description 11
- AMSSKPUHBUQBOQ-SRVKXCTJSA-N Leu-Ser-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N AMSSKPUHBUQBOQ-SRVKXCTJSA-N 0.000 description 11
- 108060001084 Luciferase Proteins 0.000 description 11
- 239000005089 Luciferase Substances 0.000 description 11
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 11
- YDTUEBLEAVANFH-RCWTZXSCSA-N Pro-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 YDTUEBLEAVANFH-RCWTZXSCSA-N 0.000 description 11
- FTVRVZNYIYWJGB-ACZMJKKPSA-N Ser-Asp-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O FTVRVZNYIYWJGB-ACZMJKKPSA-N 0.000 description 11
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 11
- XXXAXOWMBOKTRN-XPUUQOCRSA-N Ser-Gly-Val Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXXAXOWMBOKTRN-XPUUQOCRSA-N 0.000 description 11
- PPNPDKGQRFSCAC-CIUDSAMLSA-N Ser-Lys-Asp Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPNPDKGQRFSCAC-CIUDSAMLSA-N 0.000 description 11
- CYVQBKQYQGEELV-NKIYYHGXSA-N Thr-His-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O CYVQBKQYQGEELV-NKIYYHGXSA-N 0.000 description 11
- 102000040945 Transcription factor Human genes 0.000 description 11
- LHADRQBREKTRLR-DCAQKATOSA-N Val-Cys-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)N LHADRQBREKTRLR-DCAQKATOSA-N 0.000 description 11
- VCAWFLIWYNMHQP-UKJIMTQDSA-N Val-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N VCAWFLIWYNMHQP-UKJIMTQDSA-N 0.000 description 11
- 210000004899 c-terminal region Anatomy 0.000 description 11
- 108010050475 glycyl-leucyl-tyrosine Proteins 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 108010069117 seryl-lysyl-aspartic acid Proteins 0.000 description 11
- 108010079202 tyrosyl-alanyl-cysteine Proteins 0.000 description 11
- 108010071635 tyrosyl-prolyl-arginine Proteins 0.000 description 11
- PBSQFBAJKPLRJY-BYULHYEWSA-N Asn-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N PBSQFBAJKPLRJY-BYULHYEWSA-N 0.000 description 10
- NCFJQJRLQJEECD-NHCYSSNCSA-N Asn-Leu-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O NCFJQJRLQJEECD-NHCYSSNCSA-N 0.000 description 10
- XMTDCXXLDZKAGI-ACZMJKKPSA-N Cys-Ala-Gln Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CS)N XMTDCXXLDZKAGI-ACZMJKKPSA-N 0.000 description 10
- LHMWTCWZARHLPV-CIUDSAMLSA-N Gln-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)N)N LHMWTCWZARHLPV-CIUDSAMLSA-N 0.000 description 10
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- QVFGXCVIXXBFHO-AVGNSLFASA-N Leu-Glu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O QVFGXCVIXXBFHO-AVGNSLFASA-N 0.000 description 10
- MKGIILKDUGDRRO-FXQIFTODSA-N Pro-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 MKGIILKDUGDRRO-FXQIFTODSA-N 0.000 description 10
- QKWYXRPICJEQAJ-KJEVXHAQSA-N Pro-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2)O QKWYXRPICJEQAJ-KJEVXHAQSA-N 0.000 description 10
- JAWUQFCGNVEDRN-MEYUZBJRSA-N Thr-Tyr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N)O JAWUQFCGNVEDRN-MEYUZBJRSA-N 0.000 description 10
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 10
- 108010015792 glycyllysine Proteins 0.000 description 10
- 239000005090 green fluorescent protein Substances 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 108010024654 phenylalanyl-prolyl-alanine Proteins 0.000 description 10
- 108010004914 prolylarginine Proteins 0.000 description 10
- DVWVZSJAYIJZFI-FXQIFTODSA-N Ala-Arg-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O DVWVZSJAYIJZFI-FXQIFTODSA-N 0.000 description 9
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 9
- OLVIPTLKNSAYRJ-YUMQZZPRSA-N Asn-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N OLVIPTLKNSAYRJ-YUMQZZPRSA-N 0.000 description 9
- MRQQMVZUHXUPEV-IHRRRGAJSA-N Asp-Arg-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MRQQMVZUHXUPEV-IHRRRGAJSA-N 0.000 description 9
- WBDWQKRLTVCDSY-WHFBIAKZSA-N Asp-Gly-Asp Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O WBDWQKRLTVCDSY-WHFBIAKZSA-N 0.000 description 9
- KYQNAIMCTRZLNP-QSFUFRPTSA-N Asp-Ile-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O KYQNAIMCTRZLNP-QSFUFRPTSA-N 0.000 description 9
- XWKPSMRPIKKDDU-RCOVLWMOSA-N Asp-Val-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O XWKPSMRPIKKDDU-RCOVLWMOSA-N 0.000 description 9
- GEEXORWTBTUOHC-FXQIFTODSA-N Cys-Arg-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N)CN=C(N)N GEEXORWTBTUOHC-FXQIFTODSA-N 0.000 description 9
- LKDIBBOKUAASNP-FXQIFTODSA-N Glu-Ala-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LKDIBBOKUAASNP-FXQIFTODSA-N 0.000 description 9
- QJVZSVUYZFYLFQ-CIUDSAMLSA-N Glu-Pro-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O QJVZSVUYZFYLFQ-CIUDSAMLSA-N 0.000 description 9
- OCQUNKSFDYDXBG-QXEWZRGKSA-N Gly-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N OCQUNKSFDYDXBG-QXEWZRGKSA-N 0.000 description 9
- AFWYPMDMDYCKMD-KBPBESRZSA-N Gly-Leu-Tyr Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 AFWYPMDMDYCKMD-KBPBESRZSA-N 0.000 description 9
- UIQGJYUEQDOODF-KWQFWETISA-N Gly-Tyr-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 UIQGJYUEQDOODF-KWQFWETISA-N 0.000 description 9
- JYGYNWYVKXENNE-OALUTQOASA-N Gly-Tyr-Trp Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O JYGYNWYVKXENNE-OALUTQOASA-N 0.000 description 9
- FQZPTCNSNPWHLJ-AVGNSLFASA-N Leu-Gln-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O FQZPTCNSNPWHLJ-AVGNSLFASA-N 0.000 description 9
- NRFGTHFONZYFNY-MGHWNKPDSA-N Leu-Ile-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NRFGTHFONZYFNY-MGHWNKPDSA-N 0.000 description 9
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 9
- MMJJFXWMCMJMQA-STQMWFEESA-N Phe-Pro-Gly Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)C1=CC=CC=C1 MMJJFXWMCMJMQA-STQMWFEESA-N 0.000 description 9
- XNMYNGDKJNOKHH-BZSNNMDCSA-N Phe-Ser-Tyr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XNMYNGDKJNOKHH-BZSNNMDCSA-N 0.000 description 9
- HJSCRFZVGXAGNG-SRVKXCTJSA-N Pro-Gln-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1 HJSCRFZVGXAGNG-SRVKXCTJSA-N 0.000 description 9
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 9
- UIPXCLNLUUAMJU-JBDRJPRFSA-N Ser-Ile-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UIPXCLNLUUAMJU-JBDRJPRFSA-N 0.000 description 9
- KCGIREHVWRXNDH-GARJFASQSA-N Ser-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N KCGIREHVWRXNDH-GARJFASQSA-N 0.000 description 9
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 9
- SIEBDTCABMZCLF-XGEHTFHBSA-N Ser-Val-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SIEBDTCABMZCLF-XGEHTFHBSA-N 0.000 description 9
- KRPKYGOFYUNIGM-XVSYOHENSA-N Thr-Asp-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N)O KRPKYGOFYUNIGM-XVSYOHENSA-N 0.000 description 9
- DCLBXIWHLVEPMQ-JRQIVUDYSA-N Thr-Asp-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DCLBXIWHLVEPMQ-JRQIVUDYSA-N 0.000 description 9
- MECLEFZMPPOEAC-VOAKCMCISA-N Thr-Leu-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MECLEFZMPPOEAC-VOAKCMCISA-N 0.000 description 9
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 9
- DEGCBBCMYWNJNA-RHYQMDGZSA-N Thr-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O DEGCBBCMYWNJNA-RHYQMDGZSA-N 0.000 description 9
- AZBIIKDSDLVJAK-VHWLVUOQSA-N Trp-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N AZBIIKDSDLVJAK-VHWLVUOQSA-N 0.000 description 9
- RZAGEHHVNYESNR-RNXOBYDBSA-N Tyr-Trp-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O RZAGEHHVNYESNR-RNXOBYDBSA-N 0.000 description 9
- WMRWZYSRQUORHJ-YDHLFZDLSA-N Val-Phe-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)O)C(=O)O)N WMRWZYSRQUORHJ-YDHLFZDLSA-N 0.000 description 9
- DVLWZWNAQUBZBC-ZNSHCXBVSA-N Val-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N)O DVLWZWNAQUBZBC-ZNSHCXBVSA-N 0.000 description 9
- LMVWCLDJNSBOEA-FKBYEOEOSA-N Val-Tyr-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N LMVWCLDJNSBOEA-FKBYEOEOSA-N 0.000 description 9
- 108700020467 WT1 Proteins 0.000 description 9
- 101150084041 WT1 gene Proteins 0.000 description 9
- 102100022748 Wilms tumor protein Human genes 0.000 description 9
- 108010081404 acein-2 Proteins 0.000 description 9
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 108010064235 lysylglycine Proteins 0.000 description 9
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 9
- 108010029020 prolylglycine Proteins 0.000 description 9
- 108010090894 prolylleucine Proteins 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 108010080629 tryptophan-leucine Proteins 0.000 description 9
- 108010038745 tryptophylglycine Proteins 0.000 description 9
- IASNWHAGGYTEKX-IUCAKERBSA-N Arg-Arg-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(O)=O IASNWHAGGYTEKX-IUCAKERBSA-N 0.000 description 8
- GXMSVVBIAMWMKO-BQBZGAKWSA-N Asn-Arg-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCN=C(N)N GXMSVVBIAMWMKO-BQBZGAKWSA-N 0.000 description 8
- VIRYODQIWJNWNU-NRPADANISA-N Cys-Glu-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CS)N VIRYODQIWJNWNU-NRPADANISA-N 0.000 description 8
- OHLLDUNVMPPUMD-DCAQKATOSA-N Cys-Leu-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N OHLLDUNVMPPUMD-DCAQKATOSA-N 0.000 description 8
- JJKKWYQVHRUSDG-GUBZILKMSA-N Glu-Ala-Lys Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O JJKKWYQVHRUSDG-GUBZILKMSA-N 0.000 description 8
- FGMHXLULNHTPID-KKUMJFAQSA-N Lys-His-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 FGMHXLULNHTPID-KKUMJFAQSA-N 0.000 description 8
- YTJFXEDRUOQGSP-DCAQKATOSA-N Lys-Pro-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O YTJFXEDRUOQGSP-DCAQKATOSA-N 0.000 description 8
- SQXZLVXQXWILKW-KKUMJFAQSA-N Lys-Ser-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SQXZLVXQXWILKW-KKUMJFAQSA-N 0.000 description 8
- NAXPHWZXEXNDIW-JTQLQIEISA-N Phe-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 NAXPHWZXEXNDIW-JTQLQIEISA-N 0.000 description 8
- ZOHGLPQGEHSLPD-FXQIFTODSA-N Ser-Gln-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZOHGLPQGEHSLPD-FXQIFTODSA-N 0.000 description 8
- BPMRXBZYPGYPJN-WHFBIAKZSA-N Ser-Gly-Asn Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O BPMRXBZYPGYPJN-WHFBIAKZSA-N 0.000 description 8
- VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 8
- CYCGARJWIQWPQM-YJRXYDGGSA-N Thr-Tyr-Ser Chemical compound C[C@@H](O)[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CO)C([O-])=O)CC1=CC=C(O)C=C1 CYCGARJWIQWPQM-YJRXYDGGSA-N 0.000 description 8
- QUILOGWWLXMSAT-IHRRRGAJSA-N Tyr-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QUILOGWWLXMSAT-IHRRRGAJSA-N 0.000 description 8
- AUZADXNWQMBZOO-JYJNAYRXSA-N Tyr-Pro-Arg Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CC=C(O)C=C1 AUZADXNWQMBZOO-JYJNAYRXSA-N 0.000 description 8
- MQGGXGKQSVEQHR-KKUMJFAQSA-N Tyr-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MQGGXGKQSVEQHR-KKUMJFAQSA-N 0.000 description 8
- OXVPMZVGCAPFIG-BQFCYCMXSA-N Val-Gln-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N OXVPMZVGCAPFIG-BQFCYCMXSA-N 0.000 description 8
- HGJRMXOWUWVUOA-GVXVVHGQSA-N Val-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N HGJRMXOWUWVUOA-GVXVVHGQSA-N 0.000 description 8
- QPJSIBAOZBVELU-BPNCWPANSA-N Val-Tyr-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N QPJSIBAOZBVELU-BPNCWPANSA-N 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 8
- 108010068380 arginylarginine Proteins 0.000 description 8
- 239000006285 cell suspension Substances 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 108010083476 phenylalanyltryptophan Proteins 0.000 description 8
- 230000035899 viability Effects 0.000 description 8
- QRIYOHQJRDHFKF-UWJYBYFXSA-N Ala-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=C(O)C=C1 QRIYOHQJRDHFKF-UWJYBYFXSA-N 0.000 description 7
- PUUPMDXIHCOPJU-HJGDQZAQSA-N Asn-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O PUUPMDXIHCOPJU-HJGDQZAQSA-N 0.000 description 7
- NVFSJIXJZCDICF-SRVKXCTJSA-N Asp-Lys-Lys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N NVFSJIXJZCDICF-SRVKXCTJSA-N 0.000 description 7
- SQIARYGNVQWOSB-BZSNNMDCSA-N Asp-Tyr-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SQIARYGNVQWOSB-BZSNNMDCSA-N 0.000 description 7
- XKPACHRGOWQHFH-IRIUXVKKSA-N Gln-Thr-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XKPACHRGOWQHFH-IRIUXVKKSA-N 0.000 description 7
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 7
- HAOUOFNNJJLVNS-BQBZGAKWSA-N Gly-Pro-Ser Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O HAOUOFNNJJLVNS-BQBZGAKWSA-N 0.000 description 7
- FFJQHWKSGAWSTJ-BFHQHQDPSA-N Gly-Thr-Ala Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O FFJQHWKSGAWSTJ-BFHQHQDPSA-N 0.000 description 7
- LSQHWKPPOFDHHZ-YUMQZZPRSA-N His-Asp-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N LSQHWKPPOFDHHZ-YUMQZZPRSA-N 0.000 description 7
- FADXGVVLSPPEQY-GHCJXIJMSA-N Ile-Cys-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O)N FADXGVVLSPPEQY-GHCJXIJMSA-N 0.000 description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 7
- WSGXUIQTEZDVHJ-GARJFASQSA-N Leu-Ala-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(O)=O WSGXUIQTEZDVHJ-GARJFASQSA-N 0.000 description 7
- MYGQXVYRZMKRDB-SRVKXCTJSA-N Leu-Asp-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN MYGQXVYRZMKRDB-SRVKXCTJSA-N 0.000 description 7
- QESXLSQLQHHTIX-RHYQMDGZSA-N Leu-Val-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QESXLSQLQHHTIX-RHYQMDGZSA-N 0.000 description 7
- LCMWVZLBCUVDAZ-IUCAKERBSA-N Lys-Gly-Glu Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CCC([O-])=O LCMWVZLBCUVDAZ-IUCAKERBSA-N 0.000 description 7
- CTJUSALVKAWFFU-CIUDSAMLSA-N Lys-Ser-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N CTJUSALVKAWFFU-CIUDSAMLSA-N 0.000 description 7
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 7
- JLLJTMHNXQTMCK-UBHSHLNASA-N Phe-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 JLLJTMHNXQTMCK-UBHSHLNASA-N 0.000 description 7
- UPJGUQPLYWTISV-GUBZILKMSA-N Pro-Gln-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UPJGUQPLYWTISV-GUBZILKMSA-N 0.000 description 7
- LGSANCBHSMDFDY-GARJFASQSA-N Pro-Glu-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O LGSANCBHSMDFDY-GARJFASQSA-N 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- HEQPKICPPDOSIN-SRVKXCTJSA-N Ser-Asp-Tyr Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HEQPKICPPDOSIN-SRVKXCTJSA-N 0.000 description 7
- XNCUYZKGQOCOQH-YUMQZZPRSA-N Ser-Leu-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O XNCUYZKGQOCOQH-YUMQZZPRSA-N 0.000 description 7
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 7
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 description 7
- PCJLFYBAQZQOFE-KATARQTJSA-N Ser-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N)O PCJLFYBAQZQOFE-KATARQTJSA-N 0.000 description 7
- AXKJPUBALUNJEO-UBHSHLNASA-N Ser-Trp-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(O)=O AXKJPUBALUNJEO-UBHSHLNASA-N 0.000 description 7
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 7
- 102100023132 Transcription factor Jun Human genes 0.000 description 7
- GNWUWQAVVJQREM-NHCYSSNCSA-N Val-Asn-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N GNWUWQAVVJQREM-NHCYSSNCSA-N 0.000 description 7
- WDIGUPHXPBMODF-UMNHJUIQSA-N Val-Glu-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N WDIGUPHXPBMODF-UMNHJUIQSA-N 0.000 description 7
- ZIGZPYJXIWLQFC-QTKMDUPCSA-N Val-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](C(C)C)N)O ZIGZPYJXIWLQFC-QTKMDUPCSA-N 0.000 description 7
- VCIYTVOBLZHFSC-XHSDSOJGSA-N Val-Phe-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N VCIYTVOBLZHFSC-XHSDSOJGSA-N 0.000 description 7
- 108010087924 alanylproline Proteins 0.000 description 7
- 108010077245 asparaginyl-proline Proteins 0.000 description 7
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 7
- 108010053725 prolylvaline Proteins 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- XPSGESXVBSQZPL-SRVKXCTJSA-N Arg-Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XPSGESXVBSQZPL-SRVKXCTJSA-N 0.000 description 6
- MFAMTAVAFBPXDC-LPEHRKFASA-N Arg-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O MFAMTAVAFBPXDC-LPEHRKFASA-N 0.000 description 6
- 108010051330 Arg-Pro-Gly-Pro Proteins 0.000 description 6
- VENMDXUVHSKEIN-GUBZILKMSA-N Arg-Ser-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VENMDXUVHSKEIN-GUBZILKMSA-N 0.000 description 6
- XRNXPIGJPQHCPC-RCWTZXSCSA-N Arg-Thr-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)O)C(O)=O XRNXPIGJPQHCPC-RCWTZXSCSA-N 0.000 description 6
- JREOBWLIZLXRIS-GUBZILKMSA-N Asn-Glu-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JREOBWLIZLXRIS-GUBZILKMSA-N 0.000 description 6
- PBVLJOIPOGUQQP-CIUDSAMLSA-N Asp-Ala-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O PBVLJOIPOGUQQP-CIUDSAMLSA-N 0.000 description 6
- 102000014914 Carrier Proteins Human genes 0.000 description 6
- ITBHUUMCJJQUSC-LAEOZQHASA-N Glu-Ile-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O ITBHUUMCJJQUSC-LAEOZQHASA-N 0.000 description 6
- DNPCBMNFQVTHMA-DCAQKATOSA-N Glu-Leu-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O DNPCBMNFQVTHMA-DCAQKATOSA-N 0.000 description 6
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 6
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 6
- DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 description 6
- PPGBXYKMUMHFBF-KATARQTJSA-N Leu-Ser-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PPGBXYKMUMHFBF-KATARQTJSA-N 0.000 description 6
- VHTIZYYHIUHMCA-JYJNAYRXSA-N Leu-Tyr-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O VHTIZYYHIUHMCA-JYJNAYRXSA-N 0.000 description 6
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 6
- LMVOVCYVZBBWQB-SRVKXCTJSA-N Lys-Asp-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN LMVOVCYVZBBWQB-SRVKXCTJSA-N 0.000 description 6
- LUAJJLPHUXPQLH-KKUMJFAQSA-N Lys-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCCN)N LUAJJLPHUXPQLH-KKUMJFAQSA-N 0.000 description 6
- ONGCSGVHCSAATF-CIUDSAMLSA-N Met-Ala-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O ONGCSGVHCSAATF-CIUDSAMLSA-N 0.000 description 6
- DBOMZJOESVYERT-GUBZILKMSA-N Met-Asn-Met Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCSC)C(=O)O)N DBOMZJOESVYERT-GUBZILKMSA-N 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 108091008874 T cell receptors Proteins 0.000 description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 6
- GAYLGYUVTDMLKC-UWJYBYFXSA-N Tyr-Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 GAYLGYUVTDMLKC-UWJYBYFXSA-N 0.000 description 6
- 108010005233 alanylglutamic acid Proteins 0.000 description 6
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 6
- 108091008324 binding proteins Proteins 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 108010020688 glycylhistidine Proteins 0.000 description 6
- 102000006240 membrane receptors Human genes 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 108010044292 tryptophyltyrosine Proteins 0.000 description 6
- 108010003137 tyrosyltyrosine Proteins 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- SAHQGRZIQVEJPF-JXUBOQSCSA-N Ala-Thr-Lys Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN SAHQGRZIQVEJPF-JXUBOQSCSA-N 0.000 description 5
- MTDDMSUUXNQMKK-BPNCWPANSA-N Ala-Tyr-Arg Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N MTDDMSUUXNQMKK-BPNCWPANSA-N 0.000 description 5
- PNQWAUXQDBIJDY-GUBZILKMSA-N Arg-Glu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PNQWAUXQDBIJDY-GUBZILKMSA-N 0.000 description 5
- SSZGOKWBHLOCHK-DCAQKATOSA-N Arg-Lys-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N SSZGOKWBHLOCHK-DCAQKATOSA-N 0.000 description 5
- DIIGDGJKTMLQQW-IHRRRGAJSA-N Arg-Lys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)N DIIGDGJKTMLQQW-IHRRRGAJSA-N 0.000 description 5
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 5
- KXOPYFNQLVUOAQ-FXQIFTODSA-N Arg-Ser-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KXOPYFNQLVUOAQ-FXQIFTODSA-N 0.000 description 5
- JDDYEZGPYBBPBN-JRQIVUDYSA-N Asp-Thr-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JDDYEZGPYBBPBN-JRQIVUDYSA-N 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- OSCLNNWLKKIQJM-WDSKDSINSA-N Gln-Ser-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O OSCLNNWLKKIQJM-WDSKDSINSA-N 0.000 description 5
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 5
- GLACUWHUYFBSPJ-FJXKBIBVSA-N Gly-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN GLACUWHUYFBSPJ-FJXKBIBVSA-N 0.000 description 5
- NKRWVZQTPXPNRZ-SRVKXCTJSA-N His-Met-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC1=CN=CN1 NKRWVZQTPXPNRZ-SRVKXCTJSA-N 0.000 description 5
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 5
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 5
- DMSVBUWGDLYNLC-IAVJCBSLSA-N Ile-Ile-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 DMSVBUWGDLYNLC-IAVJCBSLSA-N 0.000 description 5
- WUHBLPVELFTPQK-KKUMJFAQSA-N Leu-Tyr-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O WUHBLPVELFTPQK-KKUMJFAQSA-N 0.000 description 5
- UZWMJZSOXGOVIN-LURJTMIESA-N Met-Gly-Gly Chemical compound CSCC[C@H](N)C(=O)NCC(=O)NCC(O)=O UZWMJZSOXGOVIN-LURJTMIESA-N 0.000 description 5
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 5
- KLYYKKGCPOGDPE-OEAJRASXSA-N Phe-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O KLYYKKGCPOGDPE-OEAJRASXSA-N 0.000 description 5
- LNLNHXIQPGKRJQ-SRVKXCTJSA-N Pro-Arg-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1 LNLNHXIQPGKRJQ-SRVKXCTJSA-N 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 5
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 5
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 5
- MUAFDCVOHYAFNG-RCWTZXSCSA-N Thr-Pro-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MUAFDCVOHYAFNG-RCWTZXSCSA-N 0.000 description 5
- CKHQKYHIZCRTAP-SOUVJXGZSA-N Tyr-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O CKHQKYHIZCRTAP-SOUVJXGZSA-N 0.000 description 5
- JFAWZADYPRMRCO-UBHSHLNASA-N Val-Ala-Phe Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JFAWZADYPRMRCO-UBHSHLNASA-N 0.000 description 5
- 108010041407 alanylaspartic acid Proteins 0.000 description 5
- 108010062796 arginyllysine Proteins 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000003501 co-culture Methods 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 108010003700 lysyl aspartic acid Proteins 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 108010000998 wheylin-2 peptide Proteins 0.000 description 5
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 4
- OLVCTPPSXNRGKV-GUBZILKMSA-N Ala-Pro-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OLVCTPPSXNRGKV-GUBZILKMSA-N 0.000 description 4
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 4
- TTXYKSADPSNOIF-IHRRRGAJSA-N Arg-Asp-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O TTXYKSADPSNOIF-IHRRRGAJSA-N 0.000 description 4
- HGKHPCFTRQDHCU-IUCAKERBSA-N Arg-Pro-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O HGKHPCFTRQDHCU-IUCAKERBSA-N 0.000 description 4
- JOTRDIXZHNQYGP-DCAQKATOSA-N Arg-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)N JOTRDIXZHNQYGP-DCAQKATOSA-N 0.000 description 4
- WIDVAWAQBRAKTI-YUMQZZPRSA-N Asn-Leu-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O WIDVAWAQBRAKTI-YUMQZZPRSA-N 0.000 description 4
- XPGVTUBABLRGHY-BIIVOSGPSA-N Asp-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N XPGVTUBABLRGHY-BIIVOSGPSA-N 0.000 description 4
- AHWRSSLYSGLBGD-CIUDSAMLSA-N Asp-Pro-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AHWRSSLYSGLBGD-CIUDSAMLSA-N 0.000 description 4
- 108091008875 B cell receptors Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- HSHCEAUPUPJPTE-JYJNAYRXSA-N Gln-Leu-Tyr Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N HSHCEAUPUPJPTE-JYJNAYRXSA-N 0.000 description 4
- DCWNCMRZIZSZBL-KKUMJFAQSA-N Gln-Pro-Tyr Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)N)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O DCWNCMRZIZSZBL-KKUMJFAQSA-N 0.000 description 4
- ZZIFPJZQHRJERU-WDSKDSINSA-N Glu-Cys-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O ZZIFPJZQHRJERU-WDSKDSINSA-N 0.000 description 4
- YGLCLCMAYUYZSG-AVGNSLFASA-N Glu-Lys-His Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 YGLCLCMAYUYZSG-AVGNSLFASA-N 0.000 description 4
- DMYACXMQUABZIQ-NRPADANISA-N Glu-Ser-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O DMYACXMQUABZIQ-NRPADANISA-N 0.000 description 4
- PMNHJLASAAWELO-FOHZUACHSA-N Gly-Asp-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PMNHJLASAAWELO-FOHZUACHSA-N 0.000 description 4
- BULIVUZUDBHKKZ-WDSKDSINSA-N Gly-Gln-Asn Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O BULIVUZUDBHKKZ-WDSKDSINSA-N 0.000 description 4
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 4
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 4
- BABSVXFGKFLIGW-UWVGGRQHSA-N Leu-Gly-Arg Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N BABSVXFGKFLIGW-UWVGGRQHSA-N 0.000 description 4
- OYQUOLRTJHWVSQ-SRVKXCTJSA-N Leu-His-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O OYQUOLRTJHWVSQ-SRVKXCTJSA-N 0.000 description 4
- KWUKZRFFKPLUPE-HJGDQZAQSA-N Lys-Asp-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWUKZRFFKPLUPE-HJGDQZAQSA-N 0.000 description 4
- AFLBTVGQCQLOFJ-AVGNSLFASA-N Lys-Pro-Arg Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O AFLBTVGQCQLOFJ-AVGNSLFASA-N 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 4
- BJEYSVHMGIJORT-NHCYSSNCSA-N Phe-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 BJEYSVHMGIJORT-NHCYSSNCSA-N 0.000 description 4
- WEDZFLRYSIDIRX-IHRRRGAJSA-N Phe-Ser-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=CC=C1 WEDZFLRYSIDIRX-IHRRRGAJSA-N 0.000 description 4
- SSSFPISOZOLQNP-GUBZILKMSA-N Pro-Arg-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O SSSFPISOZOLQNP-GUBZILKMSA-N 0.000 description 4
- NNFMANHDYSVNIO-DCAQKATOSA-N Ser-Lys-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NNFMANHDYSVNIO-DCAQKATOSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- IGROJMCBGRFRGI-YTLHQDLWSA-N Thr-Ala-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O IGROJMCBGRFRGI-YTLHQDLWSA-N 0.000 description 4
- CAJFZCICSVBOJK-SHGPDSBTSA-N Thr-Ala-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAJFZCICSVBOJK-SHGPDSBTSA-N 0.000 description 4
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 4
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 4
- OOEUVMFKKZYSRX-LEWSCRJBSA-N Tyr-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N OOEUVMFKKZYSRX-LEWSCRJBSA-N 0.000 description 4
- PEVVXUGSAKEPEN-AVGNSLFASA-N Tyr-Asn-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PEVVXUGSAKEPEN-AVGNSLFASA-N 0.000 description 4
- UABYBEBXFFNCIR-YDHLFZDLSA-N Tyr-Asp-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UABYBEBXFFNCIR-YDHLFZDLSA-N 0.000 description 4
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 230000009134 cell regulation Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108010079547 glutamylmethionine Proteins 0.000 description 4
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 4
- 108010034529 leucyl-lysine Proteins 0.000 description 4
- 108010038320 lysylphenylalanine Proteins 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 108010079317 prolyl-tyrosine Proteins 0.000 description 4
- 108010054624 red fluorescent protein Proteins 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 238000004114 suspension culture Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- -1 tripeptide Proteins 0.000 description 4
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 4
- JNTMAZFVYNDPLB-PEDHHIEDSA-N (2S,3S)-2-[[[(2S)-1-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JNTMAZFVYNDPLB-PEDHHIEDSA-N 0.000 description 3
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 3
- XQJAFSDFQZPYCU-UWJYBYFXSA-N Ala-Asn-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N XQJAFSDFQZPYCU-UWJYBYFXSA-N 0.000 description 3
- WCBVQNZTOKJWJS-ACZMJKKPSA-N Ala-Cys-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O WCBVQNZTOKJWJS-ACZMJKKPSA-N 0.000 description 3
- AWAXZRDKUHOPBO-GUBZILKMSA-N Ala-Gln-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O AWAXZRDKUHOPBO-GUBZILKMSA-N 0.000 description 3
- VNYMOTCMNHJGTG-JBDRJPRFSA-N Ala-Ile-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O VNYMOTCMNHJGTG-JBDRJPRFSA-N 0.000 description 3
- MEFILNJXAVSUTO-JXUBOQSCSA-N Ala-Leu-Thr Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MEFILNJXAVSUTO-JXUBOQSCSA-N 0.000 description 3
- IPZQNYYAYVRKKK-FXQIFTODSA-N Ala-Pro-Ala Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IPZQNYYAYVRKKK-FXQIFTODSA-N 0.000 description 3
- HJVGMOYJDDXLMI-AVGNSLFASA-N Arg-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCCNC(N)=N HJVGMOYJDDXLMI-AVGNSLFASA-N 0.000 description 3
- HPKSHFSEXICTLI-CIUDSAMLSA-N Arg-Glu-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O HPKSHFSEXICTLI-CIUDSAMLSA-N 0.000 description 3
- PHHRSPBBQUFULD-UWVGGRQHSA-N Arg-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N PHHRSPBBQUFULD-UWVGGRQHSA-N 0.000 description 3
- OFIYLHVAAJYRBC-HJWJTTGWSA-N Arg-Ile-Phe Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](Cc1ccccc1)C(O)=O OFIYLHVAAJYRBC-HJWJTTGWSA-N 0.000 description 3
- WPOLSNAQGVHROR-GUBZILKMSA-N Asn-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)N WPOLSNAQGVHROR-GUBZILKMSA-N 0.000 description 3
- VITDJIPIJZAVGC-VEVYYDQMSA-N Asn-Met-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VITDJIPIJZAVGC-VEVYYDQMSA-N 0.000 description 3
- JWQWPRCDYWNVNM-ACZMJKKPSA-N Asn-Ser-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N JWQWPRCDYWNVNM-ACZMJKKPSA-N 0.000 description 3
- HPBNLFLSSQDFQW-WHFBIAKZSA-N Asn-Ser-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O HPBNLFLSSQDFQW-WHFBIAKZSA-N 0.000 description 3
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 3
- SVFOIXMRMLROHO-SRVKXCTJSA-N Asp-Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SVFOIXMRMLROHO-SRVKXCTJSA-N 0.000 description 3
- PSLSTUMPZILTAH-BYULHYEWSA-N Asp-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PSLSTUMPZILTAH-BYULHYEWSA-N 0.000 description 3
- PGUYEUCYVNZGGV-QWRGUYRKSA-N Asp-Gly-Tyr Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PGUYEUCYVNZGGV-QWRGUYRKSA-N 0.000 description 3
- QNFRBNZGVVKBNJ-PEFMBERDSA-N Asp-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N QNFRBNZGVVKBNJ-PEFMBERDSA-N 0.000 description 3
- NJLLRXWFPQQPHV-SRVKXCTJSA-N Asp-Tyr-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O NJLLRXWFPQQPHV-SRVKXCTJSA-N 0.000 description 3
- WOKXEQLPBLLWHC-IHRRRGAJSA-N Asp-Tyr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 WOKXEQLPBLLWHC-IHRRRGAJSA-N 0.000 description 3
- GIKOVDMXBAFXDF-NHCYSSNCSA-N Asp-Val-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O GIKOVDMXBAFXDF-NHCYSSNCSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 3
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 3
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 3
- IKFZXRLDMYWNBU-YUMQZZPRSA-N Gln-Gly-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N IKFZXRLDMYWNBU-YUMQZZPRSA-N 0.000 description 3
- CLPQUWHBWXFJOX-BQBZGAKWSA-N Gln-Gly-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O CLPQUWHBWXFJOX-BQBZGAKWSA-N 0.000 description 3
- TWIAMTNJOMRDAK-GUBZILKMSA-N Gln-Lys-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O TWIAMTNJOMRDAK-GUBZILKMSA-N 0.000 description 3
- SYZZMPFLOLSMHL-XHNCKOQMSA-N Gln-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N)C(=O)O SYZZMPFLOLSMHL-XHNCKOQMSA-N 0.000 description 3
- WOMUDRVDJMHTCV-DCAQKATOSA-N Glu-Arg-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WOMUDRVDJMHTCV-DCAQKATOSA-N 0.000 description 3
- VMKCPNBBPGGQBJ-GUBZILKMSA-N Glu-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N VMKCPNBBPGGQBJ-GUBZILKMSA-N 0.000 description 3
- QMOSCLNJVKSHHU-YUMQZZPRSA-N Glu-Met-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)NCC(O)=O QMOSCLNJVKSHHU-YUMQZZPRSA-N 0.000 description 3
- RFTVTKBHDXCEEX-WDSKDSINSA-N Glu-Ser-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RFTVTKBHDXCEEX-WDSKDSINSA-N 0.000 description 3
- HHSKZJZWQFPSKN-AVGNSLFASA-N Glu-Tyr-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O HHSKZJZWQFPSKN-AVGNSLFASA-N 0.000 description 3
- VUUOMYFPWDYETE-WDSKDSINSA-N Gly-Gln-Cys Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)CN VUUOMYFPWDYETE-WDSKDSINSA-N 0.000 description 3
- XMPXVJIDADUOQB-RCOVLWMOSA-N Gly-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C([O-])=O)NC(=O)CNC(=O)C[NH3+] XMPXVJIDADUOQB-RCOVLWMOSA-N 0.000 description 3
- SCWYHUQOOFRVHP-MBLNEYKQSA-N Gly-Ile-Thr Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SCWYHUQOOFRVHP-MBLNEYKQSA-N 0.000 description 3
- MHZXESQPPXOING-KBPBESRZSA-N Gly-Lys-Phe Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MHZXESQPPXOING-KBPBESRZSA-N 0.000 description 3
- WDEHMRNSGHVNOH-VHSXEESVSA-N Gly-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)CN)C(=O)O WDEHMRNSGHVNOH-VHSXEESVSA-N 0.000 description 3
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 3
- CQMFNTVQVLQRLT-JHEQGTHGSA-N Gly-Thr-Gln Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CQMFNTVQVLQRLT-JHEQGTHGSA-N 0.000 description 3
- DBUNZBWUWCIELX-JHEQGTHGSA-N Gly-Thr-Glu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O DBUNZBWUWCIELX-JHEQGTHGSA-N 0.000 description 3
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 3
- HXWALXSAVBLTPK-NUTKFTJISA-N Leu-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(C)C)N HXWALXSAVBLTPK-NUTKFTJISA-N 0.000 description 3
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 3
- MPSBSKHOWJQHBS-IHRRRGAJSA-N Leu-His-Met Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCSC)C(=O)O)N MPSBSKHOWJQHBS-IHRRRGAJSA-N 0.000 description 3
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 3
- IXHKPDJKKCUKHS-GARJFASQSA-N Lys-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N IXHKPDJKKCUKHS-GARJFASQSA-N 0.000 description 3
- OIYWBDBHEGAVST-BZSNNMDCSA-N Lys-His-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OIYWBDBHEGAVST-BZSNNMDCSA-N 0.000 description 3
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 3
- URGPVYGVWLIRGT-DCAQKATOSA-N Lys-Met-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O URGPVYGVWLIRGT-DCAQKATOSA-N 0.000 description 3
- XABXVVSWUVCZST-GVXVVHGQSA-N Lys-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN XABXVVSWUVCZST-GVXVVHGQSA-N 0.000 description 3
- UGCIQUYEJIEHKX-GVXVVHGQSA-N Lys-Val-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O UGCIQUYEJIEHKX-GVXVVHGQSA-N 0.000 description 3
- HMZPYMSEAALNAE-ULQDDVLXSA-N Lys-Val-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O HMZPYMSEAALNAE-ULQDDVLXSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 3
- HXSUFWQYLPKEHF-IHRRRGAJSA-N Phe-Asn-Arg Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N HXSUFWQYLPKEHF-IHRRRGAJSA-N 0.000 description 3
- QPVFUAUFEBPIPT-CDMKHQONSA-N Phe-Gly-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O QPVFUAUFEBPIPT-CDMKHQONSA-N 0.000 description 3
- MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 3
- BTAIJUBAGLVFKQ-BVSLBCMMSA-N Phe-Trp-Val Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C(C)C)C(O)=O)C1=CC=CC=C1 BTAIJUBAGLVFKQ-BVSLBCMMSA-N 0.000 description 3
- SJRQWEDYTKYHHL-SLFFLAALSA-N Phe-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)O SJRQWEDYTKYHHL-SLFFLAALSA-N 0.000 description 3
- FMLRRBDLBJLJIK-DCAQKATOSA-N Pro-Leu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FMLRRBDLBJLJIK-DCAQKATOSA-N 0.000 description 3
- PKHDJFHFMGQMPS-RCWTZXSCSA-N Pro-Thr-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PKHDJFHFMGQMPS-RCWTZXSCSA-N 0.000 description 3
- UGJRQLURDVGULT-LKXGYXEUSA-N Ser-Asn-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UGJRQLURDVGULT-LKXGYXEUSA-N 0.000 description 3
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 3
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 3
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 3
- CKDXFSPMIDSMGV-GUBZILKMSA-N Ser-Pro-Val Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O CKDXFSPMIDSMGV-GUBZILKMSA-N 0.000 description 3
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 3
- ZKOKTQPHFMRSJP-YJRXYDGGSA-N Ser-Thr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKOKTQPHFMRSJP-YJRXYDGGSA-N 0.000 description 3
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 3
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 3
- XSEPSRUDSPHMPX-KATARQTJSA-N Thr-Lys-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O XSEPSRUDSPHMPX-KATARQTJSA-N 0.000 description 3
- SVGAWGVHFIYAEE-JSGCOSHPSA-N Trp-Gly-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 SVGAWGVHFIYAEE-JSGCOSHPSA-N 0.000 description 3
- WMBFONUKQXGLMU-WDSOQIARSA-N Trp-Leu-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N WMBFONUKQXGLMU-WDSOQIARSA-N 0.000 description 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 3
- QOIKZODVIPOPDD-AVGNSLFASA-N Tyr-Cys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOIKZODVIPOPDD-AVGNSLFASA-N 0.000 description 3
- PLVVHGFEMSDRET-IHPCNDPISA-N Tyr-Ser-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CC=C(C=C3)O)N PLVVHGFEMSDRET-IHPCNDPISA-N 0.000 description 3
- NUQZCPSZHGIYTA-HKUYNNGSSA-N Tyr-Trp-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N NUQZCPSZHGIYTA-HKUYNNGSSA-N 0.000 description 3
- UGFMVXRXULGLNO-XPUUQOCRSA-N Val-Ser-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O UGFMVXRXULGLNO-XPUUQOCRSA-N 0.000 description 3
- 241000173537 Wolbachia phage WO Species 0.000 description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 3
- 108010068265 aspartyltyrosine Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 108010016616 cysteinylglycine Proteins 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 108010054812 diprotin A Proteins 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 3
- 108010072405 glycyl-aspartyl-glycine Proteins 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 108010027338 isoleucylcysteine Proteins 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108010031719 prolyl-serine Proteins 0.000 description 3
- 108010070643 prolylglutamic acid Proteins 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000002463 transducing effect Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- TTXMOJWKNRJWQJ-FXQIFTODSA-N Ala-Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N TTXMOJWKNRJWQJ-FXQIFTODSA-N 0.000 description 2
- NHCPCLJZRSIDHS-ZLUOBGJFSA-N Ala-Asp-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O NHCPCLJZRSIDHS-ZLUOBGJFSA-N 0.000 description 2
- OMMDTNGURYRDAC-NRPADANISA-N Ala-Glu-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OMMDTNGURYRDAC-NRPADANISA-N 0.000 description 2
- YCRAFFCYWOUEOF-DLOVCJGASA-N Ala-Phe-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 YCRAFFCYWOUEOF-DLOVCJGASA-N 0.000 description 2
- XKXAZPSREVUCRT-BPNCWPANSA-N Ala-Tyr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=C(O)C=C1 XKXAZPSREVUCRT-BPNCWPANSA-N 0.000 description 2
- VWVPYNGMOCSSGK-GUBZILKMSA-N Arg-Arg-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O VWVPYNGMOCSSGK-GUBZILKMSA-N 0.000 description 2
- FEZJJKXNPSEYEV-CIUDSAMLSA-N Arg-Gln-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O FEZJJKXNPSEYEV-CIUDSAMLSA-N 0.000 description 2
- HQIZDMIGUJOSNI-IUCAKERBSA-N Arg-Gly-Arg Chemical compound N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O HQIZDMIGUJOSNI-IUCAKERBSA-N 0.000 description 2
- ULBHWNVWSCJLCO-NHCYSSNCSA-N Arg-Val-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N ULBHWNVWSCJLCO-NHCYSSNCSA-N 0.000 description 2
- WOZDCBHUGJVJPL-AVGNSLFASA-N Arg-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N WOZDCBHUGJVJPL-AVGNSLFASA-N 0.000 description 2
- OLGCWMNDJTWQAG-GUBZILKMSA-N Asn-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(N)=O OLGCWMNDJTWQAG-GUBZILKMSA-N 0.000 description 2
- QUAWOKPCAKCHQL-SRVKXCTJSA-N Asn-His-Lys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N QUAWOKPCAKCHQL-SRVKXCTJSA-N 0.000 description 2
- XMHFCUKJRCQXGI-CIUDSAMLSA-N Asn-Pro-Gln Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC(=O)N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O XMHFCUKJRCQXGI-CIUDSAMLSA-N 0.000 description 2
- UZFHNLYQWMGUHU-DCAQKATOSA-N Asp-Lys-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UZFHNLYQWMGUHU-DCAQKATOSA-N 0.000 description 2
- DPNWSMBUYCLEDG-CIUDSAMLSA-N Asp-Lys-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O DPNWSMBUYCLEDG-CIUDSAMLSA-N 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- NDUSUIGBMZCOIL-ZKWXMUAHSA-N Cys-Asn-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)N NDUSUIGBMZCOIL-ZKWXMUAHSA-N 0.000 description 2
- OXOQBEVULIBOSH-ZDLURKLDSA-N Cys-Gly-Thr Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O OXOQBEVULIBOSH-ZDLURKLDSA-N 0.000 description 2
- OZHXXYOHPLLLMI-CIUDSAMLSA-N Cys-Lys-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OZHXXYOHPLLLMI-CIUDSAMLSA-N 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- KVYVOGYEMPEXBT-GUBZILKMSA-N Gln-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O KVYVOGYEMPEXBT-GUBZILKMSA-N 0.000 description 2
- TWHDOEYLXXQYOZ-FXQIFTODSA-N Gln-Asn-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N TWHDOEYLXXQYOZ-FXQIFTODSA-N 0.000 description 2
- AAOBFSKXAVIORT-GUBZILKMSA-N Gln-Asn-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O AAOBFSKXAVIORT-GUBZILKMSA-N 0.000 description 2
- FGYPOQPQTUNESW-IUCAKERBSA-N Gln-Gly-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)N FGYPOQPQTUNESW-IUCAKERBSA-N 0.000 description 2
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 2
- XFAUJGNLHIGXET-AVGNSLFASA-N Gln-Leu-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O XFAUJGNLHIGXET-AVGNSLFASA-N 0.000 description 2
- IOFDDSNZJDIGPB-GVXVVHGQSA-N Gln-Leu-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IOFDDSNZJDIGPB-GVXVVHGQSA-N 0.000 description 2
- JILRMFFFCHUUTJ-ACZMJKKPSA-N Gln-Ser-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O JILRMFFFCHUUTJ-ACZMJKKPSA-N 0.000 description 2
- VLOLPWWCNKWRNB-LOKLDPHHSA-N Gln-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O VLOLPWWCNKWRNB-LOKLDPHHSA-N 0.000 description 2
- OGMQXTXGLDNBSS-FXQIFTODSA-N Glu-Ala-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O OGMQXTXGLDNBSS-FXQIFTODSA-N 0.000 description 2
- KBKGRMNVKPSQIF-XDTLVQLUSA-N Glu-Ala-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KBKGRMNVKPSQIF-XDTLVQLUSA-N 0.000 description 2
- WATXSTJXNBOHKD-LAEOZQHASA-N Glu-Asp-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O WATXSTJXNBOHKD-LAEOZQHASA-N 0.000 description 2
- PABVKUJVLNMOJP-WHFBIAKZSA-N Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(O)=O PABVKUJVLNMOJP-WHFBIAKZSA-N 0.000 description 2
- BUAKRRKDHSSIKK-IHRRRGAJSA-N Glu-Glu-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BUAKRRKDHSSIKK-IHRRRGAJSA-N 0.000 description 2
- LRPXYSGPOBVBEH-IUCAKERBSA-N Glu-Gly-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O LRPXYSGPOBVBEH-IUCAKERBSA-N 0.000 description 2
- FBEJIDRSQCGFJI-GUBZILKMSA-N Glu-Leu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O FBEJIDRSQCGFJI-GUBZILKMSA-N 0.000 description 2
- BFEZQZKEPRKKHV-SRVKXCTJSA-N Glu-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H](CCCCN)C(=O)O BFEZQZKEPRKKHV-SRVKXCTJSA-N 0.000 description 2
- NNQDRRUXFJYCCJ-NHCYSSNCSA-N Glu-Pro-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O NNQDRRUXFJYCCJ-NHCYSSNCSA-N 0.000 description 2
- UPOJUWHGMDJUQZ-IUCAKERBSA-N Gly-Arg-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UPOJUWHGMDJUQZ-IUCAKERBSA-N 0.000 description 2
- IXKRSKPKSLXIHN-YUMQZZPRSA-N Gly-Cys-Leu Chemical compound [H]NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O IXKRSKPKSLXIHN-YUMQZZPRSA-N 0.000 description 2
- QPDUVFSVVAOUHE-XVKPBYJWSA-N Gly-Gln-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CN)C(O)=O QPDUVFSVVAOUHE-XVKPBYJWSA-N 0.000 description 2
- XTQFHTHIAKKCTM-YFKPBYRVSA-N Gly-Glu-Gly Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O XTQFHTHIAKKCTM-YFKPBYRVSA-N 0.000 description 2
- QITBQGJOXQYMOA-ZETCQYMHSA-N Gly-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CN QITBQGJOXQYMOA-ZETCQYMHSA-N 0.000 description 2
- VAXIVIPMCTYSHI-YUMQZZPRSA-N Gly-His-Asp Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN VAXIVIPMCTYSHI-YUMQZZPRSA-N 0.000 description 2
- ULZCYBYDTUMHNF-IUCAKERBSA-N Gly-Leu-Glu Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ULZCYBYDTUMHNF-IUCAKERBSA-N 0.000 description 2
- ZWRDOVYMQAAISL-UWVGGRQHSA-N Gly-Met-Lys Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CCCCN ZWRDOVYMQAAISL-UWVGGRQHSA-N 0.000 description 2
- OHUKZZYSJBKFRR-WHFBIAKZSA-N Gly-Ser-Asp Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O OHUKZZYSJBKFRR-WHFBIAKZSA-N 0.000 description 2
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 2
- IZVICCORZOSGPT-JSGCOSHPSA-N Gly-Val-Tyr Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IZVICCORZOSGPT-JSGCOSHPSA-N 0.000 description 2
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 2
- CWSZWFILCNSNEX-CIUDSAMLSA-N His-Ser-Asn Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)O)N CWSZWFILCNSNEX-CIUDSAMLSA-N 0.000 description 2
- ALPXXNRQBMRCPZ-MEYUZBJRSA-N His-Thr-Phe Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ALPXXNRQBMRCPZ-MEYUZBJRSA-N 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- 108010021699 I-kappa B Proteins Proteins 0.000 description 2
- 102000008379 I-kappa B Proteins Human genes 0.000 description 2
- QYOGJYIRKACXEP-SLBDDTMCSA-N Ile-Asn-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N QYOGJYIRKACXEP-SLBDDTMCSA-N 0.000 description 2
- LWWILHPVAKKLQS-QXEWZRGKSA-N Ile-Gly-Met Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CCSC)C(=O)O)N LWWILHPVAKKLQS-QXEWZRGKSA-N 0.000 description 2
- CNMOKANDJMLAIF-CIQUZCHMSA-N Ile-Thr-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O CNMOKANDJMLAIF-CIQUZCHMSA-N 0.000 description 2
- ZSESFIFAYQEKRD-CYDGBPFRSA-N Ile-Val-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(=O)O)N ZSESFIFAYQEKRD-CYDGBPFRSA-N 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 2
- JKGHDYGZRDWHGA-SRVKXCTJSA-N Leu-Asn-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JKGHDYGZRDWHGA-SRVKXCTJSA-N 0.000 description 2
- MMEDVBWCMGRKKC-GARJFASQSA-N Leu-Asp-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N MMEDVBWCMGRKKC-GARJFASQSA-N 0.000 description 2
- SYRTUBLKWNDSDK-DKIMLUQUSA-N Leu-Phe-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O SYRTUBLKWNDSDK-DKIMLUQUSA-N 0.000 description 2
- DRWMRVFCKKXHCH-BZSNNMDCSA-N Leu-Phe-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=CC=C1 DRWMRVFCKKXHCH-BZSNNMDCSA-N 0.000 description 2
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 2
- VUBIPAHVHMZHCM-KKUMJFAQSA-N Leu-Tyr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 VUBIPAHVHMZHCM-KKUMJFAQSA-N 0.000 description 2
- SEOXPEFQEOYURL-PMVMPFDFSA-N Leu-Tyr-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O SEOXPEFQEOYURL-PMVMPFDFSA-N 0.000 description 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 2
- PRSBSVAVOQOAMI-BJDJZHNGSA-N Lys-Ile-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN PRSBSVAVOQOAMI-BJDJZHNGSA-N 0.000 description 2
- PINHPJWGVBKQII-SRVKXCTJSA-N Lys-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCCN)N PINHPJWGVBKQII-SRVKXCTJSA-N 0.000 description 2
- YXPJCVNIDDKGOE-MELADBBJSA-N Lys-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N)C(=O)O YXPJCVNIDDKGOE-MELADBBJSA-N 0.000 description 2
- QQPSCXKFDSORFT-IHRRRGAJSA-N Lys-Lys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN QQPSCXKFDSORFT-IHRRRGAJSA-N 0.000 description 2
- YLLWCSDBVGZLOW-CIUDSAMLSA-N Met-Gln-Ala Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O YLLWCSDBVGZLOW-CIUDSAMLSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 2
- 108010079364 N-glycylalanine Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- CUMXHKAOHNWRFQ-BZSNNMDCSA-N Phe-Asp-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 CUMXHKAOHNWRFQ-BZSNNMDCSA-N 0.000 description 2
- YYKZDTVQHTUKDW-RYUDHWBXSA-N Phe-Gly-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)N YYKZDTVQHTUKDW-RYUDHWBXSA-N 0.000 description 2
- GXDPQJUBLBZKDY-IAVJCBSLSA-N Phe-Ile-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O GXDPQJUBLBZKDY-IAVJCBSLSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- XQLBWXHVZVBNJM-FXQIFTODSA-N Pro-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 XQLBWXHVZVBNJM-FXQIFTODSA-N 0.000 description 2
- LCRSGSIRKLXZMZ-BPNCWPANSA-N Pro-Ala-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LCRSGSIRKLXZMZ-BPNCWPANSA-N 0.000 description 2
- OOLOTUZJUBOMAX-GUBZILKMSA-N Pro-Ala-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O OOLOTUZJUBOMAX-GUBZILKMSA-N 0.000 description 2
- HMNSRTLZAJHSIK-YUMQZZPRSA-N Pro-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 HMNSRTLZAJHSIK-YUMQZZPRSA-N 0.000 description 2
- VYWNORHENYEQDW-YUMQZZPRSA-N Pro-Gly-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 VYWNORHENYEQDW-YUMQZZPRSA-N 0.000 description 2
- PRKWBYCXBBSLSK-GUBZILKMSA-N Pro-Ser-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O PRKWBYCXBBSLSK-GUBZILKMSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- LVVBAKCGXXUHFO-ZLUOBGJFSA-N Ser-Ala-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O LVVBAKCGXXUHFO-ZLUOBGJFSA-N 0.000 description 2
- QVOGDCQNGLBNCR-FXQIFTODSA-N Ser-Arg-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O QVOGDCQNGLBNCR-FXQIFTODSA-N 0.000 description 2
- FIDMVVBUOCMMJG-CIUDSAMLSA-N Ser-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO FIDMVVBUOCMMJG-CIUDSAMLSA-N 0.000 description 2
- BLPYXIXXCFVIIF-FXQIFTODSA-N Ser-Cys-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N)CN=C(N)N BLPYXIXXCFVIIF-FXQIFTODSA-N 0.000 description 2
- BRGQQXQKPUCUJQ-KBIXCLLPSA-N Ser-Glu-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BRGQQXQKPUCUJQ-KBIXCLLPSA-N 0.000 description 2
- OQPNSDWGAMFJNU-QWRGUYRKSA-N Ser-Gly-Tyr Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OQPNSDWGAMFJNU-QWRGUYRKSA-N 0.000 description 2
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 2
- XKFJENWJGHMDLI-QWRGUYRKSA-N Ser-Phe-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O XKFJENWJGHMDLI-QWRGUYRKSA-N 0.000 description 2
- OZPDGESCTGGNAD-CIUDSAMLSA-N Ser-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CO OZPDGESCTGGNAD-CIUDSAMLSA-N 0.000 description 2
- GSCVDSBEYVGMJQ-SRVKXCTJSA-N Ser-Tyr-Asp Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CO)N)O GSCVDSBEYVGMJQ-SRVKXCTJSA-N 0.000 description 2
- HSWXBJCBYSWBPT-GUBZILKMSA-N Ser-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(O)=O HSWXBJCBYSWBPT-GUBZILKMSA-N 0.000 description 2
- 102100037906 T-cell surface glycoprotein CD3 zeta chain Human genes 0.000 description 2
- 101710156660 T-cell surface glycoprotein CD3 zeta chain Proteins 0.000 description 2
- JLNMFGCJODTXDH-WEDXCCLWSA-N Thr-Lys-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O JLNMFGCJODTXDH-WEDXCCLWSA-N 0.000 description 2
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 2
- RVMNUBQWPVOUKH-HEIBUPTGSA-N Thr-Ser-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMNUBQWPVOUKH-HEIBUPTGSA-N 0.000 description 2
- LECUEEHKUFYOOV-ZJDVBMNYSA-N Thr-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](N)[C@@H](C)O LECUEEHKUFYOOV-ZJDVBMNYSA-N 0.000 description 2
- RPECVQBNONKZAT-WZLNRYEVSA-N Thr-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H]([C@@H](C)O)N RPECVQBNONKZAT-WZLNRYEVSA-N 0.000 description 2
- OGOYMQWIWHGTGH-KZVJFYERSA-N Thr-Val-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O OGOYMQWIWHGTGH-KZVJFYERSA-N 0.000 description 2
- QNXZCKMXHPULME-ZNSHCXBVSA-N Thr-Val-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O QNXZCKMXHPULME-ZNSHCXBVSA-N 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- RERRMBXDSFMBQE-ZFWWWQNUSA-N Trp-Met-Gly Chemical compound CSCC[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N RERRMBXDSFMBQE-ZFWWWQNUSA-N 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- IIJWXEUNETVJPV-IHRRRGAJSA-N Tyr-Arg-Ser Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N)O IIJWXEUNETVJPV-IHRRRGAJSA-N 0.000 description 2
- SMLCYZYQFRTLCO-UWJYBYFXSA-N Tyr-Cys-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O SMLCYZYQFRTLCO-UWJYBYFXSA-N 0.000 description 2
- RYSNTWVRSLCAJZ-RYUDHWBXSA-N Tyr-Gln-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RYSNTWVRSLCAJZ-RYUDHWBXSA-N 0.000 description 2
- DXUVJJRTVACXSO-KKUMJFAQSA-N Tyr-Gln-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)N DXUVJJRTVACXSO-KKUMJFAQSA-N 0.000 description 2
- CTDPLKMBVALCGN-JSGCOSHPSA-N Tyr-Gly-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O CTDPLKMBVALCGN-JSGCOSHPSA-N 0.000 description 2
- BSCBBPKDVOZICB-KKUMJFAQSA-N Tyr-Leu-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O BSCBBPKDVOZICB-KKUMJFAQSA-N 0.000 description 2
- NKUGCYDFQKFVOJ-JYJNAYRXSA-N Tyr-Leu-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NKUGCYDFQKFVOJ-JYJNAYRXSA-N 0.000 description 2
- KHCSOLAHNLOXJR-BZSNNMDCSA-N Tyr-Leu-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KHCSOLAHNLOXJR-BZSNNMDCSA-N 0.000 description 2
- WURLIFOWSMBUAR-SLFFLAALSA-N Tyr-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)C(=O)O WURLIFOWSMBUAR-SLFFLAALSA-N 0.000 description 2
- KTEZUXISLQTDDQ-NHCYSSNCSA-N Val-Lys-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)O)N KTEZUXISLQTDDQ-NHCYSSNCSA-N 0.000 description 2
- DIOSYUIWOQCXNR-ONGXEEELSA-N Val-Lys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O DIOSYUIWOQCXNR-ONGXEEELSA-N 0.000 description 2
- HPANGHISDXDUQY-ULQDDVLXSA-N Val-Lys-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N HPANGHISDXDUQY-ULQDDVLXSA-N 0.000 description 2
- VPGCVZRRBYOGCD-AVGNSLFASA-N Val-Lys-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O VPGCVZRRBYOGCD-AVGNSLFASA-N 0.000 description 2
- ZXYPHBKIZLAQTL-QXEWZRGKSA-N Val-Pro-Asp Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N ZXYPHBKIZLAQTL-QXEWZRGKSA-N 0.000 description 2
- JAIZPWVHPQRYOU-ZJDVBMNYSA-N Val-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O JAIZPWVHPQRYOU-ZJDVBMNYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 108010011559 alanylphenylalanine Proteins 0.000 description 2
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 2
- 108091005948 blue fluorescent proteins Proteins 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- LIYGYAHYXQDGEP-UHFFFAOYSA-N firefly oxyluciferin Natural products Oc1csc(n1)-c1nc2ccc(O)cc2s1 LIYGYAHYXQDGEP-UHFFFAOYSA-N 0.000 description 2
- 108010049041 glutamylalanine Proteins 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 108010010147 glycylglutamine Proteins 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108010056582 methionylglutamic acid Proteins 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- JJVOROULKOMTKG-UHFFFAOYSA-N oxidized Photinus luciferin Chemical compound S1C2=CC(O)=CC=C2N=C1C1=NC(=O)CS1 JJVOROULKOMTKG-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940005657 pyrophosphoric acid Drugs 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- 229910052594 sapphire Inorganic materials 0.000 description 2
- 239000010980 sapphire Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 108010026333 seryl-proline Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 108010051110 tyrosyl-lysine Proteins 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XVZCXCTYGHPNEM-IHRRRGAJSA-N (2s)-1-[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O XVZCXCTYGHPNEM-IHRRRGAJSA-N 0.000 description 1
- CEHZCZCQHUNAJF-AVGNSLFASA-N (2s)-1-[2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(O)=O)CCC1 CEHZCZCQHUNAJF-AVGNSLFASA-N 0.000 description 1
- BRPMXFSTKXXNHF-IUCAKERBSA-N (2s)-1-[2-[[(2s)-pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H]1NCCC1 BRPMXFSTKXXNHF-IUCAKERBSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- JBGSZRYCXBPWGX-BQBZGAKWSA-N Ala-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N JBGSZRYCXBPWGX-BQBZGAKWSA-N 0.000 description 1
- LSLIRHLIUDVNBN-CIUDSAMLSA-N Ala-Asp-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN LSLIRHLIUDVNBN-CIUDSAMLSA-N 0.000 description 1
- BTYTYHBSJKQBQA-GCJQMDKQSA-N Ala-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)N)O BTYTYHBSJKQBQA-GCJQMDKQSA-N 0.000 description 1
- LGFCAXJBAZESCF-ACZMJKKPSA-N Ala-Gln-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O LGFCAXJBAZESCF-ACZMJKKPSA-N 0.000 description 1
- CSAHOYQKNHGDHX-ACZMJKKPSA-N Ala-Gln-Asn Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CSAHOYQKNHGDHX-ACZMJKKPSA-N 0.000 description 1
- FUSPCLTUKXQREV-ACZMJKKPSA-N Ala-Glu-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O FUSPCLTUKXQREV-ACZMJKKPSA-N 0.000 description 1
- TZDNWXDLYFIFPT-BJDJZHNGSA-N Ala-Ile-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O TZDNWXDLYFIFPT-BJDJZHNGSA-N 0.000 description 1
- SUMYEVXWCAYLLJ-GUBZILKMSA-N Ala-Leu-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O SUMYEVXWCAYLLJ-GUBZILKMSA-N 0.000 description 1
- DPNZTBKGAUAZQU-DLOVCJGASA-N Ala-Leu-His Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N DPNZTBKGAUAZQU-DLOVCJGASA-N 0.000 description 1
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 1
- SOBIAADAMRHGKH-CIUDSAMLSA-N Ala-Leu-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SOBIAADAMRHGKH-CIUDSAMLSA-N 0.000 description 1
- UWIQWPWWZUHBAO-ZLIFDBKOSA-N Ala-Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)N)CC(C)C)C(O)=O)=CNC2=C1 UWIQWPWWZUHBAO-ZLIFDBKOSA-N 0.000 description 1
- MFMDKJIPHSWSBM-GUBZILKMSA-N Ala-Lys-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O MFMDKJIPHSWSBM-GUBZILKMSA-N 0.000 description 1
- DEWWPUNXRNGMQN-LPEHRKFASA-N Ala-Met-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@@H]1C(=O)O)N DEWWPUNXRNGMQN-LPEHRKFASA-N 0.000 description 1
- YHBDGLZYNIARKJ-GUBZILKMSA-N Ala-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N YHBDGLZYNIARKJ-GUBZILKMSA-N 0.000 description 1
- WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 description 1
- ISCYZXFOCXWUJU-KZVJFYERSA-N Ala-Thr-Met Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(O)=O ISCYZXFOCXWUJU-KZVJFYERSA-N 0.000 description 1
- BHFOJPDOQPWJRN-XDTLVQLUSA-N Ala-Tyr-Gln Chemical compound C[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCC(N)=O)C(O)=O BHFOJPDOQPWJRN-XDTLVQLUSA-N 0.000 description 1
- ZDILXFDENZVOTL-BPNCWPANSA-N Ala-Val-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZDILXFDENZVOTL-BPNCWPANSA-N 0.000 description 1
- 101100424688 Arabidopsis thaliana ESK1 gene Proteins 0.000 description 1
- SGYSTDWPNPKJPP-GUBZILKMSA-N Arg-Ala-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SGYSTDWPNPKJPP-GUBZILKMSA-N 0.000 description 1
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 1
- VBFJESQBIWCWRL-DCAQKATOSA-N Arg-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VBFJESQBIWCWRL-DCAQKATOSA-N 0.000 description 1
- GIVATXIGCXFQQA-FXQIFTODSA-N Arg-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N GIVATXIGCXFQQA-FXQIFTODSA-N 0.000 description 1
- UXJCMQFPDWCHKX-DCAQKATOSA-N Arg-Arg-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O UXJCMQFPDWCHKX-DCAQKATOSA-N 0.000 description 1
- OVVUNXXROOFSIM-SDDRHHMPSA-N Arg-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O OVVUNXXROOFSIM-SDDRHHMPSA-N 0.000 description 1
- YFBGNGASPGRWEM-DCAQKATOSA-N Arg-Asp-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N YFBGNGASPGRWEM-DCAQKATOSA-N 0.000 description 1
- SKTGPBFTMNLIHQ-KKUMJFAQSA-N Arg-Glu-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SKTGPBFTMNLIHQ-KKUMJFAQSA-N 0.000 description 1
- WVNFNPGXYADPPO-BQBZGAKWSA-N Arg-Gly-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O WVNFNPGXYADPPO-BQBZGAKWSA-N 0.000 description 1
- NVUIWHJLPSZZQC-CYDGBPFRSA-N Arg-Ile-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NVUIWHJLPSZZQC-CYDGBPFRSA-N 0.000 description 1
- AGVNTAUPLWIQEN-ZPFDUUQYSA-N Arg-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AGVNTAUPLWIQEN-ZPFDUUQYSA-N 0.000 description 1
- FRBAHXABMQXSJQ-FXQIFTODSA-N Arg-Ser-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O FRBAHXABMQXSJQ-FXQIFTODSA-N 0.000 description 1
- BECXEHHOZNFFFX-IHRRRGAJSA-N Arg-Ser-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BECXEHHOZNFFFX-IHRRRGAJSA-N 0.000 description 1
- QHUOOCKNNURZSL-IHRRRGAJSA-N Arg-Tyr-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O QHUOOCKNNURZSL-IHRRRGAJSA-N 0.000 description 1
- JJGRJMKUOYXZRA-LPEHRKFASA-N Asn-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)N)N)C(=O)O JJGRJMKUOYXZRA-LPEHRKFASA-N 0.000 description 1
- BVLIJXXSXBUGEC-SRVKXCTJSA-N Asn-Asn-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BVLIJXXSXBUGEC-SRVKXCTJSA-N 0.000 description 1
- PPMTUXJSQDNUDE-CIUDSAMLSA-N Asn-Glu-Arg Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PPMTUXJSQDNUDE-CIUDSAMLSA-N 0.000 description 1
- GFFRWIJAFFMQGM-NUMRIWBASA-N Asn-Glu-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GFFRWIJAFFMQGM-NUMRIWBASA-N 0.000 description 1
- DXVMJJNAOVECBA-WHFBIAKZSA-N Asn-Gly-Asn Chemical compound NC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O DXVMJJNAOVECBA-WHFBIAKZSA-N 0.000 description 1
- GWNMUVANAWDZTI-YUMQZZPRSA-N Asn-Gly-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N GWNMUVANAWDZTI-YUMQZZPRSA-N 0.000 description 1
- RAQMSGVCGSJKCL-FOHZUACHSA-N Asn-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(N)=O RAQMSGVCGSJKCL-FOHZUACHSA-N 0.000 description 1
- SUEIIIFUBHDCCS-PBCZWWQYSA-N Asn-His-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SUEIIIFUBHDCCS-PBCZWWQYSA-N 0.000 description 1
- XVBDDUPJVQXDSI-PEFMBERDSA-N Asn-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N XVBDDUPJVQXDSI-PEFMBERDSA-N 0.000 description 1
- GQRDIVQPSMPQME-ZPFDUUQYSA-N Asn-Ile-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O GQRDIVQPSMPQME-ZPFDUUQYSA-N 0.000 description 1
- HDHZCEDPLTVHFZ-GUBZILKMSA-N Asn-Leu-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O HDHZCEDPLTVHFZ-GUBZILKMSA-N 0.000 description 1
- JEEFEQCRXKPQHC-KKUMJFAQSA-N Asn-Leu-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JEEFEQCRXKPQHC-KKUMJFAQSA-N 0.000 description 1
- JWKDQOORUCYUIW-ZPFDUUQYSA-N Asn-Lys-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JWKDQOORUCYUIW-ZPFDUUQYSA-N 0.000 description 1
- RVHGJNGNKGDCPX-KKUMJFAQSA-N Asn-Phe-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N RVHGJNGNKGDCPX-KKUMJFAQSA-N 0.000 description 1
- VWADICJNCPFKJS-ZLUOBGJFSA-N Asn-Ser-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O VWADICJNCPFKJS-ZLUOBGJFSA-N 0.000 description 1
- WLVLIYYBPPONRJ-GCJQMDKQSA-N Asn-Thr-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O WLVLIYYBPPONRJ-GCJQMDKQSA-N 0.000 description 1
- RTFXPCYMDYBZNQ-SRVKXCTJSA-N Asn-Tyr-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O RTFXPCYMDYBZNQ-SRVKXCTJSA-N 0.000 description 1
- DPWDPEVGACCWTC-SRVKXCTJSA-N Asn-Tyr-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O DPWDPEVGACCWTC-SRVKXCTJSA-N 0.000 description 1
- MJIJBEYEHBKTIM-BYULHYEWSA-N Asn-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N MJIJBEYEHBKTIM-BYULHYEWSA-N 0.000 description 1
- KBQOUDLMWYWXNP-YDHLFZDLSA-N Asn-Val-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC(=O)N)N KBQOUDLMWYWXNP-YDHLFZDLSA-N 0.000 description 1
- KVMPVNGOKHTUHZ-GCJQMDKQSA-N Asp-Ala-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KVMPVNGOKHTUHZ-GCJQMDKQSA-N 0.000 description 1
- YNQIDCRRTWGHJD-ZLUOBGJFSA-N Asp-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(O)=O YNQIDCRRTWGHJD-ZLUOBGJFSA-N 0.000 description 1
- VBVKSAFJPVXMFJ-CIUDSAMLSA-N Asp-Asn-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)N VBVKSAFJPVXMFJ-CIUDSAMLSA-N 0.000 description 1
- VAWNQIGQPUOPQW-ACZMJKKPSA-N Asp-Glu-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O VAWNQIGQPUOPQW-ACZMJKKPSA-N 0.000 description 1
- PDECQIHABNQRHN-GUBZILKMSA-N Asp-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O PDECQIHABNQRHN-GUBZILKMSA-N 0.000 description 1
- JUWZKMBALYLZCK-WHFBIAKZSA-N Asp-Gly-Asn Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O JUWZKMBALYLZCK-WHFBIAKZSA-N 0.000 description 1
- QCVXMEHGFUMKCO-YUMQZZPRSA-N Asp-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O QCVXMEHGFUMKCO-YUMQZZPRSA-N 0.000 description 1
- PZXPWHFYZXTFBI-YUMQZZPRSA-N Asp-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PZXPWHFYZXTFBI-YUMQZZPRSA-N 0.000 description 1
- POTCZYQVVNXUIG-BQBZGAKWSA-N Asp-Gly-Pro Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O POTCZYQVVNXUIG-BQBZGAKWSA-N 0.000 description 1
- SNDBKTFJWVEVPO-WHFBIAKZSA-N Asp-Gly-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SNDBKTFJWVEVPO-WHFBIAKZSA-N 0.000 description 1
- SWTQDYFZVOJVLL-KKUMJFAQSA-N Asp-His-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(=O)O)N)O SWTQDYFZVOJVLL-KKUMJFAQSA-N 0.000 description 1
- RTXQQDVBACBSCW-CFMVVWHZSA-N Asp-Ile-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O RTXQQDVBACBSCW-CFMVVWHZSA-N 0.000 description 1
- FQHBAQLBIXLWAG-DCAQKATOSA-N Asp-Lys-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N FQHBAQLBIXLWAG-DCAQKATOSA-N 0.000 description 1
- GYWQGGUCMDCUJE-DLOVCJGASA-N Asp-Phe-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(O)=O GYWQGGUCMDCUJE-DLOVCJGASA-N 0.000 description 1
- WOPJVEMFXYHZEE-SRVKXCTJSA-N Asp-Phe-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O WOPJVEMFXYHZEE-SRVKXCTJSA-N 0.000 description 1
- JUWISGAGWSDGDH-KKUMJFAQSA-N Asp-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=CC=C1 JUWISGAGWSDGDH-KKUMJFAQSA-N 0.000 description 1
- KPSHWSWFPUDEGF-FXQIFTODSA-N Asp-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(O)=O KPSHWSWFPUDEGF-FXQIFTODSA-N 0.000 description 1
- XXAMCEGRCZQGEM-ZLUOBGJFSA-N Asp-Ser-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O XXAMCEGRCZQGEM-ZLUOBGJFSA-N 0.000 description 1
- BPAUXFVCSYQDQX-JRQIVUDYSA-N Asp-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC(=O)O)N)O BPAUXFVCSYQDQX-JRQIVUDYSA-N 0.000 description 1
- ALMIMUZAWTUNIO-BZSNNMDCSA-N Asp-Tyr-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ALMIMUZAWTUNIO-BZSNNMDCSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 101100391416 Chloroflexus aggregans (strain MD-66 / DSM 9485) ftsH gene Proteins 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- CPTUXCUWQIBZIF-ZLUOBGJFSA-N Cys-Asn-Ser Chemical compound SC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O CPTUXCUWQIBZIF-ZLUOBGJFSA-N 0.000 description 1
- VZKXOWRNJDEGLZ-WHFBIAKZSA-N Cys-Asp-Gly Chemical compound SC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O VZKXOWRNJDEGLZ-WHFBIAKZSA-N 0.000 description 1
- GUKYYUFHWYRMEU-WHFBIAKZSA-N Cys-Gly-Asp Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O GUKYYUFHWYRMEU-WHFBIAKZSA-N 0.000 description 1
- CUXIOFHFFXNUGG-HTFCKZLJSA-N Cys-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H](CS)N CUXIOFHFFXNUGG-HTFCKZLJSA-N 0.000 description 1
- YXPNKXFOBHRUBL-BJDJZHNGSA-N Cys-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N YXPNKXFOBHRUBL-BJDJZHNGSA-N 0.000 description 1
- SWJYSDXMTPMBHO-FXQIFTODSA-N Cys-Pro-Ser Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SWJYSDXMTPMBHO-FXQIFTODSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- NNQHEEQNPQYPGL-FXQIFTODSA-N Gln-Ala-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O NNQHEEQNPQYPGL-FXQIFTODSA-N 0.000 description 1
- NKCZYEDZTKOFBG-GUBZILKMSA-N Gln-Gln-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NKCZYEDZTKOFBG-GUBZILKMSA-N 0.000 description 1
- CITDWMLWXNUQKD-FXQIFTODSA-N Gln-Gln-Asn Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N CITDWMLWXNUQKD-FXQIFTODSA-N 0.000 description 1
- NVEASDQHBRZPSU-BQBZGAKWSA-N Gln-Gln-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O NVEASDQHBRZPSU-BQBZGAKWSA-N 0.000 description 1
- KVXVVDFOZNYYKZ-DCAQKATOSA-N Gln-Gln-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O KVXVVDFOZNYYKZ-DCAQKATOSA-N 0.000 description 1
- MADFVRSKEIEZHZ-DCAQKATOSA-N Gln-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N MADFVRSKEIEZHZ-DCAQKATOSA-N 0.000 description 1
- KCJJFESQRXGTGC-BQBZGAKWSA-N Gln-Glu-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O KCJJFESQRXGTGC-BQBZGAKWSA-N 0.000 description 1
- NSNUZSPSADIMJQ-WDSKDSINSA-N Gln-Gly-Asp Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O NSNUZSPSADIMJQ-WDSKDSINSA-N 0.000 description 1
- HYPVLWGNBIYTNA-GUBZILKMSA-N Gln-Leu-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O HYPVLWGNBIYTNA-GUBZILKMSA-N 0.000 description 1
- JNENSVNAUWONEZ-GUBZILKMSA-N Gln-Lys-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O JNENSVNAUWONEZ-GUBZILKMSA-N 0.000 description 1
- UESYBOXFJWJVSB-AVGNSLFASA-N Gln-Phe-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O UESYBOXFJWJVSB-AVGNSLFASA-N 0.000 description 1
- WLRYGVYQFXRJDA-DCAQKATOSA-N Gln-Pro-Pro Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 WLRYGVYQFXRJDA-DCAQKATOSA-N 0.000 description 1
- VOUSELYGTNGEPB-NUMRIWBASA-N Gln-Thr-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O VOUSELYGTNGEPB-NUMRIWBASA-N 0.000 description 1
- WIMVKDYAKRAUCG-IHRRRGAJSA-N Gln-Tyr-Glu Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O WIMVKDYAKRAUCG-IHRRRGAJSA-N 0.000 description 1
- UBRQJXFDVZNYJP-AVGNSLFASA-N Gln-Tyr-Ser Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O UBRQJXFDVZNYJP-AVGNSLFASA-N 0.000 description 1
- HPBKQFJXDUVNQV-FHWLQOOXSA-N Gln-Tyr-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O HPBKQFJXDUVNQV-FHWLQOOXSA-N 0.000 description 1
- CSMHMEATMDCQNY-DZKIICNBSA-N Gln-Val-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CSMHMEATMDCQNY-DZKIICNBSA-N 0.000 description 1
- XMPAXPSENRSOSV-RYUDHWBXSA-N Glu-Gly-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XMPAXPSENRSOSV-RYUDHWBXSA-N 0.000 description 1
- XTZDZAXYPDISRR-MNXVOIDGSA-N Glu-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N XTZDZAXYPDISRR-MNXVOIDGSA-N 0.000 description 1
- PJBVXVBTTFZPHJ-GUBZILKMSA-N Glu-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)N PJBVXVBTTFZPHJ-GUBZILKMSA-N 0.000 description 1
- UGSVSNXPJJDJKL-SDDRHHMPSA-N Glu-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N UGSVSNXPJJDJKL-SDDRHHMPSA-N 0.000 description 1
- HRBYTAIBKPNZKQ-AVGNSLFASA-N Glu-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O HRBYTAIBKPNZKQ-AVGNSLFASA-N 0.000 description 1
- UERORLSAFUHDGU-AVGNSLFASA-N Glu-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N UERORLSAFUHDGU-AVGNSLFASA-N 0.000 description 1
- CHDWDBPJOZVZSE-KKUMJFAQSA-N Glu-Phe-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(O)=O CHDWDBPJOZVZSE-KKUMJFAQSA-N 0.000 description 1
- KCCNSVHJSMMGFS-NRPADANISA-N Glu-Val-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N KCCNSVHJSMMGFS-NRPADANISA-N 0.000 description 1
- QXUPRMQJDWJDFR-NRPADANISA-N Glu-Val-Ser Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O QXUPRMQJDWJDFR-NRPADANISA-N 0.000 description 1
- JVACNFOPSUPDTK-QWRGUYRKSA-N Gly-Asn-Phe Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JVACNFOPSUPDTK-QWRGUYRKSA-N 0.000 description 1
- TZOVVRJYUDETQG-RCOVLWMOSA-N Gly-Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CN TZOVVRJYUDETQG-RCOVLWMOSA-N 0.000 description 1
- SOEATRRYCIPEHA-BQBZGAKWSA-N Gly-Glu-Glu Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SOEATRRYCIPEHA-BQBZGAKWSA-N 0.000 description 1
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 1
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 1
- YTSVAIMKVLZUDU-YUMQZZPRSA-N Gly-Leu-Asp Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YTSVAIMKVLZUDU-YUMQZZPRSA-N 0.000 description 1
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 1
- BXICSAQLIHFDDL-YUMQZZPRSA-N Gly-Lys-Asn Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O BXICSAQLIHFDDL-YUMQZZPRSA-N 0.000 description 1
- GAFKBWKVXNERFA-QWRGUYRKSA-N Gly-Phe-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 GAFKBWKVXNERFA-QWRGUYRKSA-N 0.000 description 1
- JSLVAHYTAJJEQH-QWRGUYRKSA-N Gly-Ser-Phe Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JSLVAHYTAJJEQH-QWRGUYRKSA-N 0.000 description 1
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 1
- FKESCSGWBPUTPN-FOHZUACHSA-N Gly-Thr-Asn Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O FKESCSGWBPUTPN-FOHZUACHSA-N 0.000 description 1
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 1
- TVTZEOHWHUVYCG-KYNKHSRBSA-N Gly-Thr-Thr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O TVTZEOHWHUVYCG-KYNKHSRBSA-N 0.000 description 1
- ONSARSFSJHTMFJ-STQMWFEESA-N Gly-Trp-Ser Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CO)C(O)=O ONSARSFSJHTMFJ-STQMWFEESA-N 0.000 description 1
- KOYUSMBPJOVSOO-XEGUGMAKSA-N Gly-Tyr-Ile Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KOYUSMBPJOVSOO-XEGUGMAKSA-N 0.000 description 1
- FULZDMOZUZKGQU-ONGXEEELSA-N Gly-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)CN FULZDMOZUZKGQU-ONGXEEELSA-N 0.000 description 1
- KSOBNUBCYHGUKH-UWVGGRQHSA-N Gly-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN KSOBNUBCYHGUKH-UWVGGRQHSA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- MDBYBTWRMOAJAY-NHCYSSNCSA-N His-Asn-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CN=CN1)N MDBYBTWRMOAJAY-NHCYSSNCSA-N 0.000 description 1
- WGVPDSNCHDEDBP-KKUMJFAQSA-N His-Asp-Phe Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O WGVPDSNCHDEDBP-KKUMJFAQSA-N 0.000 description 1
- VBOFRJNDIOPNDO-YUMQZZPRSA-N His-Gly-Asn Chemical compound C1=C(NC=N1)C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)O)N VBOFRJNDIOPNDO-YUMQZZPRSA-N 0.000 description 1
- QMUHTRISZMFKAY-MXAVVETBSA-N His-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N QMUHTRISZMFKAY-MXAVVETBSA-N 0.000 description 1
- TTYKEFZRLKQTHH-MELADBBJSA-N His-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CN=CN2)N)C(=O)O TTYKEFZRLKQTHH-MELADBBJSA-N 0.000 description 1
- YYOCMTFVGKDNQP-IHRRRGAJSA-N His-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N YYOCMTFVGKDNQP-IHRRRGAJSA-N 0.000 description 1
- WSWAUVHXQREQQG-JYJNAYRXSA-N His-Tyr-Gln Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O WSWAUVHXQREQQG-JYJNAYRXSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 description 1
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 description 1
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 description 1
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 description 1
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 description 1
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 1
- 101000829725 Homo sapiens Phospholipid hydroperoxide glutathione peroxidase Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 101001056234 Homo sapiens Sperm mitochondrial-associated cysteine-rich protein Proteins 0.000 description 1
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 102000001284 I-kappa-B kinase Human genes 0.000 description 1
- 108060006678 I-kappa-B kinase Proteins 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- LVQDUPQUJZWKSU-PYJNHQTQSA-N Ile-Arg-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N LVQDUPQUJZWKSU-PYJNHQTQSA-N 0.000 description 1
- HDODQNPMSHDXJT-GHCJXIJMSA-N Ile-Asn-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O HDODQNPMSHDXJT-GHCJXIJMSA-N 0.000 description 1
- LPXHYGGZJOCAFR-MNXVOIDGSA-N Ile-Glu-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N LPXHYGGZJOCAFR-MNXVOIDGSA-N 0.000 description 1
- HUWYGQOISIJNMK-SIGLWIIPSA-N Ile-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N HUWYGQOISIJNMK-SIGLWIIPSA-N 0.000 description 1
- AXNGDPAKKCEKGY-QPHKQPEJSA-N Ile-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N AXNGDPAKKCEKGY-QPHKQPEJSA-N 0.000 description 1
- PHRWFSFCNJPWRO-PPCPHDFISA-N Ile-Leu-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N PHRWFSFCNJPWRO-PPCPHDFISA-N 0.000 description 1
- PARSHQDZROHERM-NHCYSSNCSA-N Ile-Lys-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)O)N PARSHQDZROHERM-NHCYSSNCSA-N 0.000 description 1
- UDBPXJNOEWDBDF-XUXIUFHCSA-N Ile-Lys-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)O)N UDBPXJNOEWDBDF-XUXIUFHCSA-N 0.000 description 1
- RKQAYOWLSFLJEE-SVSWQMSJSA-N Ile-Thr-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)O)N RKQAYOWLSFLJEE-SVSWQMSJSA-N 0.000 description 1
- YBKKLDBBPFIXBQ-MBLNEYKQSA-N Ile-Thr-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)O)N YBKKLDBBPFIXBQ-MBLNEYKQSA-N 0.000 description 1
- WXLYNEHOGRYNFU-URLPEUOOSA-N Ile-Thr-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N WXLYNEHOGRYNFU-URLPEUOOSA-N 0.000 description 1
- DZMWFIRHFFVBHS-ZEWNOJEFSA-N Ile-Tyr-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)N DZMWFIRHFFVBHS-ZEWNOJEFSA-N 0.000 description 1
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 description 1
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- QLQHWWCSCLZUMA-KKUMJFAQSA-N Leu-Asp-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QLQHWWCSCLZUMA-KKUMJFAQSA-N 0.000 description 1
- LJKJVTCIRDCITR-SRVKXCTJSA-N Leu-Cys-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N LJKJVTCIRDCITR-SRVKXCTJSA-N 0.000 description 1
- ZYLJULGXQDNXDK-GUBZILKMSA-N Leu-Gln-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ZYLJULGXQDNXDK-GUBZILKMSA-N 0.000 description 1
- ZTLGVASZOIKNIX-DCAQKATOSA-N Leu-Gln-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZTLGVASZOIKNIX-DCAQKATOSA-N 0.000 description 1
- LAGPXKYZCCTSGQ-JYJNAYRXSA-N Leu-Glu-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LAGPXKYZCCTSGQ-JYJNAYRXSA-N 0.000 description 1
- LLBQJYDYOLIQAI-JYJNAYRXSA-N Leu-Glu-Tyr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LLBQJYDYOLIQAI-JYJNAYRXSA-N 0.000 description 1
- FMEICTQWUKNAGC-YUMQZZPRSA-N Leu-Gly-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O FMEICTQWUKNAGC-YUMQZZPRSA-N 0.000 description 1
- QPXBPQUGXHURGP-UWVGGRQHSA-N Leu-Gly-Met Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CCSC)C(=O)O)N QPXBPQUGXHURGP-UWVGGRQHSA-N 0.000 description 1
- KVOFSTUWVSQMDK-KKUMJFAQSA-N Leu-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)CC1=CN=CN1 KVOFSTUWVSQMDK-KKUMJFAQSA-N 0.000 description 1
- SGIIOQQGLUUMDQ-IHRRRGAJSA-N Leu-His-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N SGIIOQQGLUUMDQ-IHRRRGAJSA-N 0.000 description 1
- JNDYEOUZBLOVOF-AVGNSLFASA-N Leu-Leu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O JNDYEOUZBLOVOF-AVGNSLFASA-N 0.000 description 1
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 1
- IEWBEPKLKUXQBU-VOAKCMCISA-N Leu-Leu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IEWBEPKLKUXQBU-VOAKCMCISA-N 0.000 description 1
- LVTJJOJKDCVZGP-QWRGUYRKSA-N Leu-Lys-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O LVTJJOJKDCVZGP-QWRGUYRKSA-N 0.000 description 1
- PTRKPHUGYULXPU-KKUMJFAQSA-N Leu-Phe-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O PTRKPHUGYULXPU-KKUMJFAQSA-N 0.000 description 1
- YWKNKRAKOCLOLH-OEAJRASXSA-N Leu-Phe-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=CC=C1 YWKNKRAKOCLOLH-OEAJRASXSA-N 0.000 description 1
- UCXQIIIFOOGYEM-ULQDDVLXSA-N Leu-Pro-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 UCXQIIIFOOGYEM-ULQDDVLXSA-N 0.000 description 1
- XGDCYUQSFDQISZ-BQBZGAKWSA-N Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O XGDCYUQSFDQISZ-BQBZGAKWSA-N 0.000 description 1
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 1
- ZDJQVSIPFLMNOX-RHYQMDGZSA-N Leu-Thr-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N ZDJQVSIPFLMNOX-RHYQMDGZSA-N 0.000 description 1
- LINKCQUOMUDLKN-KATARQTJSA-N Leu-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)N)O LINKCQUOMUDLKN-KATARQTJSA-N 0.000 description 1
- LCNASHSOFMRYFO-WDCWCFNPSA-N Leu-Thr-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O LCNASHSOFMRYFO-WDCWCFNPSA-N 0.000 description 1
- QWWPYKKLXWOITQ-VOAKCMCISA-N Leu-Thr-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(C)C QWWPYKKLXWOITQ-VOAKCMCISA-N 0.000 description 1
- YWFZWQKWNDOWPA-XIRDDKMYSA-N Leu-Trp-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(O)=O YWFZWQKWNDOWPA-XIRDDKMYSA-N 0.000 description 1
- HQBOMRTVKVKFMN-WDSOQIARSA-N Leu-Trp-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C(C)C)C(O)=O HQBOMRTVKVKFMN-WDSOQIARSA-N 0.000 description 1
- JGKHAFUAPZCCDU-BZSNNMDCSA-N Leu-Tyr-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=C(O)C=C1 JGKHAFUAPZCCDU-BZSNNMDCSA-N 0.000 description 1
- XZNJZXJZBMBGGS-NHCYSSNCSA-N Leu-Val-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O XZNJZXJZBMBGGS-NHCYSSNCSA-N 0.000 description 1
- FMFNIDICDKEMOE-XUXIUFHCSA-N Leu-Val-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FMFNIDICDKEMOE-XUXIUFHCSA-N 0.000 description 1
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 description 1
- WXJKFRMKJORORD-DCAQKATOSA-N Lys-Arg-Ala Chemical compound NC(=N)NCCC[C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CCCCN WXJKFRMKJORORD-DCAQKATOSA-N 0.000 description 1
- NQCJGQHHYZNUDK-DCAQKATOSA-N Lys-Arg-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CCCN=C(N)N NQCJGQHHYZNUDK-DCAQKATOSA-N 0.000 description 1
- NCTDKZKNBDZDOL-GARJFASQSA-N Lys-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N)C(=O)O NCTDKZKNBDZDOL-GARJFASQSA-N 0.000 description 1
- YEIYAQQKADPIBJ-GARJFASQSA-N Lys-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)N)C(=O)O YEIYAQQKADPIBJ-GARJFASQSA-N 0.000 description 1
- NTBFKPBULZGXQL-KKUMJFAQSA-N Lys-Asp-Tyr Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NTBFKPBULZGXQL-KKUMJFAQSA-N 0.000 description 1
- UETQMSASAVBGJY-QWRGUYRKSA-N Lys-Gly-His Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 UETQMSASAVBGJY-QWRGUYRKSA-N 0.000 description 1
- RFQATBGBLDAKGI-VHSXEESVSA-N Lys-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCCN)N)C(=O)O RFQATBGBLDAKGI-VHSXEESVSA-N 0.000 description 1
- HAUUXTXKJNVIFY-ONGXEEELSA-N Lys-Gly-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HAUUXTXKJNVIFY-ONGXEEELSA-N 0.000 description 1
- OWRUUFUVXFREBD-KKUMJFAQSA-N Lys-His-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O OWRUUFUVXFREBD-KKUMJFAQSA-N 0.000 description 1
- QBEPTBMRQALPEV-MNXVOIDGSA-N Lys-Ile-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN QBEPTBMRQALPEV-MNXVOIDGSA-N 0.000 description 1
- ZXFRGTAIIZHNHG-AJNGGQMLSA-N Lys-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCCCN)N ZXFRGTAIIZHNHG-AJNGGQMLSA-N 0.000 description 1
- YPLVCBKEPJPBDQ-MELADBBJSA-N Lys-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N YPLVCBKEPJPBDQ-MELADBBJSA-N 0.000 description 1
- WRODMZBHNNPRLN-SRVKXCTJSA-N Lys-Leu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O WRODMZBHNNPRLN-SRVKXCTJSA-N 0.000 description 1
- OIQSIMFSVLLWBX-VOAKCMCISA-N Lys-Leu-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OIQSIMFSVLLWBX-VOAKCMCISA-N 0.000 description 1
- ZJSZPXISKMDJKQ-JYJNAYRXSA-N Lys-Phe-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(O)=O)CC1=CC=CC=C1 ZJSZPXISKMDJKQ-JYJNAYRXSA-N 0.000 description 1
- LMGNWHDWJDIOPK-DKIMLUQUSA-N Lys-Phe-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LMGNWHDWJDIOPK-DKIMLUQUSA-N 0.000 description 1
- MIROMRNASYKZNL-ULQDDVLXSA-N Lys-Pro-Tyr Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 MIROMRNASYKZNL-ULQDDVLXSA-N 0.000 description 1
- IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 description 1
- JHNOXVASMSXSNB-WEDXCCLWSA-N Lys-Thr-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O JHNOXVASMSXSNB-WEDXCCLWSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- AXHNAGAYRGCDLG-UWVGGRQHSA-N Met-Lys-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O AXHNAGAYRGCDLG-UWVGGRQHSA-N 0.000 description 1
- DJJBHQHOZLUBCN-WDSOQIARSA-N Met-Lys-Trp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DJJBHQHOZLUBCN-WDSOQIARSA-N 0.000 description 1
- NDJSSFWDYDUQID-YTWAJWBKSA-N Met-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N)O NDJSSFWDYDUQID-YTWAJWBKSA-N 0.000 description 1
- QAVZUKIPOMBLMC-AVGNSLFASA-N Met-Val-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(C)C QAVZUKIPOMBLMC-AVGNSLFASA-N 0.000 description 1
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 101000713102 Mus musculus C-C motif chemokine 1 Proteins 0.000 description 1
- 101100404853 Mus musculus Klrk1 gene Proteins 0.000 description 1
- 101100153537 Mus musculus Tnfrsf4 gene Proteins 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 1
- PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000002673 NFATC Transcription Factors Human genes 0.000 description 1
- 108010018525 NFATC Transcription Factors Proteins 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- DPUOLKQSMYLRDR-UBHSHLNASA-N Phe-Arg-Ala Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 DPUOLKQSMYLRDR-UBHSHLNASA-N 0.000 description 1
- UUWCIPUVJJIEEP-SRVKXCTJSA-N Phe-Asn-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N UUWCIPUVJJIEEP-SRVKXCTJSA-N 0.000 description 1
- WPTYDQPGBMDUBI-QWRGUYRKSA-N Phe-Gly-Asn Chemical compound N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O WPTYDQPGBMDUBI-QWRGUYRKSA-N 0.000 description 1
- MMYUOSCXBJFUNV-QWRGUYRKSA-N Phe-Gly-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N MMYUOSCXBJFUNV-QWRGUYRKSA-N 0.000 description 1
- OQTDZEJJWWAGJT-KKUMJFAQSA-N Phe-Lys-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O OQTDZEJJWWAGJT-KKUMJFAQSA-N 0.000 description 1
- SCKXGHWQPPURGT-KKUMJFAQSA-N Phe-Lys-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O SCKXGHWQPPURGT-KKUMJFAQSA-N 0.000 description 1
- QARPMYDMYVLFMW-KKUMJFAQSA-N Phe-Pro-Glu Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=CC=C1 QARPMYDMYVLFMW-KKUMJFAQSA-N 0.000 description 1
- ZJPGOXWRFNKIQL-JYJNAYRXSA-N Phe-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 ZJPGOXWRFNKIQL-JYJNAYRXSA-N 0.000 description 1
- BPCLGWHVPVTTFM-QWRGUYRKSA-N Phe-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O BPCLGWHVPVTTFM-QWRGUYRKSA-N 0.000 description 1
- GMWNQSGWWGKTSF-LFSVMHDDSA-N Phe-Thr-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O GMWNQSGWWGKTSF-LFSVMHDDSA-N 0.000 description 1
- ZYNBEWGJFXTBDU-ACRUOGEOSA-N Phe-Tyr-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)N ZYNBEWGJFXTBDU-ACRUOGEOSA-N 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- INXAPZFIOVGHSV-CIUDSAMLSA-N Pro-Asn-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1 INXAPZFIOVGHSV-CIUDSAMLSA-N 0.000 description 1
- JARJPEMLQAWNBR-GUBZILKMSA-N Pro-Asp-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JARJPEMLQAWNBR-GUBZILKMSA-N 0.000 description 1
- QVIZLAUEAMQKGS-GUBZILKMSA-N Pro-Asp-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1 QVIZLAUEAMQKGS-GUBZILKMSA-N 0.000 description 1
- LSIWVWRUTKPXDS-DCAQKATOSA-N Pro-Gln-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O LSIWVWRUTKPXDS-DCAQKATOSA-N 0.000 description 1
- LQZZPNDMYNZPFT-KKUMJFAQSA-N Pro-Gln-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LQZZPNDMYNZPFT-KKUMJFAQSA-N 0.000 description 1
- CLNJSLSHKJECME-BQBZGAKWSA-N Pro-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1 CLNJSLSHKJECME-BQBZGAKWSA-N 0.000 description 1
- ULIWFCCJIOEHMU-BQBZGAKWSA-N Pro-Gly-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 ULIWFCCJIOEHMU-BQBZGAKWSA-N 0.000 description 1
- VZKBJNBZMZHKRC-XUXIUFHCSA-N Pro-Ile-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O VZKBJNBZMZHKRC-XUXIUFHCSA-N 0.000 description 1
- KLSOMAFWRISSNI-OSUNSFLBSA-N Pro-Ile-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1 KLSOMAFWRISSNI-OSUNSFLBSA-N 0.000 description 1
- MHHQQZIFLWFZGR-DCAQKATOSA-N Pro-Lys-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O MHHQQZIFLWFZGR-DCAQKATOSA-N 0.000 description 1
- JLMZKEQFMVORMA-SRVKXCTJSA-N Pro-Pro-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 JLMZKEQFMVORMA-SRVKXCTJSA-N 0.000 description 1
- SBVPYBFMIGDIDX-SRVKXCTJSA-N Pro-Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)[C@H]2NCCC2)CCC1 SBVPYBFMIGDIDX-SRVKXCTJSA-N 0.000 description 1
- LNICFEXCAHIJOR-DCAQKATOSA-N Pro-Ser-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LNICFEXCAHIJOR-DCAQKATOSA-N 0.000 description 1
- FDMCIBSQRKFSTJ-RHYQMDGZSA-N Pro-Thr-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O FDMCIBSQRKFSTJ-RHYQMDGZSA-N 0.000 description 1
- DLZBBDSPTJBOOD-BPNCWPANSA-N Pro-Tyr-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O DLZBBDSPTJBOOD-BPNCWPANSA-N 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- SRTCFKGBYBZRHA-ACZMJKKPSA-N Ser-Ala-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SRTCFKGBYBZRHA-ACZMJKKPSA-N 0.000 description 1
- HBZBPFLJNDXRAY-FXQIFTODSA-N Ser-Ala-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O HBZBPFLJNDXRAY-FXQIFTODSA-N 0.000 description 1
- WDXYVIIVDIDOSX-DCAQKATOSA-N Ser-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N WDXYVIIVDIDOSX-DCAQKATOSA-N 0.000 description 1
- XVAUJOAYHWWNQF-ZLUOBGJFSA-N Ser-Asn-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O XVAUJOAYHWWNQF-ZLUOBGJFSA-N 0.000 description 1
- VAUMZJHYZQXZBQ-WHFBIAKZSA-N Ser-Asn-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O VAUMZJHYZQXZBQ-WHFBIAKZSA-N 0.000 description 1
- ICHZYBVODUVUKN-SRVKXCTJSA-N Ser-Asn-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ICHZYBVODUVUKN-SRVKXCTJSA-N 0.000 description 1
- RNFKSBPHLTZHLU-WHFBIAKZSA-N Ser-Cys-Gly Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)O)N)O RNFKSBPHLTZHLU-WHFBIAKZSA-N 0.000 description 1
- KMWFXJCGRXBQAC-CIUDSAMLSA-N Ser-Cys-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N KMWFXJCGRXBQAC-CIUDSAMLSA-N 0.000 description 1
- IOVHBRCQOGWAQH-ZKWXMUAHSA-N Ser-Gly-Ile Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O IOVHBRCQOGWAQH-ZKWXMUAHSA-N 0.000 description 1
- KDGARKCAKHBEDB-NKWVEPMBSA-N Ser-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CO)N)C(=O)O KDGARKCAKHBEDB-NKWVEPMBSA-N 0.000 description 1
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 1
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 1
- JWOBLHJRDADHLN-KKUMJFAQSA-N Ser-Leu-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JWOBLHJRDADHLN-KKUMJFAQSA-N 0.000 description 1
- HDBOEVPDIDDEPC-CIUDSAMLSA-N Ser-Lys-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O HDBOEVPDIDDEPC-CIUDSAMLSA-N 0.000 description 1
- QJKPECIAWNNKIT-KKUMJFAQSA-N Ser-Lys-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O QJKPECIAWNNKIT-KKUMJFAQSA-N 0.000 description 1
- OVQZAFXWIWNYKA-GUBZILKMSA-N Ser-Pro-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)N OVQZAFXWIWNYKA-GUBZILKMSA-N 0.000 description 1
- GYDFRTRSSXOZCR-ACZMJKKPSA-N Ser-Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O GYDFRTRSSXOZCR-ACZMJKKPSA-N 0.000 description 1
- SNXUIBACCONSOH-BWBBJGPYSA-N Ser-Thr-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CO)C(O)=O SNXUIBACCONSOH-BWBBJGPYSA-N 0.000 description 1
- VAIWUNAAPZZGRI-IHPCNDPISA-N Ser-Trp-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CO)N VAIWUNAAPZZGRI-IHPCNDPISA-N 0.000 description 1
- RTXKJFWHEBTABY-IHPCNDPISA-N Ser-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CO)N RTXKJFWHEBTABY-IHPCNDPISA-N 0.000 description 1
- OSFZCEQJLWCIBG-BZSNNMDCSA-N Ser-Tyr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OSFZCEQJLWCIBG-BZSNNMDCSA-N 0.000 description 1
- HAYADTTXNZFUDM-IHRRRGAJSA-N Ser-Tyr-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O HAYADTTXNZFUDM-IHRRRGAJSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 102100026503 Sperm mitochondrial-associated cysteine-rich protein Human genes 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- XSLXHSYIVPGEER-KZVJFYERSA-N Thr-Ala-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XSLXHSYIVPGEER-KZVJFYERSA-N 0.000 description 1
- NAXBBCLCEOTAIG-RHYQMDGZSA-N Thr-Arg-Lys Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O NAXBBCLCEOTAIG-RHYQMDGZSA-N 0.000 description 1
- OJRNZRROAIAHDL-LKXGYXEUSA-N Thr-Asn-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O OJRNZRROAIAHDL-LKXGYXEUSA-N 0.000 description 1
- LIXBDERDAGNVAV-XKBZYTNZSA-N Thr-Gln-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O LIXBDERDAGNVAV-XKBZYTNZSA-N 0.000 description 1
- SLUWOCTZVGMURC-BFHQHQDPSA-N Thr-Gly-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O SLUWOCTZVGMURC-BFHQHQDPSA-N 0.000 description 1
- XFTYVCHLARBHBQ-FOHZUACHSA-N Thr-Gly-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O XFTYVCHLARBHBQ-FOHZUACHSA-N 0.000 description 1
- JKGGPMOUIAAJAA-YEPSODPASA-N Thr-Gly-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O JKGGPMOUIAAJAA-YEPSODPASA-N 0.000 description 1
- URPSJRMWHQTARR-MBLNEYKQSA-N Thr-Ile-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O URPSJRMWHQTARR-MBLNEYKQSA-N 0.000 description 1
- GMXIJHCBTZDAPD-QPHKQPEJSA-N Thr-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N GMXIJHCBTZDAPD-QPHKQPEJSA-N 0.000 description 1
- UYTYTDMCDBPDSC-URLPEUOOSA-N Thr-Ile-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N UYTYTDMCDBPDSC-URLPEUOOSA-N 0.000 description 1
- ZSPQUTWLWGWTPS-HJGDQZAQSA-N Thr-Lys-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O ZSPQUTWLWGWTPS-HJGDQZAQSA-N 0.000 description 1
- DXPURPNJDFCKKO-RHYQMDGZSA-N Thr-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O DXPURPNJDFCKKO-RHYQMDGZSA-N 0.000 description 1
- WRQLCVIALDUQEQ-UNQGMJICSA-N Thr-Phe-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WRQLCVIALDUQEQ-UNQGMJICSA-N 0.000 description 1
- JMBRNXUOLJFURW-BEAPCOKYSA-N Thr-Phe-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N)O JMBRNXUOLJFURW-BEAPCOKYSA-N 0.000 description 1
- VTMGKRABARCZAX-OSUNSFLBSA-N Thr-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O VTMGKRABARCZAX-OSUNSFLBSA-N 0.000 description 1
- UQCNIMDPYICBTR-KYNKHSRBSA-N Thr-Thr-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O UQCNIMDPYICBTR-KYNKHSRBSA-N 0.000 description 1
- LXXCHJKHJYRMIY-FQPOAREZSA-N Thr-Tyr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O LXXCHJKHJYRMIY-FQPOAREZSA-N 0.000 description 1
- BZTSQFWJNJYZSX-JRQIVUDYSA-N Thr-Tyr-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O BZTSQFWJNJYZSX-JRQIVUDYSA-N 0.000 description 1
- KAJRRNHOVMZYBL-IRIUXVKKSA-N Thr-Tyr-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O KAJRRNHOVMZYBL-IRIUXVKKSA-N 0.000 description 1
- PELIQFPESHBTMA-WLTAIBSBSA-N Thr-Tyr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 PELIQFPESHBTMA-WLTAIBSBSA-N 0.000 description 1
- XGFYGMKZKFRGAI-RCWTZXSCSA-N Thr-Val-Arg Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N XGFYGMKZKFRGAI-RCWTZXSCSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- GQHAIUPYZPTADF-FDARSICLSA-N Trp-Ile-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 GQHAIUPYZPTADF-FDARSICLSA-N 0.000 description 1
- WNGMGTMSUBARLB-RXVVDRJESA-N Trp-Trp-Gly Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)N)C(=O)NCC(O)=O)=CNC2=C1 WNGMGTMSUBARLB-RXVVDRJESA-N 0.000 description 1
- NMOIRIIIUVELLY-WDSOQIARSA-N Trp-Val-Leu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)C(C)C)=CNC2=C1 NMOIRIIIUVELLY-WDSOQIARSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- BURPTJBFWIOHEY-UWJYBYFXSA-N Tyr-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BURPTJBFWIOHEY-UWJYBYFXSA-N 0.000 description 1
- AYHSJESDFKREAR-KKUMJFAQSA-N Tyr-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AYHSJESDFKREAR-KKUMJFAQSA-N 0.000 description 1
- SCCKSNREWHMKOJ-SRVKXCTJSA-N Tyr-Asn-Ser Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O SCCKSNREWHMKOJ-SRVKXCTJSA-N 0.000 description 1
- NQJDICVXXIMMMB-XDTLVQLUSA-N Tyr-Glu-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O NQJDICVXXIMMMB-XDTLVQLUSA-N 0.000 description 1
- JKUZFODWJGEQAP-KBPBESRZSA-N Tyr-Gly-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N)O JKUZFODWJGEQAP-KBPBESRZSA-N 0.000 description 1
- JJNXZIPLIXIGBX-HJPIBITLSA-N Tyr-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N JJNXZIPLIXIGBX-HJPIBITLSA-N 0.000 description 1
- HFJJDMOFTCQGEI-STECZYCISA-N Tyr-Ile-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N HFJJDMOFTCQGEI-STECZYCISA-N 0.000 description 1
- NSGZILIDHCIZAM-KKUMJFAQSA-N Tyr-Leu-Ser Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N NSGZILIDHCIZAM-KKUMJFAQSA-N 0.000 description 1
- SINRIKQYQJRGDQ-MEYUZBJRSA-N Tyr-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 SINRIKQYQJRGDQ-MEYUZBJRSA-N 0.000 description 1
- KYPMKDGKAYQCHO-RYUDHWBXSA-N Tyr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 KYPMKDGKAYQCHO-RYUDHWBXSA-N 0.000 description 1
- XJPXTYLVMUZGNW-IHRRRGAJSA-N Tyr-Pro-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O XJPXTYLVMUZGNW-IHRRRGAJSA-N 0.000 description 1
- VXFXIBCCVLJCJT-JYJNAYRXSA-N Tyr-Pro-Pro Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(O)=O VXFXIBCCVLJCJT-JYJNAYRXSA-N 0.000 description 1
- SOAUMCDLIUGXJJ-SRVKXCTJSA-N Tyr-Ser-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O SOAUMCDLIUGXJJ-SRVKXCTJSA-N 0.000 description 1
- QFXVAFIHVWXXBJ-AVGNSLFASA-N Tyr-Ser-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O QFXVAFIHVWXXBJ-AVGNSLFASA-N 0.000 description 1
- MDXLPNRXCFOBTL-BZSNNMDCSA-N Tyr-Ser-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MDXLPNRXCFOBTL-BZSNNMDCSA-N 0.000 description 1
- QRCBQDPRKMYTMB-IHPCNDPISA-N Tyr-Trp-Ser Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N QRCBQDPRKMYTMB-IHPCNDPISA-N 0.000 description 1
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 1
- AGDDLOQMXUQPDY-BZSNNMDCSA-N Tyr-Tyr-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O AGDDLOQMXUQPDY-BZSNNMDCSA-N 0.000 description 1
- AEOFMCAKYIQQFY-YDHLFZDLSA-N Tyr-Val-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AEOFMCAKYIQQFY-YDHLFZDLSA-N 0.000 description 1
- SLLKXDSRVAOREO-KZVJFYERSA-N Val-Ala-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)N)O SLLKXDSRVAOREO-KZVJFYERSA-N 0.000 description 1
- LNYOXPDEIZJDEI-NHCYSSNCSA-N Val-Asn-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N LNYOXPDEIZJDEI-NHCYSSNCSA-N 0.000 description 1
- OVLIFGQSBSNGHY-KKHAAJSZSA-N Val-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N)O OVLIFGQSBSNGHY-KKHAAJSZSA-N 0.000 description 1
- XJFXZQKJQGYFMM-GUBZILKMSA-N Val-Cys-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)O)N XJFXZQKJQGYFMM-GUBZILKMSA-N 0.000 description 1
- LMSBRIVOCYOKMU-NRPADANISA-N Val-Gln-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N LMSBRIVOCYOKMU-NRPADANISA-N 0.000 description 1
- QHFQQRKNGCXTHL-AUTRQRHGSA-N Val-Gln-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QHFQQRKNGCXTHL-AUTRQRHGSA-N 0.000 description 1
- SZTTYWIUCGSURQ-AUTRQRHGSA-N Val-Glu-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SZTTYWIUCGSURQ-AUTRQRHGSA-N 0.000 description 1
- NXRAUQGGHPCJIB-RCOVLWMOSA-N Val-Gly-Asn Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O NXRAUQGGHPCJIB-RCOVLWMOSA-N 0.000 description 1
- WBAJDGWKRIHOAC-GVXVVHGQSA-N Val-Lys-Gln Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O WBAJDGWKRIHOAC-GVXVVHGQSA-N 0.000 description 1
- ILMVQSHENUZYIZ-JYJNAYRXSA-N Val-Met-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N ILMVQSHENUZYIZ-JYJNAYRXSA-N 0.000 description 1
- CKTMJBPRVQWPHU-JSGCOSHPSA-N Val-Phe-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)O)N CKTMJBPRVQWPHU-JSGCOSHPSA-N 0.000 description 1
- NSUUANXHLKKHQB-BZSNNMDCSA-N Val-Pro-Trp Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 NSUUANXHLKKHQB-BZSNNMDCSA-N 0.000 description 1
- QTPQHINADBYBNA-DCAQKATOSA-N Val-Ser-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN QTPQHINADBYBNA-DCAQKATOSA-N 0.000 description 1
- SDHZOOIGIUEPDY-JYJNAYRXSA-N Val-Ser-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 SDHZOOIGIUEPDY-JYJNAYRXSA-N 0.000 description 1
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 1
- UVHFONIHVHLDDQ-IFFSRLJSSA-N Val-Thr-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O UVHFONIHVHLDDQ-IFFSRLJSSA-N 0.000 description 1
- GUIYPEKUEMQBIK-JSGCOSHPSA-N Val-Tyr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(O)=O GUIYPEKUEMQBIK-JSGCOSHPSA-N 0.000 description 1
- AEFJNECXZCODJM-UWVGGRQHSA-N Val-Val-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C(=O)NCC([O-])=O AEFJNECXZCODJM-UWVGGRQHSA-N 0.000 description 1
- JVGDAEKKZKKZFO-RCWTZXSCSA-N Val-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O JVGDAEKKZKKZFO-RCWTZXSCSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 238000012436 analytical size exclusion chromatography Methods 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940125752 antibody drug candidate Drugs 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 238000011230 antibody-based therapy Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000014155 detection of activity Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000198 fluorescence anisotropy Methods 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 108010019832 glycyl-asparaginyl-glycine Proteins 0.000 description 1
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 102000057266 human FCGR3A Human genes 0.000 description 1
- 102000044042 human KLRK1 Human genes 0.000 description 1
- 102000050320 human TNFRSF4 Human genes 0.000 description 1
- 102000050327 human TNFRSF9 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000002847 impedance measurement Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004964 innate lymphoid cell Anatomy 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000000111 isothermal titration calorimetry Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 108010012058 leucyltyrosine Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 108010012988 lysyl-glutamyl-aspartyl-glycine Proteins 0.000 description 1
- 108010057952 lysyl-phenylalanyl-lysine Proteins 0.000 description 1
- 108010043322 lysyl-tryptophyl-alpha-lysine Proteins 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 108010005942 methionylglycine Proteins 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000012223 nuclear import Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 108010024607 phenylalanylalanine Proteins 0.000 description 1
- 108010018625 phenylalanylarginine Proteins 0.000 description 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 108010014614 prolyl-glycyl-proline Proteins 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002005 protein protein interaction detection Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000002762 protein-protein interaction assay Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 108010072986 threonyl-seryl-lysine Proteins 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 108010084932 tryptophyl-proline Proteins 0.000 description 1
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 108010009962 valyltyrosine Proteins 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
本发明一般性涉及使用细胞培养物的特异性测定法,特别是用于测试不同型式的抗原结合模块的嵌合抗原受体(CAR)表达性报告T(CAR‑T细胞)测定法。而且,本发明涉及用包含靶抗原结合模块的改造的嵌合抗原受体(CAR)转染/转导的CAR‑T细胞的用途,该靶抗原结合模块能够特异性结合靶抗原,例如肿瘤相关抗原。
Description
发明领域
本发明一般性涉及使用细胞培养物的特异性测定法,特别是用于测试不同型式的抗原结合模块的嵌合抗原受体(CAR)表达性报告T(CAR-T细胞)测定法。而且,本发明涉及用包含靶抗原结合模块的改造的嵌合抗原受体(CAR)转染/转导的CAR-T细胞的用途,该靶抗原结合模块能够特异性结合靶抗原,例如肿瘤相关抗原。
发明背景
化疗直到现在仍然是癌症的最常用治疗之一。另外,基于抗体的疗法在过去15年里得到发展,现在在血液学恶性和实体瘤的治疗中代表化疗办法的有价值组合或备选。与化疗不一样,抗体疗法靶向癌细胞上的特定抗原,因而容许更加定点的治疗,由此降低对健康组织的副作用。在开发基于抗体的治疗性试剂的过程中,需要各种测定法来鉴定最好的候选,带入临床试验中并最终推向市场。在第一个早期临床前阶段中,不得不生成抗体,尤其是它们的抗原结合模块并分析它们的靶物特异性,以及它们对靶物的亲和力。
可以使用各种蛋白质-蛋白质相互作用测定法来分析结合特性,诸如基于FRET的方法,表面等离振子共振(SPR)或荧光激活细胞分选(FACS)。然而,可用的测定法型式可能并不总是全面且综合地再现体内情况。例如,用结合细胞表面受体的治疗性抗体靶向癌细胞可能在多个水平上具有影响,例如经由结合和交联表面分子的细胞内信号传导以及标记肿瘤细胞以啮合免疫细胞。而且,自抗原结合至建立效应器功能(例如T细胞细胞毒性)的识别级联需要一系列精心编排的细胞表面相互作用,其中抗原结合模块的结合亲和力是数个因素中的一个。因此,虽然这些测定法对于早期候选开发是非常有价值的工具,但是单纯的蛋白质-蛋白质亲和相互作用测定法可能并不产生完整图片。
总之,仍然需要开发确实在更加全面的设置中更加密切地模拟体内情况,尽可能将对靶物-抗体结合的非特异性影响最小化的结合测定法。而且,设计容许在抗体治疗性分子的开发过程的早期阶段评估结合和功能性的组合测定法会是大大有益的。
本发明的发明人开发了一种新颖的测定法,其适用于极其多种不同癌细胞类型以评估抗体对它们的靶物的结合。该创新的测定法包括经修饰的T细胞作为报告细胞,组合直截了当的读出与全面且包容的结果。
而且,本发明提供组合抗体和抗体样构建物(例如配体)的结合和功能性的评估的测定法。该新颖的测定法例如对于治疗性抗体药物候选的筛选或表征目的是有用的,例如以高通量型式。
这种新的测定法代表一种有价值的工具,用于结合天然靶物的抗体的早期和晚期筛选和表征和评估功能性,会容许在药物候选的开发中的早期阶段鉴定最好的结合物。
发明概述
本发明一般性涉及一种用于选择新颖抗原结合模块的方法,特别是在药物开发过程中,而且组合对(例如肿瘤细胞上的)靶抗原的结合的评估与T细胞响应抗体-靶物结合的激活。
因而,本文中提供的是一种用于评估抗原结合模块的特异性的方法,其包含下述步骤:
a.提供对靶抗原特异性的抗原结合模块;
b.生成嵌合抗原受体(CAR)表达性报告T(CAR-T)细胞,其通过:
i.将该抗原结合模块转移入与应答元件可操作偶联的CAR载体系统;和
ii.将该CAR载体系统转移入包含在该应答元件控制下的报告基因的报告T细胞;
c.使该报告CAR-T细胞与在表面上包含该靶抗原的靶细胞接触,特别是其中该靶细胞是癌细胞;和
d.通过测定该报告基因的表达来测定T细胞激活以建立该抗原结合模块的特异性。
在一个实施方案中,该抗原结合模块是Fab片段,特别是自噬菌体展示文库筛选衍生的Fab片段。
在一个实施方案中,该抗原结合模块包含可变重链域(VH)和可变轻链域(VL)。在一个实施方案中,将该抗原结合模块的VH和VL域转移至该CAR。
在一个实施方案中,该CAR载体系统编码包含Fab或交叉Fab片段,锚定跨膜域和至少一个细胞内信号传导和/或共信号传导域的CAR。
在一个实施方案中,该靶抗原对该报告CAR-T细胞的结合导致该细胞内信号传导和/或共信号传导域的激活。
在一个实施方案中,该细胞内信号传导域的激活导致该应答元件的激活。
在一个实施方案中,该应答元件控制该报告基因的表达。
在一个实施方案中,该应答元件的激活导致该报告基因的表达。
在一个实施方案中,该应答元件是NFAT途径,NF-κB途径或AP-1途径的一部分。
在一个实施方案中,该报告基因编码发光蛋白,特别是荧光蛋白。
在一个实施方案中,该报告基因编码绿色荧光蛋白(GFP)或萤光素酶。
在一个实施方案中,该靶抗原是细胞表面受体。
在一个实施方案中,该靶抗原是与人主要组织相容性复合物(MHC)的分子结合的肽。
在一个实施方案中,该抗原结合模块是T细胞受体样(TCRL)抗原结合模块。
在一个实施方案中,该方法另外包含下述步骤:
e.将该报告基因的表达的水平与参照比较。
在一个实施方案中,该参照是在该靶细胞缺失下该报告基因的表达。
在一个实施方案中,该报告基因的表达与在该靶细胞缺失下该报告基因的表达相比要高至少2倍,3倍,4倍,5倍,10倍,100倍,1000倍,或10000倍。
在一个实施方案中,该方法另外包含下述步骤:
f.如果在该靶细胞存在下该报告基因的表达的水平相对于在该靶细胞缺失下该报告基因的表达比预先确定的阈值要高的话,选择该新颖抗原结合模块。
在一个实施方案中,该阈值是2,3,4,5,10,100,1000,或10000。
在一个实施方案中,在该靶细胞存在下高水平的该报告基因的表达和在该靶细胞缺失下低水平的该报告基因的表达指示该抗原结合模块的高特异性,特别是包含该抗原结合模块的T细胞双特异性(TCB)抗体的高特异性。
在一个实施方案中,该方法是体外方法
在一个实施方案中,提供的是一种用于生成TCB抗体的方法,其中该TCB抗体型式包含对靶抗原特异性的第一抗原结合模块和能够特异性结合T细胞激活性受体的第二抗原结合模块,其中该第一抗原结合模块是依照如本文中描述的方法选择的。
在一个实施方案中,该T细胞激活性受体是CD3。
附图简述
图1显示Jurkat NFAT报告CAR-T细胞测定法的示意图。肿瘤相关抗原(TAA)能受到抗TAA抗原结合受体表达性Jurkat NFAT报告CAR-T细胞识别。这种识别导致细胞的激活,其能通过测量发光(cps)来检测。
图2描绘本发明中使用的不同CAR型式的构造。图2A显示Fab型式的构造。描绘的是包含由Ig重链片段和Ig轻链组成的抗原结合模块的胞外域。附着至重链,接头连接抗原识别域与锚定跨膜域(ATD),其融合至细胞内共刺激性信号传导域(CSD),其继而融合至刺激性信号传导域(SSD)。图2B显示具有重和轻链交换的Fab型式的构造。描绘的是包含由Ig重链片段和Ig轻链组成的抗原结合模块的胞外域。附着至轻链恒定域,接头连接抗原识别域与锚定跨膜域(ATD),其融合至细胞内共刺激性信号传导域(CSD),其继而融合至刺激性信号传导域(SSD)。图2C显示scFab型式的构造。描绘的是包含由Ig重链片段和Ig轻链(二者通过接头连接)组成的抗原结合模块的胞外域。附着至重链,接头连接抗原识别域与锚定跨膜域(ATD),其融合至细胞内共刺激性信号传导域(CSD),其继而融合至刺激性信号传导域(SSD)。图2D显示具有VH-VL交换的交叉Fab型式的构造。描绘的是包含由Ig重链片段和Ig轻链(其中VH和VL域是交换的)组成的抗原结合模块的胞外域。附着至重链恒定域,接头连接抗原识别域与锚定跨膜域(ATD),其融合至细胞内共刺激性信号传导域(CSD),其继而融合至刺激性信号传导域(SSD)。图2E显示具有CH-CL交换的交叉Fab型式的构造。描绘的是包含由Ig重链片段和Ig轻链(其中该CH和CL域是交换的)组成的抗原结合模块的胞外域。附着至轻链恒定域,接头连接抗原识别域与锚定跨膜域(ATD),其融合至细胞内共刺激性信号传导域(CSD),其继而融合至刺激性信号传导域(SSD)。图2F显示具有由可变重和可变轻链(二者通过接头连接)组成的细胞外抗原识别域的经典scFv型式的构造。附着至可变轻链,接头连接抗原识别域与锚定跨膜域(ATD),其融合至细胞内共刺激性信号传导域(CSD),其继而融合至刺激性信号传导域(SSD)。
图3描绘图示编码依照本发明使用的CAR的例示性表达构建物的模块组成的示意图。图3A和图3B描绘例示性Fab型式。图3C描绘例示性scFab型式。图3D和图3E描绘例示性交叉Fab型式。图3F描绘经典scFv型式。
图4描绘使用CD20表达性SUDHDL4肿瘤细胞作为靶细胞的Jurkat NFAT报告CAR-T细胞测定法。使用抗CD20-Fab-CD28ATD-CD28CSD-CD3zSSD表达性Jurkat NFAT报告CAR-T细胞的单克隆作为报告细胞。
图5描绘使用CD20表达性SUDHDL4肿瘤细胞作为靶细胞的Jurkat NFAT报告CAR-T细胞测定法。使用抗CD20-Fab-CD28ATD-CD28CSD-CD3zSSD或抗CD20-交叉Fab-CD28ATD-CD28CSD-CD3zSSD表达性Jurkat NFAT报告CAR-T细胞的集合作为报告细胞。
图6描绘使用CD20表达性SUDHDL4肿瘤细胞作为靶细胞的Jurkat NFAT报告CAR-T细胞测定法。使用抗CD20-scFab-CD28ATD-CD28CSD-CD3zSSD表达性Jurkat NFAT报告CAR-T细胞的集合作为报告细胞。
图7描绘使用CD20表达性SUDHDL4肿瘤细胞作为靶细胞的Jurkat NFAT报告CAR-T细胞报告测定法。使用抗CD20-Fab-CD28ATD-CD28CSD-CD3zSSD或抗CD20-scFv-CD28ATD-CD28CSD-CD3zSSD表达性Jurkat NFAT报告CAR-T细胞的集合作为报告细胞。
图8A和图8B描绘用经RMF肽或VLD肽脉冲的T2细胞通过FACS对WT1/HLA结合物5E11和33H09的特异性的评估。
图9描绘与经RMF或VLD肽脉冲的T2细胞共温育后Jurkat NFAT报告抗WT1/HLA-Fab-CAR-T细胞集合中CAR-NFAT信号传导的激活。RMF肽(靶)较之VLD肽(脱靶)上的信号的比较有助于评估激活的特异性。
图10描绘与经RMF或VLD肽脉冲的T2细胞共温育后Jurkat NFAT报告抗WT1/HLA-Fab-CAR-T细胞集合中CAR-NFAT信号传导的激活。RMF肽(靶)较之VLD肽(脱靶)上信号的比较有助于评估激活的特异性。在没有靶细胞的情况下温育的NFAR报告CAR-T细胞集合的信号说明测定法的低背景。
图11描绘表达针对不同肽/HLA靶的CAR-结合物的Jurkat NFAT Fab-CAR-T细胞集合中CAR-NFAT信号传导的激活。Jurkat NFJAT CAR-T细胞集合F06,F29和F30结合具有无关肽的盲肽/HLA靶。
发明详述
定义
除非在下文另外定义,术语在本文中如本领域中一般使用的那样使用。
“激活Fc受体”是一种在抗体的Fc域衔接后,引发刺激携带该受体的细胞实施效应器功能的信号传导事件的Fc受体。人激活Fc受体包括FcγRIIIa(CD16a),FcγRI(CD64),FcγRIIa(CD32)和FcαRI(CD89)。
药剂的“有效量”指引起接受其施用的细胞或组织中的生理学变化必需的量。
“亲和力”指分子(例如受体)的单一结合位点与其结合配偶体(例如配体)之间非共价相互作用总和的强度。除非另外指示,如本文中使用的,“结合亲和力”指反映结合对的成员(例如抗原结合模块和抗原和/或受体及其配体)之间1:1相互作用的固有结合亲和力。分子X对其配偶体Y的亲和力通常可以以解离常数(KD)来表述,其为解离与结合速率常数(分别为K解离和K结合)的比率。如此,相等的亲和力可能包含不同的速率常数,只要速率常数的比率保持相同。亲和力可以通过本领域知道的确立方法来测量,包括本文中描述的那些方法。用于测量亲和力的一种优选方法是表面等离振子共振(SPR)且用于测量的优选温度是25℃。
术语“氨基酸”指天然发生的和合成的氨基酸,以及以与天然发生氨基酸相似的方式发挥功能的氨基酸类似物和氨基酸模拟物。天然发生氨基酸是那些由遗传密码编码的,以及那些稍后修饰的氨基酸,例如羟脯氨酸,γ-羧基谷氨酸,和O-磷酸丝氨酸。氨基酸类似物指具有与天然发生氨基酸相同的基础化学结构(即结合氢,羧基基团,氨基基团,和R基团的α-碳)的化合物,例如高丝氨酸,正亮氨酸,甲硫氨酸亚砜,甲硫氨酸甲基锍。此类类似物具有经过修饰的R基团(例如正亮氨酸)或经过修饰的肽主链,但是保留与天然发生氨基酸相同的基础化学结构。氨基酸模拟物指具有与氨基酸的一般化学结构不同的结构,但以与天然发生氨基酸相似的方式发挥功能的化学化合物。氨基酸在本文中可以通过由IUPAC-IUB生物化学命名委员会推荐的它们的公知的三字母符号或一字母符号来提及。
如本文中使用的,术语“氨基酸突变”意为涵盖氨基酸替代,缺失,插入和修饰。可以进行取代,缺失,插入和修饰的任意组合来实现最终构建体,只要最终构建体拥有期望的特性。氨基酸序列缺失和插入包括氨基和/或羧基端缺失和氨基酸插入。具体的氨基酸突变是氨基酸替代。为了改变例如抗原结合模块的结合特征,特别优选非保守性的氨基酸替代,即将一个氨基酸用具有不同结构和/或化学特性的另一种氨基酸替换。氨基酸替代包括由非天然存在的氨基酸或由20种标准氨基酸的天然存在的氨基酸衍生物(例如4-羟脯氨酸,3-甲基组氨酸,鸟氨酸,高丝氨酸,5-羟赖氨酸)替换。可以使用本领域中公知的遗传或化学方法生成氨基酸突变。遗传方法可以包括定点诱变,PCR,基因合成等。涵盖的是通过与遗传工程化不同的方法如化学修饰来改变氨基酸侧链基团的方法也可能可用。本文中可使用各种名称来指示同一氨基酸突变。
术语“抗体”在本文中以最广义使用且涵盖各种抗体结构,包括但不限于单克隆抗体,多克隆抗体和抗体片段,只要它们展现出期望的抗原结合活性。因而,在本发明的语境中,术语抗体涉及完整免疫球蛋白分子以及此类免疫球蛋白分子的部分。而且,如本文中讨论的,该术语涉及经过修饰和/或改变的抗体分子,特别是突变型抗体分子。该术语还涉及重组或合成生成的/合成的抗体。在本发明的语境中,术语抗体与术语免疫球蛋白可互换使用。
“抗体片段”指完整抗体外的分子,其包含完整抗体中结合与完整抗体结合的抗原的一部分。抗体片段的例子包括但不限于Fv,Fab,Fab’,Fab’-SH,F(ab’)2,双抗体,线性抗体,单链抗体分子(例如scFv),和单域抗体。对于某些抗体片段的综述,参见Hudson等,NatMed 9,129-134(2003)。对于scFv片段的综述,参见例如Plückthun,于The Pharmacologyof Monoclonal Antibodies,vol.113,Rosenburg和Moore编,Springer-Verlag,New York,pp.269-315(1994);亦参见WO 93/16185;和美国专利No.5,571,894和5,587,458。双抗体是具有两个抗原结合位点的抗体片段,其可以是二价或双特异性的。参见例如EP 404,097;WO1993/01161;Hudson等,Nat Med 9,129-134(2003);和Hollinger等,Proc Natl Acad SciUSA 90,6444-6448(1993)。三抗体和四抗体也记载于Hudson等,Nat Med 9,129-134(2003)。单域抗体是包含抗体的整个或部分重链可变域,或整个或部分轻链可变域的抗体片段(Domantis,Inc.,Waltham,MA;参见例如美国专利No.6,248,516B1)。可以通过各种技术来制备抗体片段,包括但不限于对完整抗体的蛋白水解消化以及通过重组宿主细胞(例如大肠杆菌或噬菌体)产生,如本文中描述的。
如本文中使用的,术语“抗原结合分子”在其最广义上指特异性结合抗原性决定簇的分子。抗原结合分子的例子是免疫球蛋白及其衍生物,例如其片段以及抗原结合受体,例如CAR,和其衍生物。
如本文中使用的,术语“抗原结合模块”指特异性结合抗原性决定簇的多肽分子。在一个实施方案中,抗原结合模块能够将与其附接的实体(例如免疫球蛋白或CAR)引导至靶部位,例如至特定类型的肿瘤细胞或携有抗原性决定簇的肿瘤基质。在另一个实施方案中,抗原结合模块能够经由其靶抗原来激活信号传导,例如在抗原性决定簇结合T细胞上的CAR后激活信号传导。在本发明的语境中,抗原结合模块可以包括在如本文中另外定义的抗体及其片段以及CAR及其片段中。抗原结合模块包括抗原结合域,其包含免疫球蛋白重链可变区和免疫球蛋白轻链可变区。在某些实施方案中,抗原结合模块可以包含如本文中进一步定义的和本领域已知的免疫球蛋白恒定区。有用的重链恒定区包括五种同种型任一:α,δ,ε,γ,或μ。有用的轻链恒定区包括两种同种型任一:κ和λ。
在本发明的语境中,术语“抗原结合受体”涉及包含锚定跨膜域和包含至少一个抗原结合模块的胞外域的抗原结合分子。抗原结合受体(例如CAR)可以由来自不同来源的各多肽部分构成。因而,它还可以理解为“融合蛋白”和/或“嵌合蛋白”。通常,融合蛋白是经由连接最初编码分开的蛋白质的两个或更多个基因(或优选cDNA)创建的蛋白质。这种融合基因(或融合cDNA)的翻译产生单一多肽,优选具有自每种原始蛋白质衍生的功能特性。重组融合蛋白是为了在生物学研究或治疗中使用通过重组DNA技术人工创建的。在本发明的语境中,CAR(嵌合抗原受体)理解为如下抗原结合受体,其包含包含抗原结合模块的胞外部分,胞外部分通过间隔物序列融合锚定跨膜域,锚定跨膜域自身融合CD3z和CD28的胞内信号传导域。
“抗原结合位点”指抗原结合分子上提供与抗原相互作用的位点,即一个或多个氨基酸残基。例如,抗体或CAR的抗原结合位点包含来自互补性决定区(CDR)的氨基酸残基。天然的免疫球蛋白分子通常具有两个抗原结合位点,Fab或scFv分子通常具有单个抗原结合位点。
术语“抗原结合域”指包含特异性结合部分或整个抗原且与其互补的区域的抗体或抗原结合受体(例如CAR)部分。抗原结合域可由例如一个或多个免疫球蛋白可变域(也称为可变区)提供。具体地,抗原结合域包含免疫球蛋白轻链可变区(VL)和免疫球蛋白重链可变区(VH)。
术语“可变区”或“可变域”指免疫球蛋白重链或轻链中牵涉结合抗原的域。天然抗体的重链和轻链的可变域(分别为VH和VL)一般具有类似的结构,每个域包含4个保守的框架区(FR)和3个高变区(HVR)。参见例如Kindt等,Kuby Immunology,第6版,W.H.Freemanand Co.,第91页(2007)。单个VH或VL域通常足以赋予抗原结合特异性。
如本文中使用,术语“ATD”指“锚定跨膜域”,其定义能够在细胞的细胞膜中整合的多肽段。ATD可以融合别的胞外和/或胞内多肽域,其中这些胞外和/或胞内多肽域也会约束于细胞膜。在如本发明中使用的抗原结合受体的语境中,ATD对抗原结合受体,例如依照本发明使用的CAR赋予膜附着和约束。
如依照本发明使用的抗原结合受体(例如CAR)的语境中使用的,术语“结合”限定“抗原相互作用位点”和抗原彼此的结合(相互作用)。术语“抗原相互作用位点”限定多肽中显示与一种或一组特定抗原的特异性相互作用能力的基序。所述结合/相互作用还理解为限定“特异性识别”。依照此发明的术语“特异性识别”意味着抗原结合受体能够与如本文中限定的肿瘤相关抗原(TAA)分子特异性相互作用和/或结合。抗原结合受体(例如CAR)的抗原结合模块能识别,相互作用和/或结合相同分子上的不同表位。此术语涉及抗原结合受体的特异性,即它在如本文中限定的分子的特定区域之间区分的能力。抗原相互作用位点与它的特定抗原的特异性相互作用可导致信号的启动,例如由于诱导包含抗原的多肽的构象的变化,包含抗原的多肽的寡聚化,抗原结合受体的寡聚化,等。如此,作为它们的一级,二级或三级结构的结果以及所述结构的二级修饰的结果,抗原相互作用位点和抗原的氨基酸序列中的特定基序彼此结合。因而,术语结合不仅涉及线性表位而且还可涉及由靶分子或其部分的两个区域组成的构象表位,结构表位或不连续表位。在此发明的语境中,构象表位通过在一级序列中分开的,当多肽折叠成天然蛋白质时在分子的表面上来到一起的两个或更多个离散氨基酸序列来定义(Sela,Science 166(1969),1365和Laver,Cell 61(1990),553-536)。而且,术语“结合”在本发明的语境中与术语“相互作用”可互换使用。CAR的抗原结合模块(例如Fab或scFv域)或抗体结合特定靶抗原性决定簇的能力可以经由酶联免疫吸附测定法(ELISA)或本领域技术人员熟悉的其它技术,例如表面等离振子共振(SPR)技术(在BIAcore仪器上分析)(Liljeblad et al.,Glyco J 17,323-329(2000))和传统的结合测定法(Heeley,Endocr Res 28,217-229(2002))测量。在一个实施方案中,抗原结合模块结合无关蛋白质的程度小于抗原结合模块对靶抗原的结合的约10%,如特别通过SPR测量的。在某些实施方案中,结合靶抗原的抗原结合模块具有≤1μM,≤100nM,≤10nM,≤1nM,≤0.1nM,≤0.01nM,或≤0.001nM(例如10-8M或更小,例如10-8M至10-13M,例如10-9M至10-13M)的解离常数(KD)。如依照本发明使用的,术语“特异性结合”意味着在本发明中使用的分子并不与相似结构的(多)肽交叉反应或实质性交叉反应。可测试一组处于调查中的构建物的交叉反应性,例如通过评估一组抗原结合模块在常规条件(见例如Harlow and Lane,Antibodies:A Laboratory Manual,Cold Spring Harbor Laboratory Press,(1988)和Using Antibodies:A Laboratory Manual,Cold Spring Harbor Laboratory Press,(1999))下对感兴趣抗原以及无关抗原的结合。只有那些结合感兴趣抗原但并不或本质上并不结合无关抗原的构建物(即Fab片段,scFv等等)认为是对感兴趣抗原特异性的且选择用于依照本文中提供的方法的别的研究。这些方法可格外包含结合研究,与结构上和/或功能上密切相关的多肽的阻断和竞争研究。结合研究还包含FACS分析,表面等离振子共振(SPR,例如用),分析性超速离心,等温滴定热量测定术,荧光各向异性,荧光光谱术或放射性标记的配体结合测定法。
如本文中采用的,术语“CDR”涉及“互补决定区”,其是本领域公知的。CDR是免疫球蛋白或抗原结合受体(例如CAR)中决定所述分子的特异性且与特定配体接触的部分。CDR是分子中最可变的部分且对这些分子的抗原结合多样性有贡献。每个V域中有三个CDR区,CDR1,CDR2和CDR3。CDR-H描绘可变重链的CDR区,而CDR-L涉及可变轻链的CDR区。VH意味着可变重链而VL意味着可变轻链。Ig衍生区的CDR区可以如“Kabat”(Sequences of Proteinsof Immunological Interest”,5th edit.NIH Publication no.91-3242U.S.Departmentof Health and Human Services(1991);Chothia J.Mol.Biol.196(1987),901-917)或“Chothia”(Nature 342(1989),877-883)中所述确定。
术语“CD3z”指T细胞表面糖蛋白CD3泽塔(ζ)链,还称作“T-细胞受体T3泽塔链”和“CD247”。
术语“嵌合抗原受体”或“嵌合受体”或“CAR”指如下构成的抗原结合受体:抗原结合模块(例如scFv或Fab)的胞外部分,通过间隔物序列融合至胞内信号传导域(例如CD3z和CD28的)。术语“CAR”以其最广义形式理解且包含如下构成的抗原结合受体:包含抗原结合模块的胞外部分,融合至CD3z和其片段和CD28和其片段,任选经由一个或数个肽接头。
抗体或免疫球蛋白的“类”指其重链拥有的恒定域或恒定区的类型。抗体有5种主要的类:IgA,IgD,IgE,IgG和IgM,并且这些中数种可以进一步分成亚类(同种型),例如IgG1,IgG2,IgG3,IgG4,IgA1和IgA2。对应于不同免疫球蛋白类的重链恒定域分别称为α,δ,ε,γ和μ。
“交换”Fab分子(亦称为“交叉Fab”或“交换Fab片段”)意指其中交换Fab重链和轻链的可变区或恒定区的Fab分子,即交叉Fab片段包含由轻链可变区和重链恒定区构成的肽链,和由重链可变区和轻链恒定区构成的肽链。为了清楚,在其中交换Fab轻链和Fab重链的可变区的交叉Fab片段中,包含重链恒定区的肽链在本文中称为交换Fab分子的重链。相反,在其中交换Fab轻链和Fab重链的恒定区的交叉Fab片段中,包含重链可变区的肽链在本文中称为交叉Fab片段的重链。因而,交叉Fab片段包含由重链可变和轻链恒定区构成的重或轻链(VH-CL),和由轻链可变和重链恒定区构成的重或轻链(VL-CH1)。
与之相反,“Fab”或“常规Fab”分子意指处于它的天然型式的Fab分子,即包含由重链可变和恒定区构成的重链(VH-CH1),和由轻链可变和恒定区构成的轻链(VL-CL)。
如本文中使用的,术语“CSD”指共刺激性信号传导域。
术语“效应器功能”指那些可归于抗体Fc区且随抗体同种型而变化的生物学活性。抗体效应器功能的例子包括:C1q结合和补体依赖性细胞毒性(CDC),Fc受体结合,抗体依赖性细胞介导的细胞毒性(ADCC),抗体依赖性细胞吞噬作用(ADCP),细胞因子分泌,免疫复合物介导的抗原呈递细胞的抗原摄取,细胞表面受体(例如B细胞受体)下调和B细胞活化。
如本文中使用的,术语“工程化”或“改造”视为包括对肽主链的任何操作或对天然存在或重组的多肽或其片段的翻译后修饰。工程化或改造包括对氨基酸序列,糖基化模式或各氨基酸侧链基团的修饰,以及这些办法的组合。
术语“表达盒”指重组或合成生成的,具有一系列允许特定核酸在靶细胞中转录的指定核酸元件的多核苷酸。可以将重组表达盒掺入质粒,染色体,线粒体DNA,质体DNA,病毒或核酸片段中。通常,表达载体的重组表达盒部分包含要转录的核酸序列和启动子等序列。
“Fab分子”指由抗原结合分子的重链VH和CH1域(“Fab重链”)和轻链VL和CL域(“Fab轻链”)组成的蛋白质。
本文中术语“Fc域”或“Fc区”用于定义免疫球蛋白重链中至少含有恒定区的一部分的C端区域。该术语包括天然序列Fc区和变体Fc区。虽然IgG重链的Fc区的边界可以略微变化,但是人IgG重链Fc区通常定义为自Cys226或Pro230延伸至重链的羧基端。然而,可以存在或不存在Fc区的C端赖氨酸(Lys447)。除非本文中另外指定,Fc区或恒定区中氨基酸残基的编号方式依照“EU编号系统”,也称为EU索引,如记载于Kabat等,Sequences ofProteins of Immunological Interest,第5版Public Health Service,NationalInstitutes of Health,Bethesda,MD,1991的。如本文中使用的,Fc域的亚基指形成二聚体Fc域的两个多肽之一,即包含免疫球蛋白重链中能够稳定自身联合的C端恒定区的多肽。例如,IgG Fc域的亚基包含IgG CH2和IgG CH3恒定域。
“框架”或“FR”指除高变区(HVR)残基外的可变域残基。可变域的FR一般由4个FR域组成:FR1,FR2,FR3和FR4。因而,HVR和FR序列一般以下列顺序出现在VH(或VL)中:FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4。
术语“全长抗体”表示由两条“全长抗体重链”和两条“全长抗体轻链”组成的抗体。“全长抗体重链”是以N端至C端方向由抗体重链可变域(VH),抗体恒定重链域1(CH1),抗体铰链区(HR),抗体重链恒定域2(CH2),和抗体重链恒定域3(CH3)(缩写为VH-CH1-HR-CH2-CH3);和在亚类IgE的抗体的情况中任选的抗体重链恒定域4(CH4)组成的多肽。优选地,“全长抗体重链”是以N端至C端方向由VH,CH1,HR,CH2和CH3组成的多肽。“全长抗体轻链”是以N端至C端方向由抗体轻链可变域(VL)和抗体轻链恒定域(CL)(缩写为VL-CL)组成的多肽。抗体轻链恒定域(CL)可以是κ(卡帕)或λ(拉姆达)。两条全长抗体链经由CL域和CH1域之间的和全长抗体重链的铰链区之间的多肽间二硫键连接到一起。典型的全长抗体的例子是天然抗体,像IgG(例如IgG1和IgG2),IgM,IgA,IgD,和IgE)。
“融合”意指组分(例如Fab和跨膜域)直接地或经由一种或多种肽接头通过肽键连接。
术语“宿主细胞”,“宿主细胞系”和“宿主细胞培养物”可交换使用并指已引入外源核酸的细胞,包括此类细胞的后代。宿主细胞包括“转化体”和“经转化的细胞”,其包括初始转化的细胞和自其衍生的后代(不考虑传代数)。后代在核酸内含物上可能与亲本细胞不完全相同,但可以含有突变。本文中包括具有如原始转化细胞中筛选或选择的相同的功能或生物学活性的突变体后代。宿主细胞包括培养的细胞,例如哺乳动物培养细胞如CHO细胞,BHK细胞,NS0细胞,SP2/0细胞,YO骨髓瘤细胞,P3X63小鼠骨髓瘤细胞,PER细胞,PER.C6细胞或杂交瘤细胞,酵母细胞,昆虫细胞和植物细胞等,而且还包括在转基因动物,转基因植物或培养的植物或动物组织中包含的细胞。
如本文中使用的,术语“高变区”或“HVR”指抗体可变域中序列中高度可变和/或形成结构上定义的环(“高变环”)的每个区域。通常,天然的四链抗体包含六个HVR;三个在VH中(H1,H2,H3),三个在VL中(L1,L2,L3)。HVR一般包含来自高变环和/或来自互补性决定区(CDR)的氨基酸残基,后者具有最高序列变异性和/或涉及抗原识别。除了VH中CDR1外,CDR一般包含形成高变环的氨基酸残基。高变区(HVR)也称为互补性决定区(CDR),并且在述及形成抗原结合区的可变区部分时,这些术语在本文中可互换使用。此特定区域已由Kabat等,U.S.Dept.of Health and Human Services,Sequences of Proteins ofImmunological Interest(1983)及由Chothia等,J Mol Biol 196:901-917(1987)描述,其中定义包括在彼此比较时氨基酸残基的重叠或子集。然而,应用任一种定义来指抗体和/或抗原结合受体或其变体的CDR意图在如本文中定义和使用的术语的范围内。涵盖如由上文引用的每篇参考文献定义的CDR的适宜的氨基酸残基在下表1中列出作为比较。涵盖特定CDR的确切残基数将随着CDR的序列和大小而变化。鉴于抗体的可变区氨基酸序列,本领域技术人员可以常规确定哪些残基构成特定CDR。
表1:CDR定义1
CDR | Kabat | Chothia | AbM<sup>2</sup> |
V<sub>H</sub> CDR1 | 31-35 | 26-32 | 26-35 |
V<sub>H</sub> CDR2 | 50-65 | 52-58 | 50-58 |
V<sub>H</sub> CDR3 | 95-102 | 95-102 | 95-102 |
V<sub>L</sub> CDR1 | 24-34 | 26-32 | 24-34 |
V<sub>L</sub> CDR2 | 50-56 | 50-52 | 50-56 |
V<sub>L</sub> CDR3 | 89-97 | 91-96 | 89-97 |
1表1中所有CDR定义的编号方式依照由Kabat等提出的编号惯例(见下文)。
2如表1中使用的具有小写字母“b”的“AbM”指由Oxford Molecular的“AbM”抗体建模软件定义的CDR。
Kabat等还定义针对可变区序列的编号系统,其可应用于任何抗体。本领域的普通技术人员可以明确地将此Kabat编号系统归入任何可变区序列,不依赖于序列本身外的任何实验数据。如本文中使用的,“Kabat编号方式”指由Kabat等,U.S.Dept.of Health andHuman Services,“Sequence of Proteins of Immunological Interest”(1983)提出的编号系统。除非另外说明,提及抗原结合模块可变区中特定氨基酸残基位置的编号方式依照Kabat编号系统。序列表的多肽序列并不依照Kabat编号系统编号。然而,本领域中普通技术人员完全能将序列表的序列编号方式转变成Kabat编号方式。
“个体”或“受试者”是哺乳动物。哺乳动物包括但不限于驯养的动物(例如牛,绵羊,猫,犬和马),灵长类(例如人和非人灵长类如猴),家兔和啮齿动物(例如小鼠和大鼠)。具体地,所述个体或受试者是人。
“分离的核酸”分子或多核苷酸意指已从其天然环境取出的核酸分子,DNA或RNA。例如,就本发明目的而言,包含在载体中的编码多肽的重组多核苷酸被视为分离的。分离的多核苷酸的别的例子包括在异源宿主细胞中保持的重组多核苷酸或溶液中的(部分或基本上)纯化的多核苷酸。分离的多核苷酸包括在普遍含有该多核苷酸分子的细胞中含有的多核苷酸分子,但该多核苷酸分子存在于染色体外或在不同于其天然染色体位置的染色体位置处。分离的RNA分子包括本发明的体内或体外RNA转录本,以及正链和负链形式,和双链形式。依照本发明的分离的多核苷酸或核酸还包括合成生成的此类分子。另外,多核苷酸或核酸可以为或可以包括调节元件如启动子,核糖体结合位点或转录终止子。
与本发明的参照核苷酸序列具有至少例如95%“相同的”核苷酸序列的核酸或多核苷酸意指该多核苷酸的核苷酸序列与参照序列相同,只不过按照参照核苷酸序列的每100个核苷酸,该多核苷酸序列可以包含多达5处点突变。换言之,为了获得与参照核苷酸序列具有至少95%相同的核苷酸序列的多核苷酸,可以删除或用另一种核苷酸取代参照序列中高达5%的核苷酸,或者可以将占参照序列中总核苷酸的高达5%的数目的核苷酸插入到参照序列中。参照序列的这些变更可以发生在参照核苷酸序列的5’或3’端位置或那些末端位置之间的任何地方,个别分散在参照序列中的残基间或分散在参照序列内的一或多个连续组中。作为一个实际问题,可以使用已知的计算机程序,如下文针对多肽论述的程序(例如ALIGN-2)来常规确定任何特定的多核苷酸序列是否与本发明的核苷酸序列为至少80%,85%,90%,95%,96%,97%,98%或99%相同。
“分离的多肽”或其变体或衍生物意图为不处于其天然环境中的多肽。不需要特定水平的纯化。例如,分离的多肽可以是从其天然或自然环境中取出。就本发明目的而言,在宿主细胞中表达的重组生成的多肽和蛋白质被视为分离的,已通过任何合适的技术分开,分级,或部分或基本上纯化的天然的或重组的多肽也是如此。
关于参照多肽序列的“百分比(%)氨基酸序列同一性”定义为在比对序列并在必要时引入缺口以获取最大百分比序列同一性后,且不将任何保守性取代视为序列同一性的一部分时,候选序列中与参照多肽序列中的氨基酸残基相同的氨基酸残基的百分比。为测定百分比氨基酸序列同一性目的比对可以以本领域技术范围内的多种方式进行,例如使用公众可得到的计算机软件,如BLAST,BLAST-2,ALIGN或Megalign(DNASTAR)软件。本领域技术人员可决定用于比对序列的适宜参数,包括在比较序列的全长里获得最大比对需要的任何算法。然而,就本文中目的而言,使用序列比较计算机程序ALIGN-2来生成%氨基酸序列同一性值。ALIGN-2序列比较计算机程序由Genentech,Inc.创作,并且源代码已与用户文档一起提交到美国版权局(U.S.Copyright Office),Washington D.C.,20559,其在美国版权注册No.TXU510087下注册。ALIGN-2程序可从Genentech,Inc.,South San Francisco,California公开获得,或可从源代码汇编。ALIGN-2程序应当汇编用于UNIX操作系统,包括数字UNIX V4.0D。所有序列比较参数均由ALIGN-2程序设定且不改变。在采用ALIGN-2进行氨基酸序列比较的情况下,给定的氨基酸序列A对/与/相对给定的氨基酸序列B的%氨基酸序列同一性(或其可以用短语表示为对/与/相对给定的氨基酸序列B具有或包含特定%氨基酸序列同一性的给定氨基酸序列A)如下计算:
分数X/Y的100倍
其中X是由序列比对程序ALIGN-2在所述程序对A和B的比对中评为相同匹配的氨基酸残基数,而其中Y是B中氨基酸残基的总数。会领会的是,当氨基酸序列A的长度不等于氨基酸序列B的长度时,A对B的%氨基酸序列同一性将不等于B对A的%氨基酸序列同一性。除非另外明确说明,本文中使用的所有%氨基酸序列同一性值如在上一段中描述的那样使用ALIGN-2计算机程序获得。
术语“核酸分子”涉及多核苷酸包含的包含嘌呤和嘧啶碱基的碱基序列,由此所述碱基代表核酸分子的主要结构。在本文中,术语核酸分子包括DNA,cDNA,基因组DNA,RNA,合成形式的DNA和包含两种或更多种这些分子的混合聚合物。另外,术语核酸分子包括有义和反义链二者。而且,本文中描述的核酸分子可以含有非天然的或衍生化的核苷酸碱基,正如本领域技术人员会容易领会的。
如本文中使用的,“NFAT”指“激活的T细胞的核因子”且是在大多数免疫细胞中表达的一个转录因子家族。NFAT家族的转录因子的激活依赖于钙信号传导。例如,经由T细胞突触的T细胞激活导致钙流入。升高的细胞内钙水平激活钙敏感性磷酸酶,钙依赖磷酸酶,其迅速使NFAT蛋白的氨基端中的富丝氨酸区(SRR)和SP重复脱磷酸化。这导致暴露核定位信号的构象变化,促进NFAT核输入和靶基因激活。
如本文中使用的,“NFAT途径”指导致对NFAT转录因子家族的成员的活性的调控的刺激。NFAT DNA元件是本领域已知的且在本文中还称作“NFAT途径的应答元件”。因此,“NFAT途径的受体”指能触发对NFAT的活性的调控的受体。“NFAT途径的受体”的例子是例如T细胞受体和B细胞受体。
如本文中使用的,“NF-κB”指“激活的B细胞的核因子卡帕轻链增强子”且是牵涉调节编码凋亡,病毒复制,肿瘤发生,各种自身免疫性疾病和炎症应答的介导物的许多基因的转录因子。NFκB存在于几乎所有真核细胞中。一般地,它以无活性状态位于胞质溶胶中,因为它与抑制性κB(IκB)蛋白形成复合物。经由配体与整合膜受体(还称作“NF-κB途径的受体”)的结合,IκB激酶(IKK)得到激活。IKK是由两个激酶和一个调节亚基组成的酶复合物。这种复合物磷酸化IκB蛋白,其导致那些蛋白质遍在蛋白化和因此被蛋白酶体降解。最后,游离的NFκB处于活性状态,易位至核并结合κB DNA元件并诱导靶基因转录。
如本文中使用的,“NF-κB途径”指导致对NF-κB的活性的调控的刺激。例如,Toll样受体信号传导,TNF受体信号传导,T细胞受体和B细胞受体信号传导经由配体或抗体的结合的激活导致NF-κB的激活。随后,磷酸化的NF-κB二聚体结合κB DNA元件并诱导靶基因转录。κB DNA元件是本领域已知的且在本文中还称作“NF-κB途径的应答元件”。因此,“NF-κB途径的受体”指能触发对NF-κB的活性的调控的受体。“NF-κB途径的受体”的例子是Toll样受体,TNF受体,T细胞受体和B细胞受体。
如本文中使用的,“AP-1”指“激活蛋白1”且是牵涉包括分化,增殖,和凋亡在内的一些细胞过程的转录因子。AP-1功能依赖于对AP-1二聚体有贡献的特定Fos和Jun亚基。AP-1结合回文DNA基序(5’-TGA G/C TCA-3’)以调节基因表达。
术语“药学组合物”指其形式使得容许其中含有的活性成分的生物学活性有效,且不含对会接受配制剂施用的受试者有不可接受的毒性的别的成分的制剂。药学组合物通常包含一种或多种药学可接受载体。
“药学可接受载体”指药学组合物中活性成分以外对受试者无毒的成分。药学可接受载体包括但不限于缓冲剂,赋形剂,稳定剂或防腐剂。
如本文中使用的,术语“多肽”指由通过酰胺键(也称为肽键)线性连接的单体(氨基酸)构成的分子。术语多肽指具有两个或更多个氨基酸的任何链,并且不指特定长度的产物。如此,肽,二肽,三肽,寡肽,蛋白质,氨基酸链或任何其它用于指具有两个或更多个氨基酸的链的术语均包括在多肽的定义中,而且术语多肽可以代替这些术语中任一个或与其可互换使用。术语多肽还意图指多肽的表达后修饰的产物,包括但不限于糖基化,乙酰化,磷酸化,酰化,通过已知的保护性/封闭性基团衍生化,蛋白水解切割,或通过非天然存在的氨基酸的修饰。多肽可以自天然的生物学来源衍生或通过重组技术生成,但不必从指定的核酸序列翻译。它可以以任何方式来生成,包括通过化学合成。本发明的多肽大小可以是约3个或更多,5个或更多,10个或更多,20个或更多,25个或更多,50个或更多,75个或更多,100个或更多,200个或更多,500个或更多,1,000个或更多,或2,000个或更多氨基酸。多肽可以具有限定的三维结构,尽管它们不必具有此类结构。具有限定的三维结构的多肽被称为折叠的,而不具有限定的三维结构而可以采用大量不同构象的多肽被称为未折叠的。
术语“多核苷酸”指分离的核酸分子或构建体,例如信使RNA(mRNA),病毒衍生的RNA或质粒DNA(pDNA)。多核苷酸可以包含常规的磷酸二酯键或非常规的键(例如酰胺键,如在肽核酸(PNA)中发现的)。术语核酸分子指任何一种或多种存在于多核苷酸中的核酸区段,例如DNA或RNA片段。
术语“具有固有荧光的蛋白质”指能够经由蛋白质内的内部氨基酸的环化和氧化或经由酶促添加荧光辅因子而形成高度发荧光的,固有发色团的蛋白质。术语“具有固有荧光的蛋白质”包括野生型荧光蛋白和展现改变的光谱或物理特性的突变体。该术语不包括仅仅凭借蛋白质内的非修饰的酪氨酸,色氨酸,组氨酸和苯丙氨酸基团的荧光贡献而展现弱荧光的蛋白质。具有固有荧光的蛋白质是本领域已知的,例如绿色荧光蛋白(GFP),红色荧光蛋白(RFP),蓝色荧光蛋白(BFP,Heim et al.1994,1996),称作CFP的青色荧光变体(Heim et al.1996;Tsien 1998);称作YFP的黄色荧光变体(Ormo et al.1996;Wachter etal.1998);称作Sapphire的紫色可激发绿色荧光变体(Tsien 1998;Zapata-Hommer etal.2003);和称作增强型绿色荧光蛋白或EGFP的青色可激发绿色荧光变体(Yang etal.1996),而且可以例如通过活细胞成像(例如Incucyte)或荧光分光光度法来测量。
“降低的结合”指相应相互作用的亲和力降低,如例如通过SPR测量的。为了清楚,该术语还包括亲和力降低至0(或低于分析方法的检测限),即完全消除相互作用。相反,“升高的结合”指相应相互作用的结合亲和力升高。
术语“调节序列”指实现与它们连接的编码序列表达所必需的DNA序列。此类控制序列的性质随生物体而不同。在原核生物中,控制序列一般包括启动子,核糖体结合位点,和终止子。在真核生物中,控制序列一般包括启动子,终止子和一些情况中的增强子,反式激活子(transactivator)或转录因子。术语“控制序列”意图最低限度包括其存在是表达所必需的所有成分,而且还可以包括另外的有利成分。
如本文中使用的,“报告基因”意味着其表达可以测定的基因。在一个优选的实施方案中,“报告基因”是编码使用其生成和检测作为替代品来间接检测要测试的抗体或配体的活性的蛋白质的基因。报告蛋白是由报告基因编码的蛋白质。优选地,报告基因编码其催化活性可以通过简单的测定方法来检测的酶或具有诸如固有荧光或发光等特性,使得报告基因的表达可以在需要最低限度的样品制备的简单且快速的测定法中检测的蛋白质。其催化活性可以检测的酶的非限制性例子是萤光素酶,β-半乳糖苷酶,碱性磷酸酶。萤光素酶是具有61kDa的分子量(MW)的单体酶。它起催化剂的作用且能够在三磷酸腺苷(ATP)和Mg2+存在下将D-萤光素转变成萤光素腺苷酸。另外,作为副产物生成焦磷酸(PPi)和腺苷单磷酸(AMP)。然后将中间体萤光素腺苷酸氧化成氧化萤光素,二氧化碳(CO2)和光。氧化萤光素是生物发光产物,能通过自反应释放的光在发光计中定量测量。萤光素酶报告测定法可商购且是本领域已知的,例如萤光素酶1000测定系统和ONE-GloTM萤光素酶测定系统。
“应答元件”指能在某种转录因子结合时激活或沉默的特定转录因子结合元件,或顺式作用元件。在一个实施方案中,应答元件是位于在转录因子结合时驱动报告基因表达的最小限度启动子(例如TATA盒启动子)上游的顺式作用增强子元件。
如本文中使用的,术语“单链”指包含通过肽键线性连接的氨基酸单体的分子。在某些实施方案中,抗原结合模块之一是scFv片段,即通过肽接头连接的VH域和VL域。在某些实施方案中,抗原结合模块之一是单链Fab分子,即其中通过肽接头连接Fab轻链和Fab重链以形成单一肽链的Fab分子。在一个具体的此类实施方案中,在单链Fab分子中Fab轻链的C端连接于Fab重链的N端。
如本文中使用的,术语“SSD”指刺激性信号传导域。
如本文中使用的,“治疗/处理”(及其语法变体)指试图改变治疗个体中疾病的自然进程,并且可以是为了预防或在临床病理学的过程期间实施的临床干预。治疗的期望效果包括但不限于预防疾病的发生或复发,缓解症状,降低疾病的任何直接或间接病理学后果,预防转移,减缓疾病进展速率,改善或减轻疾病状态,及消退或改善的预后。
如本文中使用的,术语“靶抗原性决定簇”与“靶抗原”,“靶表位”,“肿瘤相关抗原”和“靶细胞抗原”同义,并且指多肽大分子上与抗体结合,从而形成抗原结合模块-抗原复合物的位点(例如氨基酸的连续区段或由不连续氨基酸的不同区构成的构象性构造)。可用的抗原性决定簇可以在例如肿瘤细胞表面上,病毒感染的细胞的表面上,其它患病细胞的表面上,免疫细胞的表面上,游离在血液血清中和/或在胞外基质(ECM)中找到。除非另外指示,本文中称为抗原的蛋白质(例如CD20,CEA,FAP,TNC)可以是来自任何脊椎动物来源,包括哺乳动物如灵长类(例如人)和啮齿类(例如小鼠和大鼠)的任何天然形式的蛋白质。在一个具体的实施方案中,靶抗原是人蛋白。在对本文中的特定靶蛋白质进行提述的情况下,该术语涵盖“全长”,未加工的靶蛋白质以及起因于靶细胞中加工的靶蛋白质的任何形式。该术语还涵盖靶蛋白质的天然存在变体,例如剪接变体或等位变体。可用作抗原的例示性人靶蛋白包括但不限于:CD20,CEA,FAP,TNC,MSLN,FolR1,HER1和HER2。抗原结合受体(例如CAR)结合特定靶抗原性决定簇的能力可以经由酶联免疫吸附测定法(ELISA)或本领域技术人员熟悉的其它技术,例如表面等离振子共振(SPR)技术(在BIAcore仪器上分析)(Liljeblad et al.,Glyco J 17,323-329(2000))和传统的结合测定法(Heeley,EndocrRes 28,217-229(2002))测量。在一个实施方案中,抗原结合受体结合无关蛋白质的程度小于抗体对靶抗原的结合的约10%,如例如通过SPR测量的。在某些实施方案中,结合靶抗原的抗原结合受体具有≤1μM,≤100nM,≤10nM,≤1nM,≤0.1nM,≤0.01nM,或≤0.001nM(例如10-8M或更小,例如10-8M至10-13M,例如10-9M至10-13M)的亲和解离常数(KD)。
如本文中使用的,“T细胞活化”指T淋巴细胞,特别是细胞毒性T淋巴细胞的一种或多种细胞应答,其选自:增殖,分化,细胞因子分泌,细胞毒性效应分子释放,细胞毒性活性和活化标志物的表达。合适的测量T细胞活化的测定法是本文中所述技术领域中已知的。
依照本发明,术语“T细胞受体”或“TCR”是本领域普遍知道的。特别是,本文中术语“T细胞受体”指任何T细胞受体,前提是满足下面的三项标准:(i)肿瘤特异性,(ii)识别(大多数)肿瘤细胞,这意味着抗原或靶物应当在(大多数)肿瘤细胞中表达,和(iii)TCR与要治疗的受试者的HLA型匹配。在此语境中,满足上文所述三项标准的合适的T细胞受体是本领域已知的,诸如识别NY-ESO-1(序列信息见例如PCT/GB2005/001924)和/或HER2neu(序列信息见WO-A1 2011/0280894)的受体。
药剂例如药学组合物的“治疗有效量”指有效实现期望的治疗或预防结果的量(以必要的剂量且持续必要的时间)。治疗有效量的药剂例如消除,降低,延迟,最小化或预防疾病的不良作用。
术语“载体”或“表达载体”与“表达构建体”同义,并指用于在靶细胞中导入与其可操作联合的特定基因及指导其表达的DNA分子。该术语包括作为自主复制核酸结构的载体以及掺入到已经接受其导入的宿主细胞的基因组中的载体。本发明的表达载体包含表达盒。表达载体允许转录大量稳定的mRNA。一旦表达载体在靶细胞内,就通过细胞转录和/或翻译装置生成基因编码的核糖核酸分子或蛋白质。在一个实施方案中,本发明的表达载体包含表达盒,其包含编码本发明的抗原结合受体或其片段的多核苷酸序列。
本文中提供的是用于选择新颖抗原结合模块的方法,用于进一步的开发,其依照它们的特异性,特别是关于接触靶细胞后报告细胞(例如T细胞)的激活。在此语境中,该新颖抗原结合模块介导靶细胞(特别是癌细胞)和报告细胞(特别是T细胞)之间的接触。在一个实施方案中,提供的是用于评估抗原结合模块的特异性的方法,其包含下述步骤:
a)提供对靶抗原特异性的抗原结合模块;
b)生成嵌合抗原受体(CAR)表达性报告T(CAR-T)细胞,其通过:
i.将该抗原结合模块转移入与应答元件可操作偶联的CAR载体系统;和
ii.将该CAR载体系统转移入包含在该应答元件控制下的报告基因的报告T细胞;
c)使该报告CAR-T细胞与在表面上包含该靶抗原的靶细胞接触,特别是其中该靶细胞是癌细胞;和
d)通过测定该报告基因的表达来测定T细胞激活以建立该抗原结合模块的特异性。
免疫球蛋白典型地包含能够稳定折叠的可变和恒定域,其中可变域赋予免疫球蛋白分子针对靶抗原的特异性。可以通过转移候选抗原结合模块的可变域将候选抗原结合模块的特异性(例如针对肿瘤细胞上的靶抗原的)转移至不同抗原结合分子(例如CAR)。这种转移是本领域已知的且例如可以通过将候选抗原结合模块的编码区亚克隆入不同DNA载体系统(例如如本文中描述的CAR载体系统)来进行。为此目的,本领域广泛使用适宜重组DNA技术,自一种载体系统转移至另一种载体系统是直截了当的。然而,将抗原结合物(例如免疫球蛋白)的可变域(特别是VH和VL域)转移入包含相似抗原结合型式的抗原结合受体的抗原结合模块(例如Fab至Fab,交叉Fab或scFab)以保留结合特征和生成有意义的测定系统可能是合适的。因而,本文中提供的是使用不同CAR型式(例如scFv,Fab,交叉Fab和scFab;scFv至scFv)的方法,可以依照源免疫球蛋白的型式来选择。在将VH和VL域转移入CAR载体系统之后,用CAR载体系统转染或转导的细胞变成针对靶抗原,例如肿瘤细胞上的靶抗原反应性的。在CAR的抗原结合模块结合肿瘤细胞上的靶抗原时CAR载体系统的激活会导致报告基因的激活,其可以测定。
这种办法具有胜过常规结合测定法的显著优点,因为不受理论束缚,如本文中描述的基于T细胞的系统更加密切地类似例如啮合T细胞的治疗性抗体(例如T细胞双特异性抗体)遭遇的体内情况。
因而,本发明提供一种通用筛选平台,其中可以使用包含抗原结合模块的工程化CAR来验定针对靶细胞(例如肿瘤细胞)的新颖抗原结合模块。在结合肿瘤细胞的表面上的靶抗原(例如肿瘤相关抗原)之后,T细胞变成激活的,其中可以例如通过荧光或发光信号的读出来测量激活。通过容许使用多种多样新开发的靶抗原结合模块,该平台具有灵活性和特异性。
在本发明的语境中,CAR包含并不在T细胞中或上天然发生的胞外域。如此,依照如本文中描述的用于评估新型抗原结合模块的结合和功能性的方法,CAR能够提供特制的对识别域,例如肿瘤细胞的靶抗原的结合特异性。用CAR转导且依照本发明使用的细胞(例如T细胞)变成能够特异性结合靶抗原,即通过CAR的胞外域的抗原结合模块提供对靶抗原域的特异性。
在此语境中,提供包含锚定跨膜域和胞外域(包含抗原结合模块)的抗原结合受体,例如CAR,其中抗原结合模块是Fab,交叉Fab或scFab片段。
在某些实施方案中,抗原结合模块是Fab片段,特别是自噬菌体展示文库筛选衍生的Fab片段。在此语境中,CAR载体系统的抗原结合模块优选也是Fab片段。在此类实施方案中,优选地,CAR包含抗原结合模块,特别是其中CAR的抗原结合模块是Fab片段。在一个实施方案中,抗原结合模块包含可变重链域(VH)和可变轻链域(VL)。在一个实施方案中,将抗原结合模块的VH和VL域转移至CAR。
因而,在一个实施方案中,至少一个抗原结合模块是常规Fab片段,即由Fab轻链和Fab重链组成的Fab分子。在一个实施方案中,至少一个抗原结合模块是交叉Fab片段,即由Fab轻链和Fab重链组成的Fab分子,其中Fab重和轻链的可变区或恒定区是交换的。在一个实施方案中,至少一个抗原结合模块是scFv片段。在一个特定的实施方案中,在scFv分子中可变重链(VH)的C端连接可变轻链(VL)的N端,任选经由肽接头。在某些实施方案中,至少一个抗原结合模块是单链Fab分子,即其中Fab轻链和Fab重链通过肽接头连接以形成单一肽链的Fab分子。在一个特定的此类实施方案中,在单链Fab分子中Fab轻链的C端连接Fab重链的N端,任选经由肽接头。
可以通过例如哺乳动物免疫系统的免疫接种来生成能够特异性结合靶抗原,例如肿瘤相关抗原的抗原结合模块。此类方法是本领域已知的且例如描述于Burns,Methods inMolecular Biology 295:1-12(2005)。或者,可以通过对组合文库筛选具有一种或多种期望活性的抗体来分离本发明的抗原结合模块。用于筛选组合文库的方法综述于例如Lerneret al.,Nature Reviews 16:498-508(2016)。例如,多种方法是本领域已知的,用于生成噬菌体展示文库和对此类文库筛选拥有期望结合特征的抗原结合模块。此类方法综述于例如Frenzel et al.,mAbs 8:1177-1194(2016);Bazan et al.,Human Vaccines andImmunotherapeutics 8:1817-1828(2012)和Zhao et al.,Critical Reviews inBiotechnology 36:276-289(2016)以及Hoogenboom et al.,Methods in MolecularBiology 178:1-37(O’Brien et al.,ed.,Human Press,Totowa,NJ,2001)且进一步描述于例如McCafferty et al.,Nature 348:552-554;Clackson et al.,Nature 352:624-628(1991);Marks et al.,J.Mol.Biol.222:581-597(1992)和Marks and Bradbury inMethods in Molecular Biology 248:161-175(Lo,ed.,Human Press,Totowa,NJ,2003);Sidhu et al.,J.Mol.Biol.338(2):299-310(2004);Lee et al.,J.Mol.Biol.340(5):1073-1093(2004);Fellouse,Proc.Natl.Acad.Sci.USA 101(34):12467-12472(2004);和Lee et al.,J.Immunol.Methods 284(1-2):119-132(2004)。在某些噬菌体展示方法中,通过聚合酶链式反应(PCR)分开克隆VH和VL基因的全集并在噬菌体文库中随机重组,然后能对其筛选抗原结合噬菌体,如描述于Winter et al.,Annual Review of Immunology 12:433-455(1994)。噬菌体典型地或是作为单链Fv(scFv)片段或是作为Fab片段展示抗体片段。来自经免疫来源的文库提供针对免疫原的高亲和力抗原结合模块,不需要构建杂交瘤。或者,可以(例如自人)克隆未免疫全集以提供针对广泛非自身,还有自身抗原的抗原结合模块的单一来源,无需任何免疫接种,如描述于Griffiths et al.,EMBO Journal 12:725-734(1993)。最后,还可以通过克隆来自干细胞的未重排V基因区段,和使用含有随机序列以编码高度可变CDR3区和实现体外重排的PCR引物来合成生成未免疫文库,如描述于Hoogenboom and Winter,Journal of Molecular Biology 227:381-388(1992)。描述人抗体噬菌体文库的专利公开文本包括例如美国专利No.5,750,373;7,985,840;7,785,903和8,679,490以及美国专利公开文本No.2005/0079574,2007/0117126,2007/0237764和2007/0292936,和2009/0002360。本领域已知的用于对组合文库筛选具有一种或多种期望活性的抗原结合模块的方法的别的例子包括核糖体和mRNA展示,以及用于细菌,哺乳动物细胞,昆虫细胞或酵母细胞上的抗体展示和选择的方法。用于酵母表面展示的方法综述于例如Scholler et al.,Methods in Molecular Biology 503:135-56(2012)和Cherf et al.,Methods in Molecular biology 1319:155-175(2015)以及Zhao et al.,Methods inMolecular Biology 889:73-84(2012)。用于核糖体展示的方法描述于例如He et al.,Nucleic Acids Research 25:5132-5134(1997)和Hanes et al.,PNAS 94:4937-4942(1997)。本发明的方法的一项特定优点是直截了当整合和表征文库衍生抗原结合模块,无需改变型式,例如,可以以如本文中描述的Fab和/或交叉Fab型式包括自筛选噬菌体展示文库衍生的Fab抗原结合物。因而,可以在本文中描述的抗原结合受体,例如CAR中包括自Fab展示噬菌体文库衍生抗原结合模块,无需将型式改变成例如可能影响文库衍生结合物的结合特性的scFv型式。
在本发明的语境中,本文中提供的是包含能够特异性结合靶抗原,即肿瘤相关抗原的抗原结合模块的CAR。因而,表达如本文中描述的CAR的转导细胞,即T细胞能够特异性结合肿瘤细胞。
在本发明的一个例示性实施方案中,作为概念证明,提供的是能够特异性结合CD20的CAR和表达所述抗原结合受体的报告细胞。靶细胞是表达CD20多肽的且是特异性表达或过表达CD20多肽的细胞类型的。细胞可以是特定细胞类型的癌性或正常细胞。细胞可以是牵涉自身免疫的正常B细胞。在一个实施方案中,细胞是癌细胞,优选恶性B细胞。可以用如本文中描述的CAR靶向其它肿瘤相关抗原。
因而,在一个具体的实施方案中,CAR的胞外域包含能够特异性结合CD20的抗原结合模块,其中该抗原结合模块包含:
(i)重链可变区(VH),其包含
(a)重链互补决定区(CDR H)1氨基酸序列YSWIN(SEQ ID NO:1);
(b)CDR H2氨基酸序列RIFPGDGDTDYNGKFKG(SEQ ID NO:2);和
(c)CDR H3氨基酸序列NVFDGYWLVY(SEQ ID NO:3);和
(ii)轻链可变区(VL),其包含
(d)轻链互补决定区(CDR L)1氨基酸序列RSSKSLLHSNGITYLY(SEQ ID NO:4);
(e)CDR L2氨基酸序列QMSNLVS(SEQ ID NO:5);和
(f)CDR L3氨基酸序列AQNLELPYT(SEQ ID NO:6)。
在一个实施方案中,CAR的胞外域包含能够特异性结合CD20的抗原结合模块,其中该抗原结合模块包含包含与SEQ ID NO:12的氨基酸序列至少约95%,96%,97%,98%,99%或100%同一的氨基酸序列的重链可变区(VH)和包含与SEQ ID NO:10的氨基酸序列至少约95%,96%,97%,98%,99%或100%同一的氨基酸序列的轻链可变区(VL)。
在一个实施方案中,CAR的胞外域包含能够特异性结合CD20的抗原结合模块,其中该抗原结合模块包含SEQ ID NO:12的重链可变区(VH)和SEQ ID NO:10的轻链可变区(VL)。
在一个实施方案中,抗原结合模块是Fab,交叉Fab或scFab片段。
在一个优选的实施方案中,CAR的胞外域包含能够特异性结合CD20的抗原结合模块,其中该抗原结合模块是Fab片段。
在一个实施方案中,CAR的胞外域包含能够特异性结合CD20的抗原结合模块,其中该Fab片段包含SEQ ID NO:8的重链和SEQ ID NO:9的轻链。
在一个实施方案中,CAR的抗原结合模块是scFv片段,其是由重链可变域(VH),轻链可变域(VL)和接头组成的多肽,其中所述可变域和所述接头以N端至C端方向具有下面的构造之一:a)VH-接头-VL或b)VL-接头-VH。在一个优选的实施方案中,scFv片段具有构造VH-接头-VL。
在某些实施方案中,如本文中使用的CAR包含包含能够特异性结合靶抗原的抗原结合模块的胞外域,锚定跨膜域和至少一个细胞内信号传导和/或至少一个共刺激性信号传导域。因而,在一个实施方案中,依照本发明使用的CAR载体系统编码包含抗原结合模块,锚定跨膜域和至少一个细胞内信号传导和/或共信号传导域的CAR。CAR的锚定跨膜域可以特征在于并不具有哺乳动物蛋白酶的切割位点。蛋白酶指能够水解包含蛋白酶的切割位点的跨膜域的氨基酸序列的蛋白水解酶。术语蛋白酶包括内肽酶和外肽酶二者。在本发明的语境中,可以使用如通过CD命名法等等规定的跨膜蛋白的任何锚定跨膜域来生成依照本发明使用的CAR,其在结合如本文中定义的抗原后激活T细胞,优选CD8+T细胞。
因而,在本发明的语境中,锚定跨膜域可以包含鼠/小鼠或优选人跨膜域的一部分。此类锚定跨膜域的一个例子是CD28的跨膜域,例如具有如本文中在SEQ ID NO:14中显示的氨基酸序列(如由在SEQ ID NO:29中显示的DNA序列编码的)。在本发明的语境中,CAR的跨膜域可以包含如SEQ ID NO:14中显示的氨基酸序列(如由SEQ ID NO:29中显示的DNA序列编码的)/由其组成。
在本发明的一个例示性实施方案中,作为概念证明,提供包含SEQ ID NO:7的氨基酸序列(如由SEQ ID NO:22中显示的DNA序列编码的),且包含如本文中作为SEQ ID NO:73(如由SEQ ID NO:72中显示的DNA序列编码的)显示的CD28的片段/多肽部分(人CD28的Uniprot条目号是P10747(该序列的版本号173和版本1))的CAR。或者,可以使用具有如通过CD命名法等等提供的跨膜域的任何蛋白作为本发明的抗原结合受体蛋白的锚定跨膜域。如上文描述的,本文中提供的CAR可以包含CD28的锚定跨膜域,其位于如SEQ ID NO:69中显示的人全长CD28蛋白(如由SEQ ID NO:68中显示的cDNA编码的)的氨基酸153至179,154至179,155至179,156至179,157至179,158至179,159至179,160至179,161至179,162至179,163至179,164至179,165至179,166至179,167至179,168至179,169至179,170至179,171至179,172至179,173至179,174至179,175至179,176至179,177至179或178至179。因而,在本发明的语境中,锚定跨膜域可以包含如SEQ ID NO:14中显示的氨基酸序列(如由SEQ IDNO:29中显示的DNA序列编码的)或由其组成。
如本文中描述的,依照本发明使用的CAR包含至少一个刺激性信号传导域和/或至少一个共刺激性信号传导域以将CAR的抗原结合模块对靶抗原的结合转导至CAR-T细胞中的细胞内信号。因而,本文中描述的CAR优选包含刺激性信号传导域,其提供T细胞激活。本文中描述的CAR可以包含刺激性信号传导域,其是鼠/小鼠或人CD3z(人CD3z的UniProt条目是P20963(版本号177及序列号2;鼠/小鼠CD3z的UniProt条目是P24161(主要可引用登录号)或Q9D3G3(次要可引用登录号)版本号143和序列号1)),FCGR3A(人FCGR3A的UniProt条目是P08637(版本号178及序列号2)),或NKG2D(人NKG2D的UniProt条目是P26718(版本号151及序列号1);鼠/小鼠NKG2D的UniProt条目是O54709(版本号132及序列号2))的片段/多肽部分。
如此,本文中描述的CAR中包含的刺激性信号传导域可以是全长CD3z,FCGR3A或NKG2D的片段/多肽部分。鼠/小鼠全长CD3z的氨基酸序列在本文中作为SEQ ID NO:70显示(鼠/小鼠,如由SEQ ID NO:71中显示的DNA序列编码的)。人全长CD3z的氨基酸序列在本文中作为SEQ ID NO:68显示(人,如由SEQ ID NO:69中显示的DNA序列编码的)。依照本发明使用的CAR可以包含CD3z,FCGR3A或NKG2D的片段作为刺激域,前提是包含至少一个信号传导域。特别是,CD3z,FCGR3A,或NKG2D的任何部分/片段作为刺激域是合适的,只要包含至少一个信号传导基序。然而,更加优选地,本发明的CAR包含自人起源衍生的多肽。优选地,所描述的CAR包含如本文中作为SEQ ID NO:68(CD3z)显示的氨基酸序列(人,如由SEQ ID NO:69中显示的DNA序列编码的)。例如,可以在依照本发明使用的CAR中包含的人CD3z的片段/多肽部分可以包含在SEQ ID NO:16中显示的氨基酸序列(如由SEQ ID NO:31中显示的DNA序列编码的)或由其组成。因而,在一个实施方案中,CAR包含如SEQ ID NO:16中显示的序列或与SEQ ID NO:16相比具有多至1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,23,24,25,26,27,28,29或30处替代,删除或插入且特征在于具有刺激性信号传导活性的序列。在本文中下文和在实施例和图中提供包含刺激性信号传导域(SSD)的CAR的具体构造。可以测定刺激性信号传导活性;例如通过增强的细胞因子释放(如通过ELISA测量的(IL-2,IFNγ,TNFα)),增强的增殖活性(如通过升高的细胞数目测量的),或增强的裂解活性(如通过LDH释放测定法测量的)。
依照本发明使用的CAR优选包含至少一个共刺激性信号传导域,其对T细胞提供另外的活性。本文中描述的CAR可以包含共刺激性信号传导域,其是鼠/小鼠或人CD28(人CD28的UniProt条目是P10747(版本号173及序列号1);鼠/小鼠CD28的UniProt条目是P31041(版本号134及序列号2)),CD137(人CD137的UniProt条目是Q07011(版本号145及序列号1);鼠/小鼠CD137的UniProt条目是P20334(版本号139及序列号1)),OX40(人OX40的UniProt条目是P23510(版本号138及序列号1);鼠/小鼠OX40的UniProt条目是P43488(版本号119及序列号1)),ICOS(人ICOS的UniProt条目是Q9Y6W8(版本号126及序列号1));鼠/小鼠ICOS的UniProt条目是Q9WV40(主要可引用登录号)或Q9JL17(次要可引用登录号)版本号102和序列版本2)),CD27(人CD27的UniProt条目是P26842(版本号160及序列号2);鼠/小鼠CD27的UniProt条目是P41272(版本号137及序列版本1)),4-1-BB(鼠/小鼠4-1-BB的UniProt条目是P20334(版本号140及序列版本1);人4-1-BB的UniProt条目是Q07011(版本号146及序列版本)),DAP10(人DAP10的UniProt条目是Q9UBJ5(版本号25及序列号1);鼠/小鼠DAP10的UniProt条目是Q9QUJ0(主要可引用登录号)或Q9R1E7(次要可引用登录号)版本号101和序列号1))或DAP12(人DAP12的UniProt条目是O43914(版本号146和序列号1);鼠/小鼠DAP12的UniProt条目是O054885(主要可引用登录号)或Q9R1E7(次要可引用登录号)版本号123和该序列号1)的片段/多肽部分。在本发明的某些实施方案中,依照本发明使用的CAR可以包含一个或多个,即1,2,3,4,5,6或7个本文中定义的共刺激性信号传导域。因而,在本发明的语境中,CAR可以包含鼠/小鼠或优选人CD28的片段/多肽部分作为第一共刺激性信号传导域且第二共刺激性信号传导域选自由鼠/小鼠或优选人CD27,CD28,CD137,OX40,ICOS,DAP10和DAP12,或其片段组成的组。优选地,依照本发明使用的CAR包含自人起源衍生的共刺激性信号传导域。如此,更加优选地,CAR中包含的共刺激性信号传导域可以包含如SEQID NO:15中显示的氨基酸序列(如由SEQ ID NO:30中显示的DNA序列编码的)或由其组成。
如此,可以任选地在本文中描述的CAR中包含的共刺激性信号传导域是全长CD27,CD28,CD137,OX40,ICOS,DAP10和DAP12的片段/多肽部分。鼠/小鼠全长CD28的氨基酸序列在本文中作为SEQ ID NO:75显示(鼠/小鼠,如由SEQ ID NO:74中显示的DNA序列编码的)。然而,因为在本发明的语境中最优选人序列,所以可以任选地在本文中描述的CAR中包含的共刺激性信号传导域是人全长CD27,CD28,CD137,OX40,ICOS,DAP10或DAP12的片段/多肽部分。人全长CD28的氨基酸序列在本文中作为SEQ ID NO:73显示(人,如由SEQ ID NO:72中显示的DNA序列编码的)。
在一个优选的实施方案中,CAR包含CD28或其片段作为共刺激性信号传导域。本文中描述的CAR可以包含CD28的片段作为共刺激性信号传导域,前提是包含至少一个CD28的信号传导域。特别是,CD28的任何部分/片段对于如本文中描述的CAR是合适的,只要包含至少一个CD28的信号传导基序。例如,依照本发明使用的CAR中包含的CD28多肽可以包含SEQID NO:15中显示的氨基酸序列(如由SEQ ID NO:30中显示的DNA序列编码的)或由其组成。作为共刺激性信号传导域发挥功能的CD28的胞内域可以包含具有序列YMNM(SEQ ID NO:76)和/或PYAP(SEQ ID NO:77)的自CD28多肽的胞内域衍生的序列。优选地,CAR包含自人起源衍生的多肽。例如,在CAR中可以包含的人CD28的片段/多肽部分可以包含SEQ ID NO:15中显示的氨基酸序列(如由SEQ ID NO:30中显示的DNA序列编码的)或由其组成。因而,在一个实施方案中,CAR包含如SEQ ID NO:15中显示的序列或与SEQ ID NO:15相比具有多至1,2,3,4,5,6,7,8,9或10处替代,删除或插入且特征在于具有共刺激性信号传导活性的序列。在本文中下文和在实施例和图中提供包含共刺激性信号传导域(CSD)的CAR的具体构造。可以测定共刺激性信号传导活性;例如通过增强的细胞因子释放(如通过ELISA测量的(IL-2,IFNγ,TNFα)),增强的增殖活性(如通过升高的细胞数目测量的),或增强的裂解活性(如通过LDH释放测定法测量的)。
如上文提到的,在本发明的一个实施方案中,CAR的共刺激性信号传导域可以衍生自人CD28基因(UniProt条目号:P10747(登录号及该序列的条目版本:173和版本1))且提供CD28活性,定义为本文中描述的转导细胞,像转导T细胞的细胞因子生成,增殖和裂解活性。可以如下测量CD28活性,即通过细胞因子的释放,通过细胞因子,诸如干扰素伽马(IFN-γ)或白介素2(IL-2)的ELISA或流式细胞术,T细胞的增殖,例如通过ki67测量来测量,细胞量化,通过流式细胞术,或裂解活性,如通过靶细胞的实时阻抗测量评估的(通过使用例如ICELLligence仪器,如描述于例如Thakur et al.,Biosens Bioelectron.35(1)(2012),503-506;Krutzik et al.,Methods Mol Biol.699(2011),179-202;Ekkens et al.,Infect Immun.75(5)(2007),2291-2296;Ge et al.,Proc Natl Acad Sci U S A.99(5)(2002),2983-2988;Düwell et al.,Cell Death Differ.21(12)(2014),1825-1837;Erratum,Cell Death Differ.21(12)(2014),161)。共刺激性信号传导域PYAP和YMNM对于CD28多肽的功能和上文列举的功能效果是有益的。YMNM域的氨基酸序列在SEQ ID NO:76中显示;PYAP域的氨基酸序列在SEQ ID NO:77中显示。因而,在本发明的抗原结合受体中,CD28多肽优选包含具有序列YMNM(SEQ ID NO:76)和/或PYAP(SEQ ID NO:77)的自CD28多肽的胞内域衍生的序列。这些信号传导基序可以存在于所描述CAR的胞内域内的任何位点。
而且,本文中描述的CAR可以包含至少一个接头(或“间隔物”)。接头通常是具有多至20个氨基酸的长度的肽。因而,在本发明的语境中,接头可以具有1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19或20个氨基酸的长度。例如,本文中描述的CAR可以包含包含抗原结合模块的胞外域,锚定跨膜域,共刺激性信号传导域和/或刺激性信号传导域之间的接头。此类接头具有它们提高CAR的不同多肽(即胞外域,锚定跨膜域,共刺激性信号传导域和/或刺激性信号传导域)独立折叠且如预期表现的概率的优势。如此,在本发明的语境中,包含至少一个抗原结合模块的胞外域,并不具有哺乳动物蛋白酶的切割位点的锚定跨膜域,共刺激性信号传导域和刺激性信号传导域可以包含在单链多功能多肽链中。融合构建物可以例如由一种或多种多肽组成,其包含包含至少一个抗原结合模块的一个或多个胞外域,一个或多个锚定跨膜域,一个或多个共刺激性信号传导域和/或一个或多个刺激性信号传导域。在优选的实施方案中,CAR包含并非单链构建物的抗原结合模块,即抗原结合模块是Fab或交叉Fab片段。优选地,此类构建物会包含如本文中描述的与免疫球蛋白轻或重链组合的单链重或轻链融合多肽,例如重链融合多肽包含一个或多个免疫球蛋白重链,一个或多个锚定跨膜域,一个或多个共刺激性信号传导域和/或一个或多个刺激性信号传导域且与一个或多个免疫球蛋白轻链组合,或轻链融合多肽包含一个或多个免疫球蛋白轻链,一个或多个锚定跨膜域,一个或多个共刺激性信号传导域和/或一个或多个刺激性信号传导域且与一个或多个免疫球蛋白重链组合。因而,抗原结合模块,锚定跨膜域,共刺激性信号传导域和刺激性信号传导域可以通过一个或多个相同或不同的如本文中描述的肽接头连接。例如,在本文中描述的CAR中,包含抗原结合模块的胞外域和锚定跨膜域之间的接头可以包含如SEQ ID NO:20中显示的氨基酸序列或由其组成。因而,锚定跨膜域,共刺激性信号传导域和/或刺激域可以通过肽接头或通过域的直接融合而彼此连接。
在一些实施方案中,胞外域中包含的抗原结合模块是单链可变片段(scFv),其是用10至约25个氨基酸的短接头肽连接的抗体的重(VH)和轻链(VL)的可变区的融合蛋白。接头通常富含甘氨酸(为了柔性),以及丝氨酸或苏氨酸(为了溶解度),而且可以连接VH的N端与VL的C端,或反之。例如,接头可以具有如SEQ ID NO:19中显示的氨基酸序列。
在依照本发明的一些实施方案中,胞外域中包含的抗原结合模块是单链Fab片段或scFab,其是由重链可变域(VH),抗体恒定域1(CH1),抗体轻链可变域(VL),抗体轻链恒定域(CL)和接头组成的多肽,其中所述抗体域和所述接头以N端至C端方向具有下面的次序之一:a)VH-CH1-接头-VL-CL,b)VL-CL-接头-VH-CH1,c)VH-CL-接头-VL-CH1或d)VL-CH1-接头-VH-CL;且其中所述接头是至少30个氨基酸,优选介于32个和50个之间氨基酸的多肽。经由CL域和CH1域之间的天然二硫键稳定所述单链Fab片段。
在一些实施方案中,胞外域中包含的抗原结合模块是交换单链Fab片段,其是由抗体重链可变域(VH),抗体恒定域1(CH1),抗体轻链可变域(VL),抗体轻链恒定域(CL)和接头组成的多肽,其中所述抗体域和所述接头以N端至C端方向具有下面的次序之一:a)VH-CL-接头-VL-CH1和b)VL-CH1-接头-VH-CL;其中VH和VL一起形成特异性结合抗原的抗原结合位点且其中所述接头是至少30个氨基酸的多肽。
本文中描述的CAR或其部分可以包含信号肽。此类信号肽会将蛋白质带至T细胞膜的表面。例如,在本文中描述的CAR中,信号肽可以具有如SEQ ID NO:78中显示的氨基酸序列(如由SEQ ID NO:79中显示的DNA序列编码的)。
如本文中描述的CAR的各成分可以以多种构造彼此融合以生成T细胞激活性CAR。
在一些实施方案中,CAR包含由与锚定跨膜域连接的重链可变域(VH)和轻链可变域(VL)构成的胞外域。在一些实施方案中,VH域在C端融合至VL域的N端,任选经由肽接头。在其它实施方案中,CAR进一步包含刺激性信号传导域和/或共刺激性信号传导域。在一个具体的此类实施方案中,CAR本质上由通过一个或多个肽接头连接的VH域和VL域,锚定跨膜域,和任选的刺激性信号传导域组成,其中VH域在C端融合至VL域的N端,且VL域在C端融合至锚定跨膜域的N端,其中锚定跨膜域在C端融合至刺激性信号传导域的N端。任选地,CAR进一步包含共刺激性信号传导域。在一个此类具体的实施方案中,抗原结合受体本质上由通过一个或多个肽接头连接的VH域和VL域,锚定跨膜域,刺激性信号传导域和共刺激性信号传导域组成,其中VH域在C端融合至VL域的N端,且VL域在C端融合至锚定跨膜域的N端,其中锚定跨膜域在C端融合至刺激性信号传导域的N端,其中刺激性信号传导域在C端融合至共刺激性信号传导域的N端。在一个备选的实施方案中,共刺激性信号传导域连接锚定跨膜域代替刺激性信号传导域。在一个优选的实施方案中,CAR本质上由通过一个或多个肽接头连接的VH域和VL域,锚定跨膜域,共刺激性信号传导域和刺激性信号传导域组成,其中VH域在C端融合至VL域的N端,且VL域在C端融合至锚定跨膜域的N端,其中锚定跨膜域在C端融合至共刺激性信号传导域的N端,其中共刺激性信号传导域在C端融合至刺激性信号传导域的N端。
在优选的实施方案中,抗原结合模块是Fab片段或交叉Fab片段。在一个优选的实施方案中,抗原结合模块在Fab或交叉Fab重链的C端融合至锚定跨膜域的N端,任选地经由肽接头。在一个备选的实施方案,抗原结合模块在Fab或交叉Fab轻链的C端融合至锚定跨膜域的N端,任选地经由肽接头。在其它实施方案中,CAR进一步包含刺激性信号传导域和/或共刺激性信号传导域。在一个具体的此类实施方案中,CAR本质上由通过一个或多个肽接头连接的Fab或交叉Fab片段,锚定跨膜域,和任选地刺激性信号传导域组成,其中Fab或交叉Fab片段在重或轻链的C端融合至锚定跨膜域的N端,其中锚定跨膜域在C端融合至刺激性信号传导域的N端。优选地,CAR进一步包含共刺激性信号传导域。在一个此类实施方案中,CAR本质上由通过一个或多个肽接头连接的Fab或交叉Fab片段,锚定跨膜域,刺激性信号传导域和共刺激性信号传导域组成,其中Fab或交叉Fab片段在重或轻链的C端融合至锚定跨膜域的N端,其中刺激性信号传导域在C端融合至共刺激性信号传导域的N端。在一个优选的实施方案中,共刺激性信号传导域连接锚定跨膜域代替刺激性信号传导域。在一个最优选的实施方案中,CAR本质上由Fab或交叉Fab片段,锚定跨膜域,共刺激性信号传导域和刺激性信号传导域组成,其中Fab或交叉Fab片段经由肽接头在重链的C端融合至锚定跨膜域的N端,其中锚定跨膜域在C端融合至共刺激性信号传导域的N端,其中共刺激性信号传导域在C端融合至刺激性信号传导域的N端。
如本文中描述的,依照本发明使用的CAR包含包含抗原结合模块的胞外域。具有一个能够特异性结合靶细胞抗原的抗原结合模块的CAR是有用的且优选的,特别是在需要CAR的高表达的情况中。在此类情况中,多于一个对靶细胞抗原特异性的抗原结合模块的存在可能限制CAR的表达效率。然而,在其它情况中,具有包含对靶细胞抗原特异性的两个或更多个抗原结合模块的CAR会是有利的,例如为了优化对靶位点的靶向或容许靶细胞抗原的交联。
在一个特定的实施方案中,抗原结合模块是能够特异性结合CD20的Fab片段,其中该抗原结合受体包含包含与SEQ ID NO:7的氨基酸序列至少约95%,96%,97%,98%,99%或100%同一的氨基酸序列的重链融合多肽和包含与SEQ ID NO:9的氨基酸序列至少约95%,96%,97%,98%,99%或100%同一的氨基酸序列的轻链多肽。
在一个特定的实施方案中,抗原结合模块是能够特异性结合CD20的Fab片段,其中该抗原结合受体包含包含与SEQ ID NO:50的氨基酸序列至少约95%,96%,97%,98%,99%或100%同一的氨基酸序列的轻链融合多肽和包含与SEQ ID NO:8的氨基酸序列至少约95%,96%,97%,98%,99%或100%同一的氨基酸序列的重链多肽。
在一个优选的实施方案中,抗原结合模块是能够特异性结合CD20的Fab片段,其中该抗原结合受体包含包含SEQ ID NO:7的氨基酸序列的轻链融合多肽和包含SEQ ID NO:9的氨基酸序列的重链多肽。
在本发明的语境中,靶抗原对T细胞,例如报告CAR-T细胞的结合导致细胞内信号传导和/或共信号传导域的激活。如本文中描述的,在一个实施方案中,细胞内信号传导和/或共信号传导域的激活导致如本文中描述的应答元件的激活。在一个优选的实施方案中,应答元件控制报告基因的表达。在此语境中,在CAR的抗原结合模块结合靶抗原之时或之后,应答元件激活如本文中描述的报告基因的表达。因而,在包含候选抗原结合模块的CAR结合靶抗原时报告细胞(例如CAR-T报告细胞)中的报告基因表达。在一个实施方案中,报告基因的表达指示抗原结合模块对靶抗原的结合。在此语境中,靶抗原对CAR的结合引发细胞应答,其导致对应答元件的活性的调控,或是直接地或是经由细胞信号传导的级联。应答元件是能受到转录因子等等沉默或激活的DNA元件。应答元件是本领域已知的且可商购的,例如在报告载体中。通常,应答元件包含DNA重复元件且是位于在转录因子结合时驱动报告基因表达的最小限度启动子上游的顺式作用增强子元件。
CAR对靶抗原,例如肿瘤相关抗原的结合激活应答元件。在一个实施方案中,应答元件是位于细胞核中的核应答元件。在另一个实施方案中,所述应答元件位于报告细胞中的质粒上。在一个实施方案中,测定法包含用包含编码在应答元件控制下的报告基因的DNA序列的表达载体转染报告细胞(例如CAR-T细胞)的预备步骤。另外,可以用包含编码CAR的DNA序列的表达载体转染报告细胞。可以用包含信号传导级联的所有元件(例如CAR,应答元件和报告基因)的表达载体或用分别表达不同成分的不同载体转染报告细胞。在一个实施方案中,报告细胞包含编码在应答元件控制下的报告基因的DNA序列和编码CAR的DNA序列。
因而,如本文中描述的,CAR功能性连接应答元件。在一个实施方案中,应答元件控制报告基因的表达。在一个实施方案中,应答元件的激活导致报告基因的表达。在一个实施方案中,应答元件是NFAT途径,NF-κB途径或AP-1途径的一部分。在一个优选的实施方案中,应答元件是NFAT途径的一部分。
在一个实施方案中,报告基因选自编码荧光蛋白的基因或编码其催化活性能检测的酶的基因。在一个实施方案中,报告基因编码荧光或发光蛋白。在一个实施方案中,报告基因编码绿色荧光蛋白(GFP)或萤光素酶。在又一个实施方案中,荧光蛋白选自由绿色荧光蛋白(GFP),黄色荧光蛋白(YFP),红色荧光蛋白(RFP),蓝色荧光蛋白(BFP,Heim etal.1994,1996),称作CFP的青色荧光变体(Heim et al.1996;Tsien 1998);称作YFP的黄色荧光变体(Ormo et al.1996;Wachter et al.1998);称作Sapphire的紫色可激发绿色荧光变体(Tsien 1998;Zapata-Hommer et al.2003);和称作增强型绿色荧光蛋白或EGFP的青色可激发绿色荧光变体(Yang et al.1996)增强型绿色荧光蛋白(EGFP)组成的组且可以例如通过活细胞成像(例如Incucyte)或荧光分光光度法来测量。在一个实施方案中,其催化活性能检测的酶选自由萤光素酶,β-半乳糖苷酶和碱性磷酸酶组成的组。在一个实施方案中,报告基因编码GFP。在一个优选的实施方案中,报告基因编码萤光素酶。可以通过可商购的测定法,例如通过萤光素酶1000测定系统或ONE-GloTM萤光素酶测定系统(均来自Promega)来检测萤光素酶的活性。在作为底物的萤光素以外,萤光素酶1000测定系统含有辅酶A(CoA),导致持续至少一分钟的强光强度。对于测定细胞内萤光素酶,必须在检测前裂解细胞。通过发光计自整个可见光谱收集作为反应的副产物生成的光。在本文中显示的实施例中,信号与所生成的萤光素酶的量成比例且因此与所使用的NFAT启动子的激活的强度成比例。在另一个实施方案中,使用萤光素酶测定法,其中萤光素酶是自细胞分泌的,因此,还可以在不裂解细胞的情况下实施测定法。
本文中进一步描述的是能够表达如本文中描述的CAR的转导T细胞,即报告CAR-T细胞。CAR涉及一种分子,其并不天然包含在T细胞中和/或表面上且其并不在正常(非转导)T细胞中或上(内源)表达。如此,将T细胞中和/或上如本文中描述的CAR人工引入T细胞。因而,人工引入且随后呈递在所述T细胞,例如报告CAR-T细胞中和/或表面上的如本文中描述的CAR包含如下域,其包含靶细胞,特别是肿瘤细胞的表面上呈递的抗原可及(体外或体内)的一个或多个抗原结合模块。另外,T细胞包含表达载体或经表达载体转染,该表达载体包含编码在应答元件控制下的报告基因的DNA序列,例如用于生成如本文中描述的报告CAR-T细胞。可以用包含信号传导级联的所有元件(例如CAR,应答元件和报告基因)的表达载体或用分别表达不同成分的不同载体转染T细胞。在此语境中,报告细胞包含编码在应答元件控制下的报告基因的DNA序列和编码CAR的DNA序列。因而,在转导之后,可以通过靶抗原,特别是通过抗原结合模块的靶抗原来激活如本文中描述的T细胞,例如报告CAR-T细胞。本文中描述的还是表达由编码如本文中描述的CAR的一种或多种核酸分子编码的CAR的转导T细胞。因而,在本发明的语境中,转导细胞可以包含编码如本文中描述的CAR和/或应答元件和报告基因的核酸分子。
在本发明的语境中,术语“转导T细胞”涉及遗传修饰的T细胞(即其中已经有意引入核酸分子的T细胞)。特别是,可以通过使用逆转录病毒或慢病毒转导将编码如本文中描述的CAR,应答元件和报告基因的核酸分子稳定整合入T细胞的基因组。CAR的胞外域可以包含如本文中描述的抗原结合模块的整个胞外域,但是也可以是其部分。所需要的最小大小是CAR中的抗原结合模块的抗原结合位点。在细胞表面上能检测到CAR的胞外部分,同时在细胞表面上检测不到细胞内部分(即共刺激性信号传导域和刺激性信号传导域)。可以通过使用特异性结合这种胞外域的抗体或通过抗原结合模块能够结合的识别域,例如靶抗原来进行CAR的胞外域的检测。可以使用这些抗体或抗原通过流式细胞术或显微术来检测胞外域。
转导细胞可以是任何免疫细胞。这些包括但不限于B细胞,T细胞,天然杀伤(NK)细胞,天然杀伤(NK)T细胞,γδT细胞,先天性淋巴样细胞,巨噬细胞,单核细胞,树突细胞,或嗜中性细胞及其永生化细胞系。优选地,所述免疫细胞会是淋巴细胞,优选NK或T细胞。所述T细胞包括CD4+T细胞和CD8+T细胞。触发白细胞的表面上的CAR会使得细胞针对靶细胞是响应性的,不管细胞起源的谱系。会发生激活,不管为CAR选择的刺激性信号传导域或共刺激性信号传导域且不依赖于另外的细胞因子的外源供应。
在实施例中和作为本发明的创造性概念证明,描述了基于Jurkat NFAT报告CAR-T细胞的激活测定法。在一个实施方案中,报告细胞是Jurkat NFAT细胞。Jurkat细胞是永生化人T淋巴细胞细胞系。Jurkat NFAT细胞系是本领域已知的且含有稳定整合入细胞的在NFAT应答元件控制下的萤火虫萤光素酶基因。依照如本文中描述的创造性概念和作为概念证明,用如本文中和所附实施例中描述的CAR转导Jukat NFAT细胞以生成如本文中描述的和如依照本发明使用的Jurkat NFAT报告CAR-T细胞。因而,在一个优选的实施方案中,Jurkat NFAT细胞另外包含如本文中描述的CAR,即这些细胞称作Jurkat NFAT报告CAR-T细胞。
在此语境中,可以用另外的核酸分子,例如编码如本文中描述的CAR和/或应答元件和/或报告基因的核酸分子共转导细胞。
具体地,本发明涉及一种用于生成表达一种或多种CAR和一种或多种应答元件和报告基因的报告CAR-T细胞的方法,其包含用一种或数种如本文中描述的载体转导T细胞和在容许在所述转导细胞中或上表达抗原结合受体的条件下培养转导T细胞的步骤。
用于转导细胞(例如T细胞)的方法是本领域已知的且包括但不限于(在转导核酸或重组核酸的情况中)例如电穿孔方法,磷酸钙方法,阳离子脂质方法或脂质体方法。可以通过使用可商购的转染试剂,例如Lipofectamine(由Invitrogen制造,目录号:11668027)常规和高度有效地转导要转导的核酸。在使用载体的情况中,可以以与上文所述核酸相同的方式转导载体,只要载体是质粒载体(即不是病毒载体的载体)。
优选转导T细胞在受控条件下,在它们的天然环境之外生长。特别是,术语“培养”意味着在体外的细胞(例如转导细胞)。培养细胞是保持与它们的原始组织来源分开的细胞活着的实验室技术。在本文中,在容许CAR在所述转导细胞中或上表达的条件下培养本发明的转导细胞。容许表达或转基因(即CAR和/或报告基因的)的条件是本领域普通知道的。
如本文中描述的,可以直接关联报告基因的表达与要测试的抗原结合模块的功能性和所得T细胞,例如报告CAR-T细胞的激活。例如,当使用编码荧光蛋白的基因或编码萤光素酶的基因作为报告基因时,直接关联自细胞检测光的量与要测试的抗体的靶抗原结合和特异性。
在一个实施方案中,靶抗原是细胞表面受体。在一个实施方案中,靶抗原是肿瘤相关抗原。在一个实施方案中,肿瘤相关抗原选自由CEA,Her2,TYRP,EGFR,MCSP,STEAP1,WT1和FolR1组成的组。
靶抗原不限于位于细胞表面上的蛋白质,而且还可以衍生自暂时或永久位于细胞内的多肽或蛋白质。在此类情况中,衍生自细胞内多肽或蛋白质的靶抗原可以由主要组织相容性复合物(MHC)的一种或数种分子呈递在细胞表面上。在一个实施方案中,靶抗原是MHC的分子结合的肽。在一个实施方案中,MHC是人MHC。在一个实施方案中,MHC的分子结合的肽具有介于8和100个之间,优选介于8和30个之间,更加优选介于8和16个之间氨基酸的总体长度。在一个实施方案中,靶抗原衍生自唯独或主要在肿瘤组织中表达的蛋白质。在一个实施方案中,蛋白质是细胞内蛋白质且肽是通过MHC-I或MHC-II途径生成并由MHC I类或MHC II类复合物呈递的。在一个实施方案中,肽是通过MHC-I途径生成并由MHC I类复合物呈递的。主要组织相容性复合物(MHC)I类分子将来自内源抗原的肽呈递至CD8+细胞毒性T细胞,而且因此,MHC肽复合物是免疫治疗办法的合适靶物。可以通过重组T细胞受体(TCR)靶向MHC肽复合物。然而,大多数TCR可能具有对于免疫疗法而言太低的亲和力,而具有TCR特异性的高亲和力结合模块会是有益的。为此目的,可以例如通过生成噬菌体展示文库(例如组合文库)和筛选此类文库来生成具有TCR样特异性的高亲和力可溶性抗体分子,如本文中进一步描述的。具有TCR样特异性的这些可溶性抗原结合模块(例如scFv或Fab)在本文中称作“T细胞受体样抗原结合模块”或“TCRL抗原结合模块”。在一个实施方案中,抗原结合模块是T细胞受体样(TCRL)抗原结合模块。TCRL抗原结合模块能够特异性结合唯独或主要在肿瘤组织中表达的肽抗原,其中肽抗原结合位于细胞,特别是癌细胞的表面上的MHC的分子。在此语境中,本发明的方法适合于以高通量测定法型式评估已建立的或新颖的TCRL抗原结合模块的特异性。
可以定性或定量,即通过报告基因的表达的存在或缺失测定抗原结合模块对靶抗原的结合;任何荧光或发光的缺失指示没有结合。对于结合和激活的定量测量,可以与参照比较报告基因激活的量。因而,如本文中描述的方法可以另外包含比较报告基因的表达的水平与参照的步骤。合适的参照通常包含阴性对照,其与参考测定法实质性相同,省略测定法或方法的一种本质成分。对于本发明的方法,省略的成分可以是例如省略添加靶细胞。或者,可以使用结合在测定法中不存在的不同靶抗原的报告CAR-T细胞。因而,在一个实施方案中,参照是在靶抗原缺失下报告基因的表达。在一个优选的实施方案中,参照是在靶细胞缺失下报告基因的表达。在具体的实施方案中,报告基因的表达与在靶细胞缺失下报告基因的表达相比要高至少2倍,3倍,4倍,5倍,10倍,100倍,1000x,或10000倍。
或者,可以通过某个阈来定义报告基因表达的缺失,即在扣除背景信号之后。通常通过用除了要测试的抗原结合模块的靶抗原以外的所有试剂或在包含所述靶抗原的靶细胞缺失下实施测定法来测定背景信号。可以例如依照本发明的方法选择新颖抗原结合模块,其通过为报告基因表达的基线激活定义阈并如果在靶细胞存在下报告基因的表达的水平相对于在靶细胞缺失下报告基因的表达比预先确定的阈值要高的话选择新颖抗原结合模块。因而,如本文中描述的方法可以另外包含如果在靶细胞存在下报告基因的表达的水平相对于在靶细胞缺失下报告基因的表达比预先确定的阈值要高的话选择新颖抗原结合模块的步骤。在具体的实施方案中,阈值是2,3,4,5,10,100,1000,或10000。
如本文中描述的新颖测定法是稳健的,适合于以高通量型式使用且就完成测定法需要的动手时间而言是有效的。而且,本发明的测定法耐受要分析的样品中死细胞的存在。这与其中通过测量细胞存活力或细胞死亡来测定抗体的结合和功能性的细胞测定法,例如杀伤测定法形成对比。
本文中描述的新测定法的一项别的优点是不需要清洗步骤。可以以任一次序将报告细胞添加至靶细胞,例如肿瘤细胞。在一个实施方案中,在合适的细胞培养型式中,例如在24孔板的孔中,在96孔板的孔中,或在384孔板的孔中将肿瘤样品添加至含有报告CAR-T细胞的细胞培养培养基。优选地,测试培养基是为细胞提供可存活长至48小时的条件的培养基。合适的培养基是例如Jurkat培养基,如实施例中概述的。在一个实施方案中,在微量滴定板中实施测定法。在一个实施方案中,微量滴定板适合于高通量筛选。可以以容许快速制备,加工,和分析多个反应的任何型式实施本发明的测定法。这可以是例如在多孔测定法板中(例如24孔,96孔或386孔)。可以手工或以机器人生成各种药剂的储液,并且可以使用可商购的分析软件,机器人,和能够检测荧光和/或发光信号的检测仪器以机器人进行所有后续移液,稀释,混合,分配,清洗,温育,样品读出,数据收集和分析。
在一个实施方案中,在步骤1.c)中提供约100000至约1000000个报告CAR-T细胞每个24孔板的孔。在一个优选的实施方案中,提供约300000至约700000个细胞或约400000至约600000个报告CAR-T细胞每个24孔板的孔。在一个实施方案中,在步骤1.c)中提供约500000个报告CAR-T细胞每个24孔板的孔。在一个实施方案中,在步骤1.c)中提供约10000至约100000个报告CAR-T每个96孔板的孔。在一个优选的实施方案中,提供约30000至约70000个报告CAR-T或约40000至约60000个报告CAR-T每个96孔板的孔。在一个实施方案中在步骤1.c)中提供约50000个报告CAR-T每个96孔板的孔。在一个实施方案中,在步骤1.c)中提供约3000至约30000个报告CAR-T细胞每个384孔板的孔。在一个优选的实施方案中,提供约5000至约15000个细胞或约8000至约12000个报告CAR-T细胞每个384孔板的孔。在一个实施方案中,在步骤1.c)中提供约10000个报告CAR-T细胞每个384孔板的孔。在一个实施方案中,在步骤1.c)中提供约200000至约2000000个报告CAR-T每ml细胞培养培养基。在一个优选的实施方案中,提供约600000至约1400000个报告CAR-T或约800000至约1200000个报告CAR-T每ml细胞培养培养基。在一个实施方案中,在步骤1.c)中提供约1000000个报告CAR-T每ml细胞培养培养基。
在一个实施方案中,在细胞培养物插入物中提供靶细胞,例如肿瘤细胞或肿瘤样品。在一个实施方案中,在Matrigel中包埋靶细胞,例如肿瘤样品。
在某些实施方案中,可以使用本发明的方法来评估要在T细胞双特异性(TCB)型式中包括的新颖抗原结合模块的特异性。依照本发明的方法特别适合于为TCB评估和选择新颖抗原结合模块,因为本发明的方法测量T细胞激活。本领域已知的测定法(例如基于亲和力的FACS测定法)的一项缺点是测量的亲和力并不总是反映TCB型式的特异性。TCB是高度有力的分子,早就能够经由微摩尔范围中的结合亲和力介导T细胞激活和杀伤。因此,包含新颖靶抗原结合模块的TCB需要是高度选择性的以避免非特异性反应性,例如杀伤健康细胞或同种异体反应性。如本发明中描述的方法满足此类型式的高要求,不受理论束缚,本发明的测定法基于T细胞激活和相当的作用机制。因而,提供的是一种如本文中描述的方法,其中在靶细胞存在下高水平的报告基因的表达和在靶细胞缺失下低水平的报告基因的表达指示抗原结合模块的高特异性,特别是当将抗原结合模块转移入T细胞双特异性(TCB)抗体型式时。而且,提供的是一种用于生成TCB抗体的方法,其中TCB抗体型式包含对靶抗原特异性的第一抗原结合模块和能够特异性结合T细胞激活性受体的第二抗原结合模块,其中第一抗原结合模块是依照如本文中描述的方法选择的。在优选的实施方案中,T细胞激活性受体是CD3。
在一个此类实施方案中,TCB型式包含
(a)第一抗原结合模块,特别是能够特异性结合靶细胞抗原的Fab分子;
(b)第二抗原结合模块,特别是能够特异性结合CD3的Fab分子。
在一个具体的实施方案中,双特异性抗体包含
(a)第一抗原结合模块,其是能够特异性结合靶细胞抗原的Fab分子;
(b)第二抗原结合模块,其是能够特异性结合CD3的Fab分子,且其包含SEQ ID NO:88,SEQ ID NO:89和SEQ ID NO:90的重链互补决定区(CDR)和SEQ ID NO:91,SEQ ID NO:92,SEQ ID NO:93的轻链CDR。
具有一个能够特异性结合靶细胞抗原的抗原结合模块的双特异性抗体是有用的,特别是在其中在高亲和力抗原结合模块的结合后预期靶细胞抗原的内在化的情况中。在此类情况中,多于一个对靶细胞抗原特异性的抗原结合模块的存在可能增强靶细胞抗原的内在化,由此降低它的可用度。
然而,在许多其它情况中,具有包含两个或更多个对靶细胞抗原特异性的抗原结合模块的双特异性抗体会是有利的,例如为了优化对靶位点的靶向。
因而,在某些实施方案中,TCB型式包含能够特异性结合靶细胞抗原的第三抗原结合模块。在又一个实施方案中,第三抗原结合模块是常规Fab分子,或交换Fab分子,其中Fab轻链和Fab重链的可变或恒定区任一是交换的。在一个实施方案中,第三抗原结合模块能够与第一抗原结合模块特异性结合相同靶细胞抗原。在一个特定的实施方案中,第二抗原结合模块能够特异性结合CD3,且第一和第三抗原结合模块能够特异性结合靶细胞抗原。在一个特定的实施方案中,第一和该第三抗原结合模块是相同的(即它们包含相同的氨基酸序列)。
本方面的又一个方面是编码依照本发明使用的一种或数种CAR的核酸和载体。核酸分子可以在调节序列控制下。例如,可以采用启动子,转录增强子和/或容许CAR的诱导表达的序列。在本发明的语境中,核酸分子在组成性或可诱导启动子控制下表达。合适的启动子是例如CMV启动子(Qin et al.,PLoS One 5(5)(2010),e10611),UBC启动子(Qin etal.,PLoS One 5(5)(2010),e10611),PGK(Qin et al.,PLoS One 5(5)(2010),e10611),EF1A启动子(Qin et al.,PLoS One 5(5)(2010),e10611),CAGG启动子(Qin et al.,PLoSOne 5(5)(2010),e10611),SV40启动子(Qin et al.,PLoS One 5(5)(2010),e10611),COPIA启动子(Qin et al.,PLoS One 5(5)(2010),e10611),ACT5C启动子(Qin et al.,PLoS One 5(5)(2010),e10611),TRE启动子(Qin et al.,PLoS One 5(5)(2010),e10611),Oct3/4启动子(Chang et al.,Molecular Therapy 9(2004),S367-S367(doi:10.1016/j.ymthe.2004.06.904)),或Nanog启动子(Wu et al.,Cell Res.15(5)(2005),317-24)。在本文中,术语载体涉及能在它所引入的细胞中(即在转导细胞中)自主复制的环状或线性核酸分子。分子生物学的技术人员知道许多合适的载体,其选择会取决于想要的功能且包括质粒,粘粒,病毒,噬菌体和遗传工程中常规使用的其它载体。可以使用本领域技术人员公知的方法来构建各种质粒和载体;见例如Sambrook et al.(同上)和Ausubel,CurrentProtocols in Molecular Biology,Green Publishing Associates and WileyInterscience,N.Y.(1989),(1994)中描述的技术。或者,可以将本发明的多核苷酸和载体重建入脂质体用于投递至靶细胞。如下文更为详细讨论的,使用克隆载体来分离DNA的各个序列。在需要特定多肽的表达的情况中,可以将有关序列转移入表达载体。典型的克隆载体包括pBluescript SK,pGEM,pUC9,pBR322,pGA18和pGBT9。典型的表达载体包括pTRE,pCAL-n-EK,pESP-1,pOP13CAT。
在本发明的语境中,载体可以是多顺反子。此类调节序列(控制元件)是技术人员已知的且可以包括启动子,剪接盒,翻译起始密码子,用于将插入物引入载体的翻译和插入位点。在本发明的语境中,所述核酸分子可操作连接所述表达控制序列,容许在真核或原核细胞中表达。涵盖的是所述载体是包含编码如本文中定义的CAR的核酸分子的表达载体。可操作连接指其中所描述的成分处于允许它们以它们的预定方式发挥功能的相互关系的并列。控制序列可操作连接编码序列是如下方式的连接,使得在与控制序列相容的条件下实现编码序列的表达。在控制序列是启动子的情况中,对技术人员显而易见的是优选使用双链核酸。
在本发明的语境中,所述载体是表达载体。表达载体是可用于转化选定的细胞并在选定的细胞中提供编码序列的表达的构建物。例如,表达载体可以是克隆载体,二元载体或整合载体。表达包含核酸分子的转录,优选转录成可翻译mRNA。确保在原核生物和/或真核细胞中表达的调节元件是本领域技术人员公知的。在真核细胞的情况中,它们在正常情况下包含确保起始转录的启动子和任选地确保终止转录和稳定转录物的polyA信号。允许在原核宿主细胞中表达的可能的调节元件包含例如大肠杆菌中的PL,lac,trp或tac启动子,而允许在真核宿主细胞中表达的调节元件的例子是酵母中的AOX1或GAL1启动子或哺乳动物和其它动物细胞中的CMV,SV40,RSV启动子(劳斯肉瘤病毒),CMV增强子,SV40增强子或珠蛋白内含子。
在负责起始转录的元件之外,此类调节元件还可以包含多核苷酸下游的转录终止信号,诸如SV40-polyA位点或tk-polyA位点。而且,取决于使用的表达系统,可以将编码能够将多肽指导至细胞隔室或将它分泌入培养基的信号肽的前导序列添加至所述核酸序列的编码序列且是本领域公知的t;还见例如所附实施例。
将前导序列以适宜状态与翻译起始和终止序列组装在一起,而且优选地,前导序列能够指导翻译的蛋白质或其部分分泌入周质空间或胞外培养基。任选地,异源序列可以编码CAR,其包括赋予期望特征的N端鉴定肽,例如稳定表达的重组产物或简化其纯化;见上文。在此语境中,合适的表达载体是本领域已知的,诸如Okayama-Berg cDNA表达载体pcDV1(Pharmacia),pCDM8,pRc/CMV,pcDNA1,pcDNA3(In-vitrogene),pEF-DHFR,pEF-ADA或pEF-neo(Raum et al.Cancer Immunol Immunother 50(2001),141-150)或pSPORT1(GIBCOBRL)。
在T细胞或它的前体细胞中引入的所描述的核酸分子或载体可以或是整合入细胞的基因组或是可以在染色体外维持。
例示性实施方案
1.一种用于评估抗原结合模块的特异性的方法,其包含下述步骤:
a.提供对靶抗原特异性的抗原结合模块;
b.生成嵌合抗原受体(CAR)表达性报告T(CAR-T)细胞,其通过:
i.将该抗原结合模块转移入与应答元件可操作偶联的CAR载体系统;和
ii.将该CAR载体系统转移入包含在该应答元件控制下的报告基因的报告T细胞;
c.使该报告CAR-T细胞与在表面上包含该靶抗原的靶细胞接触,特别是其中该靶细胞是癌细胞;和
d.通过测定该报告基因的表达来测定T细胞激活以建立该抗原结合模块的特异性。
2.实施方案1的方法,其中该抗原结合模块是Fab片段,特别是自噬菌体展示文库筛选衍生的Fab片段。
3.实施方案1或2的方法,其中该抗原结合模块包含可变重链域(VH)和可变轻链域(VL)且其中将该抗原结合模块的VH和VL域转移至该CAR,特别是其中将该抗原结合模块的VH和VL域的编码多核苷酸序列转移至该CAR载体系统。
4.实施方案1至3任一项的方法,其中该CAR载体系统编码包含抗原结合模块,锚定跨膜域和至少一个细胞内信号传导和/或共信号传导域的CAR。
5.实施方案4的方法,其中该靶抗原对该报告CAR-T细胞的结合导致该细胞内信号传导和/或共信号传导域的激活。
6.实施方案5或6任一项的方法,其中该细胞内信号传导域的激活导致该应答元件的激活。
7.依照实施方案1至6任一项的方法,其中该应答元件控制该报告基因的表达。
8.依照实施方案1至7任一项的方法,其中该应答元件的激活导致该报告基因的表达。
9.依照实施方案1至8任一项的方法,其中该应答元件是NFAT途径,NF-κB途径或AP-1途径的一部分。
10.依照实施方案1至9任一项的方法,其中该报告基因编码发光蛋白,特别是荧光蛋白。
11.依照实施方案1至10任一项的方法,其中该报告基因编码绿色荧光蛋白(GFP)或萤光素酶。
12.依照实施方案1至11任一项的方法,其中该靶抗原是细胞表面受体。
13.依照实施方案1至12任一项的方法,其中该靶抗原是与人主要组织相容性复合物(MHC)的分子结合的肽。
14.依照实施方案13的方法,其中该抗原结合模块是T细胞受体样(TCRL)抗原结合模块。
15.依照实施方案1至14任一项的方法,其另外包含下述步骤:
e.将该报告基因的表达的水平与参照比较。
16.依照实施方案15的方法,其中该参照是在该靶细胞缺失下该报告基因的表达。
17.依照实施方案16的方法,其中该报告基因的表达与在该靶细胞缺失下该报告基因的表达相比要高至少2倍,3倍,4倍,5倍,10倍,100倍,1000倍,或10000倍。
18.依照实施方案15的方法,其另外包含下述步骤:
f.如果在该靶细胞存在下该报告基因的表达的水平相对于在该靶细胞缺失下该报告基因的表达比预先确定的阈值要高的话,选择该新颖抗原结合模块。
19.依照实施方案18的方法,其中该阈值是2,3,4,5,10,100,1000,或10000。
20.依照实施方案1至19任一项的方法,其中在该靶细胞存在下高水平的该报告基因的表达和在该靶细胞缺失下低水平的该报告基因的表达指示该抗原结合模块的高特异性。
21.依照实施方案1至20任一项的方法,其中在该靶细胞存在下高水平的该报告基因的表达和在该靶细胞缺失下低水平的该报告基因的表达指示包含该抗原结合模块的T细胞双特异性(TCB)抗体的高特异性。
22.依照实施方案1至21任一项的方法,其中该方法是体外方法。
23.一种用于生成TCB抗体的方法,其中该TCB抗体型式包含对靶抗原特异性的第一抗原结合模块和能够特异性结合T细胞激活性受体的第二抗原结合模块,其中该第一抗原结合模块是依照实施方案1至22任一项的方法选择的。
24.实施方案23的方法,其中该T细胞激活性受体是CD3。
25.如本文中之前描述的方法。
实施例
下面是本发明的方法和组合物的实施例。理解的是,鉴于上文提供的一般性描述,可以实践多种其它实施方案。
重组DNA技术
使用标准方法来操作DNA,如Sambrook et al.,Molecular cloning:Alaboratory manual;Cold Spring Harbor Laboratory Press,Cold Spring Harbor,NewYork,1989中描述的。依照制造商的说明书使用分子生物学试剂。关于人免疫球蛋白轻和重链的核苷酸序列的一般信息在Kabat,E.A.et al.,(1991)Sequences of Proteins ofImmunological Interest,Fifth Ed.,NIH Publication No 91-3242中给出。
DNA测序
通过双链测序来测定DNA序列。
基因合成
想要的基因区段或是使用适宜的模板通过PCR来生成或是由Geneart AG(Regensburg,Germany)自合成的寡核苷酸和PCR产物通过自动化基因合成来合成。将侧翼为单一限制性内切核酸酶切割位点的基因区段克隆入标准克隆/测序载体。自转化细菌纯化质粒DNA并通过UV光谱术测定浓度。通过DNA测序确认亚克隆基因片段的DNA序列。基因区段设计成具有合适的限制性位点以容许亚克隆入相应的表达载体。所有构建物均设计成具有编码在真核细胞中将蛋白质靶向分泌的前导肽的5’端DNA序列。
蛋白质纯化
参考标准方案,自经过过滤的细胞培养物上清液纯化蛋白质。简言之,将抗体应用于蛋白A Sepharose柱(GE Healthcare)并用PBS清洗。于pH 2.8实现抗体的洗脱,继以立即中和样品。在PBS中或在20mM组氨酸,150mM NaCl,pH 6.0中通过大小排阻层析术(Superdex200,GE Healthcare)将聚集的蛋白质与单体抗体分开。合并单体抗体级分,使用例如MILLIPORE Amicon Ultra(30MWCO)离心浓缩机浓缩(在需要时),冷冻并贮存于-20℃或-80℃。提供部分样品用于后续蛋白质分析和分析性表征,例如通过SDS-PAGE和大小排阻层析术(SEC)。
SDS-PAGE
依照制造商的说明书使用预制凝胶系统(Invitrogen)。特别地,使用10%或4-12%Bis-TRIS预制凝胶(pH 6.4)和MES(还原凝胶,具有抗氧化剂运行缓冲液添加剂)或MOPS(非还原凝胶)运行缓冲液。
分析性大小排阻层析术
通过HPLC层析术实施大小排阻层析术(SEC),用于测定抗体的聚集和寡聚状态。简言之,将经过蛋白A纯化的抗体应用于Agilent HPLC 1100系统上的300mM NaCl,50mMKH2PO4/K2HPO4,pH 7.5中的Tosoh TSKgel G3000SW柱或Dionex HPLC系统上的2x PBS中的Superdex 200柱(GE Healthcare)。通过UV吸光度和峰面积积分量化洗脱的蛋白质。BioRad凝胶过滤标准品151-1901充当标准品。
Jurkat NFAT T细胞的慢病毒转导
为了生成慢病毒载体,在慢病毒多核苷酸载体中在组成性有活性的人巨细胞病毒立即早期启动子(CMV)下同框克隆CAR的正确装配体的相应DNA序列。逆转录病毒载体含有旱獭肝炎病毒转录后调节元件(WPRE),中央多聚嘌呤束(cPPT)元件,pUC复制起点和编码用于推进细菌中的繁殖和选择的抗生素抗性的基因。
为了生成功能性病毒颗粒,使用60-70%汇合的Hek293T细胞(ATCC CRL3216)和含有CAR的载体以及pCMV-VSV-G:pRSV-REV:pCgpV转移载体以3:1:1:1比实施基于Lipofectamine LTXTM的转染。48小时后收集上清液,以250g离心5分钟以去除细胞碎片并穿过0.45或0.22μm聚醚砜滤器过滤。使用浓缩的病毒颗粒(Lenti-x-Concentrator,Takara)来转导Jurkat NFAT细胞(Signosis)。使用FACSARIA分选仪(BD Bioscience)作为集合或单一克隆分选阳性转导细胞。在细胞扩充至适宜密度之后将Jurkat NFAT T细胞用于实验。
实施例1
本文中描述的是Jurkat NFAT T细胞报告测定法,使用CD20表达性SUDHDL4肿瘤细胞作为靶细胞和抗CD20-Fab-CD28ATD-CD28CSD-CD3zSSD表达性Jurkat NFAT T细胞的分选单克隆作为靶细胞(图4)。作为阳性对照,将96孔板(Cellstar Greiner-bio-one,目录号655185)的一些孔在磷酸盐缓冲盐水(PBS)中用10μg/ml CD3抗体(来自)或是于4℃包被过夜或是于37℃包被至少1小时。将CD3抗体包被的孔用PBS清洗两次,在最终的清洗步骤之后完全去除PBS。对Jurkat NFAT野生型细胞或改造成表达抗原结合受体抗CD20-Fab-CD28ATD-CD28CSD-CD3zSSD的Jurkat NFAT CAR细胞(进一步称作报告细胞)计数并使用Cedex HiRes检查它们的存活力。将细胞数调节至1x106个可存活细胞/ml。因此将细胞悬浮液的适宜小份于室温(RT)以210g成团粒5分钟并在新鲜的RPMI-160+10%FCS+1%Glutamax(生长培养基)中重悬浮。同样对表达感兴趣抗原的靶细胞计数并检查它们的存活力。将细胞数在生长培养基中调节至1x106个可存活细胞/ml。以200μl的终体积在96孔悬浮培养板(Greiner-bio one)中一式三份以10:1,5:1,2:1或1:1E:T比(总共110,000个细胞每孔)分配靶细胞和报告细胞。在那之后将96孔板以190g于室温离心2分钟并用密封。
在增湿气氛中于37℃和5%CO2温育20小时后,通过使用多通道移液器上下移液10次来混合每个孔的内容。将100μl细胞悬浮液转移至新的白色透明底96孔板(Greiner-bio-one)并添加100μl ONE-GloTM萤光素酶测定法(Promega)。在黑暗中在旋转摇床上以300rpm于室温温育15分钟后使用Spark10M读板仪测量发光,1秒/孔作为检测时间。
条形图显示依赖于不同E:T比且依赖于与靶细胞共培养的时间的抗CD20-Fab-CD28ATD-CD28CSD-CD3zSSD表达性Jurkat NFAT T细胞的激活。显示了Jurkat NFAT T细胞激活依赖于与靶细胞共培养的持续时间且依赖于E:T比。对于所有测试的条件,20小时的温育时间展示最高的发光信号。而且,在不同E:T比中,10:1E:T比描绘最高的可检测发光信号。Jurkat NFAT野生型T细胞仅仅显示时间依赖性发光信号升高,由此在40小时后能检测到最高的发光信号。检测到的发光信号不依赖于E:T比且一般还明显低于在各自时间点为抗CD20-Fab-CD28ATD-CD28CSD-CD3zSSD表达性Jurkat NFAT T细胞检测到的每一个发光信号。一般地,如果在CD3抗体包被的孔中温育细胞的话,能检测到最高的发光信号。抗CD20-Fab-CD28ATD-CD28CSD-CD3zSSD表达性Jurkat NFAT T细胞描绘与未转导的Jurkat NFAT对照T细胞相比更高的信号。每个点代表技术上的一式两份的均值。
实施例2
本文中描述的是Jurkat NFAT T细胞报告测定法,使用CD20表达性SUDHDL4肿瘤细胞作为靶细胞和抗CD20-Fab-CD28ATD-CD28CSD-CD3zSSD或抗CD20-交叉Fab-CD28ATD-CD28CSD-CD3zSSD表达性Jurkat NFAT T细胞的分选单克隆作为靶细胞(图5)。作为阳性对照,将96孔板(Cellstar Greiner-bio-one,目录号655185)的孔在磷酸盐缓冲盐水(PBS)中用10μg/ml CD3抗体(来自)于4℃包被过夜。将CD3抗体包被的孔用PBS清洗两次,在最终的清洗步骤之后完全去除PBS。对Jurkat NFAT野生型细胞或改造成表达抗CD20-Fab-CD28ATD-CD28CSD-CD3zSSD或抗CD20-交叉Fab-CD28ATD-CD28CSD-CD3zSSD的JurkatNFAT T细胞(进一步称作报告细胞)计数并使用Cedex HiRes检查它们的存活力。将细胞数调节至1x106个可存活细胞/ml。因此将细胞悬浮液的适宜小份于室温(RT)以210g成团粒5分钟并在新鲜的RPMI-160+10%FCS+1%Glutamax(生长培养基)中重悬浮。同样对表达感兴趣抗原的靶细胞计数并检查它们的存活力。将细胞数在生长培养基中调节至1x106个可存活细胞/ml。以200μl的终体积在96孔悬浮培养板(Greiner-bio one)中一式三份以5:1E:T比(总共110,000个细胞每孔)分配靶细胞和报告细胞。在那之后将96孔板以190g于室温离心2分钟并用密封。
在增湿气氛中于37℃和5%CO2温育20小时后,通过使用多通道移液器上下移液10次来混合每个孔的内容。将100μl细胞悬浮液转移至新的白色透明底96孔板(Greiner-bio-one)并添加100μl ONE-GloTM萤光素酶测定法(Promega)。在黑暗中在旋转摇床上以300rpm于室温温育15分钟后使用Spark10M读板仪测量发光,1秒/孔作为检测时间。
条形图显示与靶细胞共培养后抗CD20-Fab-CD28ATD-CD28CSD-CD3zSSD表达性Jurkat NFAT T细胞和抗CD20-交叉Fab-CD28ATD-CD28CSD-CD3zSSD表达性Jurkat NFAT T细胞的激活。如果在没有靶细胞的情况下培养抗CD20-Fab-CD28ATD-CD28CSD-CD3zSSD或抗CD20-交叉Fab-CD28ATD-CD28CSD-CD3zSSD表达性Jurkat NFAT T细胞或Jurkat NFAT对照T细胞的话,检测不到发光信号。当用CD3抗体包被的板共培养抗CD20-Fab-CD28ATD-CD28CSD-CD3zSSD或抗CD20-交叉Fab-CD28ATD-CD28CSD-CD3zSSD表达性Jurkat NFAT T细胞或Jurkat NFAT对照T细胞与靶细胞时检测当最高的发光信号。令人惊讶地,交叉Fab型式导致Jurkat NFAT T细胞的强激活连同CD3介导的信号传导。每个点代表技术上的一式三份的均值。通过误差条来指示标准偏差。
实施例3
本文中描述的是使用CD20表达性SUDHDL4肿瘤细胞作为靶细胞和抗CD20-scFab-CD28ATD-CD28CSD-CD3zSSD表达性Jurkat NFAT T细胞的分选集合作为靶细胞实施的Jurkat NFAT T细胞报告测定法(图6)。
作为阳性对照,将96孔板(Cellstar Greiner-bio-one,目录号655185)的孔在磷酸盐缓冲盐水(PBS)中用10μg/ml CD3抗体(来自)或是于4℃包被过夜或是于37℃包被至少1小时。将CD3抗体包被的孔用PBS清洗两次,在最终的清洗步骤之后完全去除PBS。对Jurkat NFAT野生型T细胞或改造成表达抗CD20-scFab-CD28ATD-CD28CSD-CD3zSSD的Jurkat NFAT T细胞(进一步称作报告细胞)计数并使用Cedex HiRes检查它们的存活力。将细胞数调节至1x106个可存活细胞/ml。因此将细胞悬浮液的适宜小份于室温(RT)以210g成团粒5分钟并在新鲜的RPMI-160+10%FCS+1%Glutamax(生长培养基)中重悬浮。同样对表达感兴趣抗原的靶细胞计数并检查它们的存活力。将细胞数在生长培养基中调节至1x106个可存活细胞/ml。以200μl的终体积在96孔悬浮培养板(Greiner-bio one)中一式三份以10:1,5:1,2:1或1:1E:T比(总共110,000个细胞每孔)分配靶细胞和报告细胞。在那之后将96孔板以190g于室温离心2分钟并用密封。
在增湿气氛中于37℃和5%CO2温育20小时后,通过使用多通道移液器上下移液10次来混合每个孔的内容。将100μl细胞悬浮液转移至新的白色透明底96孔板(Greiner-bio-one)并添加100μl ONE-GloTM萤光素酶测定法(Promega)。在黑暗中在旋转摇床上以300rpm于室温温育15分钟后使用Spark10M读板仪测量发光,1秒/孔作为检测时间。
条形图显示以不同E:T比与SUDHL4靶细胞共培养20小时后抗CD20-scFab-CD28ATD-CD28CSD-CD3zSSD表达性Jurkat NFAT T细胞的激活。在不同E:T比中,10:1和5:1E:T比显示最高的发光信号(图6黑色条)。还有,在CD3抗体包被的孔中以10:1E:T比共培养的抗CD20-scFab-CD28ATD-CD28CSD-CD3zSSD表达性Jurkat NFAT T细胞显示与没有CD3刺激的相同条件相当的高发光信号。
而且,Jurkat NFAT野生型细胞不显示任何激活,不依赖于不同E:T比,但是如果在CD3抗体包被的孔中以10:1E:T比共培养的话能检测到明显的发光信号,这证明它们的功能性。
别的对照实验显示单独的靶细胞或抗CD20-scFab-CD28ATD-CD28CSD-CD3zSSD表达性T细胞以及具有靶细胞的CD3抗体包被的孔不显示任何激活。每个点代表技术上的一式三份的均值。通过误差条来指示标准偏差。
实施例4
本文中描述的是使用CD20表达性SUDHDL4肿瘤细胞作为靶细胞和抗CD20-Fab-CD28ATD-CD28CSD-CD3zSSD表达性Jurkat NFAT T细胞或抗CD20-scFv-CD28ATD-CD28CSD-CD3zSSD表达性Jurkat NFAT T细胞的分选集合作为靶细胞实施的Jurkat NFAT T细胞报告测定法(图7)。
作为阳性对照,将96孔板(Cellstar Greiner-bio-one,目录号655185)的孔在磷酸盐缓冲盐水(PBS)中用10μg/ml CD3抗体(来自)或是于4℃包被过夜或是于37℃包被至少1小时。将CD3抗体包被的孔用PBS清洗两次,在最终的清洗步骤之后完全去除PBS。对Jurkat NFAT野生型T细胞或改造成表达抗CD20-Fab-CD28ATD-CD28CSD-CD3zSSD或抗CD20-scFv-CD28ATD-CD28CSD-CD3zSSD的Jurkat NFAT T细胞(进一步称作报告细胞)计数并使用Cedex HiRes检查它们的存活力。将细胞数调节至1x106个可存活细胞/ml。因此将细胞悬浮液的适宜小份于室温(RT)以210g成团粒5分钟并在新鲜的RPMI-160+10%FCS+1%Glutamax(生长培养基)中重悬浮。同样对表达感兴趣抗原的靶细胞计数并检查它们的存活力。将细胞数在生长培养基中调节至1x106个可存活细胞/ml。以200μl的终体积在96孔悬浮培养板(Greiner-bio one)中一式三份以10:1,5:1,2:1或1:1E:T比(总共110,000个细胞每孔)分配靶细胞和报告细胞。在那之后将96孔板以190g于室温离心2分钟并用密封。
在增湿气氛中于37℃和5%CO2温育20小时后,通过使用多通道移液器上下移液10次来混合每个孔的内容。将100μl细胞悬浮液转移至新的白色透明底96孔板(Greiner-bio-one)并添加100μl ONE-GloTM萤光素酶测定法(Promega)。在黑暗中在旋转摇床上以300rpm于室温温育15分钟后使用Spark10M读板仪测量发光,1秒/孔作为检测时间。
条形图显示以5:1E:T比与SUDHL4靶细胞共培养20小时后抗CD20-scFv-CD28ATD-CD28CSD-CD3zSSD表达性Jurkat NFAT T细胞的激活。在CD3抗体包被的孔中与靶细胞共培养的抗CD20-scFv-CD28ATD-CD28CSD-CD3zSSD表达性Jurkat NFAT T细胞显示最高发光信号,其与没有CD3刺激相同条件相当。令人惊讶地,交叉Fab型式导致差异的Jurkat NFAT T细胞激活,其中连同CD3介导的信号传导发现强激活。而且,Jurkat NFAT野生型细胞不显示任何激活,但是如果在CD3抗体包被的孔中以10:1E:T比共培养的话能检测到明显的发光信号,这证明它们的功能性。每个条代表技术上的一式三份的均值。通过误差条来指示标准偏差。
实施例5
最初通过噬菌体展示文库筛选选择两种抗体候选5E11和33H09来结合与MHCI复合的WT1肽“RMF”。通过流式细胞术对IgG型式的两种结合物的稀释系列检查结合。因此,将经10μM靶肽“RMF”,10μM脱靶肽“VLD”脉冲或留置未脉冲的T2细胞与抗体的稀释系列一起在冰上温育30分钟。在去除未结合的结合物的清洗步骤后,将细胞与荧光标记的二抗(抗huFc,Jackson ImmunoResearch)一起温育,继以另一个清洗步骤和通过流式细胞术检测剩余抗体。重要的是,在这种测定法中,两种评估的候选(5E11和33H09)就特异性而言看来是相似的,在经靶肽“RMF”脉冲的T2细胞上有明显的浓度依赖性信号,比较而言,对经脱靶肽“VLD”脉冲的T2细胞或未脉冲的T2细胞没有结合(图8)。
在图9中描绘的Jurkat NFAT报告CAR-T细胞测定法中评估相同的两种抗体候选(5E11和33H09)加上两种针对相同靶肽/MHC的别的候选(ESK1和11D06)。
这种Jurkat NFAT报告CAR-T细胞测定法采用经由四种不同的嵌入在细胞表面上表达的嵌合抗原受体的Fab(分别是5E11(SEQ ID NO 86和87),ESK1,33H09(SEQ ID NO 84和85)或11D06(SEQ ID NO 82和83))识别HLA-A2/WT1肽RMF的Jurkat NFAT报告细胞的集合。
在与Jurkat NFAT报告细胞共温育前,于37℃以10-5M用各自肽脉冲T2细胞2小时或留置不脉冲。在384孔白色透明平底板(Greiner-bio-one)中一式三份以5:1E:T比(10,000个效应细胞每2000个靶细胞每孔)分配靶细胞和报告细胞。将Jurkat NFAT报告CAR-T细胞和靶细胞于37℃共温育7小时,继以添加6μl/孔ONE-GloTM萤光素酶底物(Promega)和使用TECAN infinite M1000Pro读板仪直接测量发光。作为柱图呈现来自经RMF或VLD肽脉冲的T2细胞上的一式三份测量的CAR-NFAT信号传导的激活(图9)。与萤光素酶底物一起温育但没有报告细胞的在RMF肽(靶)较之VLD肽(脱靶)和不同脉冲的T2细胞上的信号的比较有助于评估各自结合物的激活的特异性。
与图8中描绘的基于FACS的筛选不同,这种Jurkat NFAT报告CAR-T细胞测定法确实就与在脱靶上的非特异性激活相反,在靶上的特异性T细胞激活而言清楚地区分候选5E11和33H09。
如上但没有任何与靶细胞的共温育的与萤光素酶底物一起温育的各自JurkatNFAT报告细胞集合的背景信号较低,如图10中描绘的。
实施例6
这种Jurkat NFAT报告CAR-T细胞测定法采用识别两种不同HLA-A2/肽靶的JurkatNFAT报告细胞的集合。集合F06,F29和F30表达候选Fab,选择它们来结合盲肽/HLA靶,而具有Fab 33H09的集合是对HLA-A2/WT1肽RMF特异性的。
在与Jurkat NFAT报告细胞共温育前,于37℃以10-5M用各自肽脉冲T2细胞2小时或留置不脉冲。在384孔白色透明平底板(Greiner-bio-one)中一式三份以5:1E:T比(10,000个效应细胞每2000个靶细胞每孔)分配靶细胞和报告细胞。将Jurkat NFAT报告细胞和靶细胞于37℃共温育7小时,继以添加6μl/孔ONE-GloTM萤光素酶底物(Promega)和使用TECANinfinite M1000Pro读板仪直接测量发光。作为柱图呈现来自T2细胞上的一式三份测量的CAR-NFAT信号传导的激活(图11)。在不同肽上自四种不同细胞集合获得的信号的比较指示各自候选针对它们的期望靶肽/HLA的激活的高特异性。
例示性序列
表2:抗CD20Fab氨基酸序列
表3:抗CD20 Fab DNA序列
表4:抗CD20交叉Fab(VH-CL-ATD)氨基酸序列
表5:抗CD20交叉Fab(VL-CH1-ATD)氨基酸序列
表6:抗CD20交叉Fab(VH-CL-ATD)DNA序列
表7:抗CD20Fab(VL-CL-ATD)氨基酸序列
表8:抗CD20scFab氨基酸序列
表9:抗CD20 scFab DNA序列
表10:抗CD20-ds-scFv氨基酸序列
表11:抗CD20 ds scFv DNA序列
表12
序列表
<110> 豪夫迈·罗氏有限公司(F.Hoffmann-La Roche Ltd)
<120> 用于新颖抗原结合模块的特异性测试的CAR-T细胞测定法
<130> P34478
<160> 93
<170> PatentIn version 3.5
<210> 1
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗CD20 ( GA101) CDR H1 Kabat
<400> 1
Tyr Ser Trp Ile Asn
1 5
<210> 2
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 抗CD20 ( GA101) CDR H2 Kabat
<400> 2
Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe Lys
1 5 10 15
Gly
<210> 3
<211> 10
<212> PRT
<213> 人工序列
<220>
<223> 抗CD20 ( GA101) CDR H3 Kabat
<400> 3
Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr
1 5 10
<210> 4
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 抗CD20 ( GA101) CDR L1 Kabat
<400> 4
Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Ile Thr Tyr Leu Tyr
1 5 10 15
<210> 5
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗CD20 ( GA101) CDR L2 Kabat
<400> 5
Gln Met Ser Asn Leu Val Ser
1 5
<210> 6
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 抗CD20 ( GA101) CDR L3 Kabat
<400> 6
Ala Gln Asn Leu Glu Leu Pro Tyr Thr
1 5
<210> 7
<211> 407
<212> PRT
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-Fab重链-CD28ATD-CD28CSD-CD3zSSD融合物pETR17097
<400> 7
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser
20 25 30
Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205
Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Gly Gly
210 215 220
Gly Gly Ser Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys
225 230 235 240
Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser
245 250 255
Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg
260 265 270
Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg
275 280 285
Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp
290 295 300
Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn
305 310 315 320
Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg
325 330 335
Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly
340 345 350
Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu
355 360 365
Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu
370 375 380
Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His
385 390 395 400
Met Gln Ala Leu Pro Pro Arg
405
<210> 8
<211> 222
<212> PRT
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-Fab重链
<400> 8
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser
20 25 30
Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205
Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220
<210> 9
<211> 219
<212> PRT
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-Fab轻链
<400> 9
Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser
20 25 30
Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Val Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn
85 90 95
Leu Glu Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130 135 140
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145 150 155 160
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215
<210> 10
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> 抗CD20-(GA101) VL
<400> 10
Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser
20 25 30
Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Val Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn
85 90 95
Leu Glu Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
<210> 11
<211> 107
<212> PRT
<213> 人工序列
<220>
<223> CL
<400> 11
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
1 5 10 15
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
20 25 30
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
35 40 45
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
50 55 60
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
65 70 75 80
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
85 90 95
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
100 105
<210> 12
<211> 119
<212> PRT
<213> 人工序列
<220>
<223> 抗CD20-(GA101) VH
<400> 12
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser
20 25 30
Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210> 13
<211> 103
<212> PRT
<213> 人工序列
<220>
<223> CH1
<400> 13
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Lys Val Glu Pro Lys Ser Cys
100
<210> 14
<211> 27
<212> PRT
<213> 人工序列
<220>
<223> CD28ATD
<400> 14
Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu
1 5 10 15
Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val
20 25
<210> 15
<211> 41
<212> PRT
<213> 人工序列
<220>
<223> CD28CSD
<400> 15
Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr
1 5 10 15
Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro
20 25 30
Pro Arg Asp Phe Ala Ala Tyr Arg Ser
35 40
<210> 16
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> CD3zSSD
<400> 16
Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly
1 5 10 15
Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
20 25 30
Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
35 40 45
Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys
50 55 60
Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
65 70 75 80
Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala
85 90 95
Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
100 105 110
<210> 17
<211> 180
<212> PRT
<213> 人工序列
<220>
<223> CD28ATD-CD28CSD-CD3zSSD
<400> 17
Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu
1 5 10 15
Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser
20 25 30
Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly
35 40 45
Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala
50 55 60
Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala
65 70 75 80
Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg
85 90 95
Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu
100 105 110
Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn
115 120 125
Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met
130 135 140
Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly
145 150 155 160
Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala
165 170 175
Leu Pro Pro Arg
180
<210> 18
<211> 238
<212> PRT
<213> 人工序列
<220>
<223> eGFP
<400> 18
Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val
1 5 10 15
Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
20 25 30
Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys
35 40 45
Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Leu
50 55 60
Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Gln
65 70 75 80
His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
85 90 95
Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
100 105 110
Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
115 120 125
Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
130 135 140
Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
145 150 155 160
Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val
165 170 175
Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
180 185 190
Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser
195 200 205
Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val
210 215 220
Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys
225 230 235
<210> 19
<211> 20
<212> PRT
<213> 人工序列
<220>
<223> (G4S)4接头
<400> 19
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5 10 15
Gly Gly Gly Ser
20
<210> 20
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> G4S接头
<400> 20
Gly Gly Gly Gly Ser
1 5
<210> 21
<211> 19
<212> PRT
<213> 人工序列
<220>
<223> T2A接头
<400> 21
Gly Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp Val Glu Glu Asn
1 5 10 15
Pro Gly Pro
<210> 22
<211> 2659
<212> DNA
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-Fab-CD28ATD-CD28CSD-CD3zSSD pETR17097
<400> 22
atgggatgga gctgtatcat cctcttcttg gtagcaacag ctaccggtgt gcattccgat 60
atcgtgatga cccagactcc actctccctg cccgtcaccc ctggagagcc cgccagcatt 120
agctgcaggt ctagcaagag cctcttgcac agcaatggca tcacttattt gtattggtac 180
ctgcaaaagc cagggcagtc tccacagctc ctgatttatc aaatgtccaa ccttgtctct 240
ggcgtccctg accggttctc cggatccggg tcaggcactg atttcacact gaaaatcagc 300
agggtggagg ctgaggatgt tggagtttat tactgcgctc agaatctaga acttccttac 360
accttcggcg gagggaccaa ggtggagatc aaaccgtacg gtggctgcac catctgtctt 420
catcttcccg ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct 480
gaataacttc tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc 540
gggtaactcc caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag 600
cagcaccctg acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt 660
cacccatcag ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgttagaa 720
tagaattccc cgaagtaact tagaagctgt aaatcaacga tcaatagcag gtgtggcaca 780
ccagtcatac cttgatcaag cacttctgtt tccccggact gagtatcaat aggctgctcg 840
cgcggctgaa ggagaaaacg ttcgttaccc gaccaactac ttcgagaagc ttagtaccac 900
catgaacgag gcagggtgtt tcgctcagca caaccccagt gtagatcagg ctgatgagtc 960
actgcaaccc ccatgggcga ccatggcagt ggctgcgttg gcggcctgcc catggagaaa 1020
tccatgggac gctctaattc tgacatggtg tgaagtgcct attgagctaa ctggtagtcc 1080
tccggcccct gattgcggct aatcctaact gcggagcaca tgctcacaaa ccagtgggtg 1140
gtgtgtcgta acgggcaact ctgcagcgga accgactact ttgggtgtcc gtgtttcctt 1200
ttattcctat attggctgct tatggtgaca atcaaaaagt tgttaccata tagctattgg 1260
attggccatc cggtgtgcaa cagggcaact gtttacctat ttattggttt tgtaccatta 1320
tcactgaagt ctgtgatcac tctcaaattc attttgaccc tcaacacaat caaacgccac 1380
catgggatgg agctgtatca tcctcttctt ggtagcaaca gctaccggtg tgcactccca 1440
ggtgcaattg gtgcagtctg gcgctgaagt taagaagcct gggagttcag tgaaggtctc 1500
ctgcaaggct tcgggatacg ccttcagcta ttcttggatc aattgggtgc ggcaggcgcc 1560
tggacaaggg ctcgagtgga tgggacggat ctttcccggc gatggggata ctgactacaa 1620
tgggaaattc aagggcagag tcacaattac cgccgacaaa tccactagca cagcctatat 1680
ggagctgagc agcctgagat ctgaggacac ggccgtgtat tactgtgcaa gaaatgtctt 1740
tgatggttac tggcttgttt actggggcca gggaaccctg gtcaccgtct ccagcgctag 1800
caccaagggc ccctccgtgt tccccctggc ccccagcagc aagagcacca gcggcggcac 1860
agccgctctg ggctgcctgg tcaaggacta cttccccgag cccgtgaccg tgtcctggaa 1920
cagcggagcc ctgacctccg gcgtgcacac cttccccgcc gtgctgcaga gttctggcct 1980
gtatagcctg agcagcgtgg tcaccgtgcc ttctagcagc ctgggcaccc agacctacat 2040
ctgcaacgtg aaccacaagc ccagcaacac caaggtggac aagaaggtgg agcccaagag 2100
ctgcggaggg ggcggatcct tctgggtgct ggtggtggtg ggcggcgtgc tggcctgcta 2160
cagcctgctg gtgaccgtgg ccttcatcat cttctgggtg aggagcaaga ggagcaggct 2220
gctgcacagc gactacatga acatgacccc caggaggccc ggccccacca ggaagcacta 2280
ccagccctac gcccccccca gggacttcgc cgcctacagg agcagggtga agttcagcag 2340
gagcgccgac gcccccgcct accagcaggg ccagaaccag ctgtataacg agctgaacct 2400
gggcaggagg gaggagtacg acgtgctgga caagaggagg ggcagggacc ccgagatggg 2460
cggcaagccc aggaggaaga acccccagga gggcctgtat aacgagctgc agaaggacaa 2520
gatggccgag gcctacagcg agatcggcat gaagggcgag aggaggaggg gcaagggcca 2580
cgacggcctg taccagggcc tgagcaccgc caccaaggac acctacgacg ccctgcacat 2640
gcaggccctg ccccccagg 2659
<210> 23
<211> 336
<212> DNA
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-Fab-VL
<400> 23
gatatcgtga tgacccagac tccactctcc ctgcccgtca cccctggaga gcccgccagc 60
attagctgca ggtctagcaa gagcctcttg cacagcaatg gcatcactta tttgtattgg 120
tacctgcaaa agccagggca gtctccacag ctcctgattt atcaaatgtc caaccttgtc 180
tctggcgtcc ctgaccggtt ctccggatcc gggtcaggca ctgatttcac actgaaaatc 240
agcagggtgg aggctgagga tgttggagtt tattactgcg ctcagaatct agaacttcct 300
tacaccttcg gcggagggac caaggtggag atcaaa 336
<210> 24
<211> 324
<212> DNA
<213> 人工序列
<220>
<223> Fab CL
<400> 24
cgtacggtgg ctgcaccatc tgtcttcatc ttcccgccat ctgatgagca gttgaaatct 60
ggaactgcct ctgttgtgtg cctgctgaat aacttctatc ccagagaggc caaagtacag 120
tggaaggtgg ataacgccct ccaatcgggt aactcccagg agagtgtcac agagcaggac 180
agcaaggaca gcacctacag cctcagcagc accctgacgc tgagcaaagc agactacgag 240
aaacacaaag tctacgcctg cgaagtcacc catcagggcc tgagctcgcc cgtcacaaag 300
agcttcaaca ggggagagtg ttag 324
<210> 25
<211> 357
<212> DNA
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-Fab-VH
<400> 25
caggtgcaat tggtgcagtc tggcgctgaa gttaagaagc ctgggagttc agtgaaggtc 60
tcctgcaagg cttcgggata cgccttcagc tattcttgga tcaattgggt gcggcaggcg 120
cctggacaag ggctcgagtg gatgggacgg atctttcccg gcgatgggga tactgactac 180
aatgggaaat tcaagggcag agtcacaatt accgccgaca aatccactag cacagcctat 240
atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc aagaaatgtc 300
tttgatggtt actggcttgt ttactggggc cagggaaccc tggtcaccgt ctccagc 357
<210> 26
<211> 309
<212> DNA
<213> 人工序列
<220>
<223> Fab CH1
<400> 26
gctagcacca agggcccctc cgtgttcccc ctggccccca gcagcaagag caccagcggc 60
ggcacagccg ctctgggctg cctggtcaag gactacttcc ccgagcccgt gaccgtgtcc 120
tggaacagcg gagccctgac ctccggcgtg cacaccttcc ccgccgtgct gcagagttct 180
ggcctgtata gcctgagcag cgtggtcacc gtgccttcta gcagcctggg cacccagacc 240
tacatctgca acgtgaacca caagcccagc aacaccaagg tggacaagaa ggtggagccc 300
aagagctgc 309
<210> 27
<211> 647
<212> DNA
<213> 人工序列
<220>
<223> IRES EV71内部核糖体进入位点
<400> 27
cccgaagtaa cttagaagct gtaaatcaac gatcaatagc aggtgtggca caccagtcat 60
accttgatca agcacttctg tttccccgga ctgagtatca ataggctgct cgcgcggctg 120
aaggagaaaa cgttcgttac ccgaccaact acttcgagaa gcttagtacc accatgaacg 180
aggcagggtg tttcgctcag cacaacccca gtgtagatca ggctgatgag tcactgcaac 240
ccccatgggc gaccatggca gtggctgcgt tggcggcctg cccatggaga aatccatggg 300
acgctctaat tctgacatgg tgtgaagtgc ctattgagct aactggtagt cctccggccc 360
ctgattgcgg ctaatcctaa ctgcggagca catgctcaca aaccagtggg tggtgtgtcg 420
taacgggcaa ctctgcagcg gaaccgacta ctttgggtgt ccgtgtttcc ttttattcct 480
atattggctg cttatggtga caatcaaaaa gttgttacca tatagctatt ggattggcca 540
tccggtgtgc aacagggcaa ctgtttacct atttattggt tttgtaccat tatcactgaa 600
gtctgtgatc actctcaaat tcattttgac cctcaacaca atcaaac 647
<210> 28
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> G4S接头
<400> 28
ggagggggcg gatcc 15
<210> 29
<211> 81
<212> DNA
<213> 人工序列
<220>
<223> CD28ATD
<400> 29
ttttgggtgc tggtggtggt tggtggagtc ctggcttgct atagcttgct agtaacagtg 60
gcctttatta ttttctgggt g 81
<210> 30
<211> 123
<212> DNA
<213> 人工序列
<220>
<223> CD28CSD
<400> 30
aggagtaaga ggagcaggct cctgcacagt gactacatga acatgactcc ccgccgcccc 60
gggcccaccc gcaagcatta ccagccctat gccccaccac gcgacttcgc agcctatcgc 120
tcc 123
<210> 31
<211> 336
<212> DNA
<213> 人工序列
<220>
<223> CD3zSSD
<400> 31
agagtgaagt tcagcaggag cgcagacgcc cccgcgtacc agcagggcca gaaccagctc 60
tataacgagc tcaatctagg acgaagagag gagtacgatg ttttggacaa gagacgtggc 120
cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg cctgtacaat 180
gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc 240
cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc 300
tacgacgccc ttcacatgca ggccctgccc cctcgc 336
<210> 32
<211> 540
<212> DNA
<213> 人工序列
<220>
<223> CD28ATD-CD28CSD-CD3zSSD
<400> 32
ttctgggtgc tggtggtggt gggcggcgtg ctggcctgct acagcctgct ggtgaccgtg 60
gccttcatca tcttctgggt gaggagcaag aggagcaggc tgctgcacag cgactacatg 120
aacatgaccc ccaggaggcc cggccccacc aggaagcact accagcccta cgcccccccc 180
agggacttcg ccgcctacag gagcagggtg aagttcagca ggagcgccga cgcccccgcc 240
taccagcagg gccagaacca gctgtataac gagctgaacc tgggcaggag ggaggagtac 300
gacgtgctgg acaagaggag gggcagggac cccgagatgg gcggcaagcc caggaggaag 360
aacccccagg agggcctgta taacgagctg cagaaggaca agatggccga ggcctacagc 420
gagatcggca tgaagggcga gaggaggagg ggcaagggcc acgacggcct gtaccagggc 480
ctgagcaccg ccaccaagga cacctacgac gccctgcaca tgcaggccct gccccccagg 540
<210> 33
<211> 63
<212> DNA
<213> 人工序列
<220>
<223> T2A接头
<400> 33
tccggagagg gcagaggaag tcttctaaca tgcggtgacg tggaggagaa tcccggccct 60
agg 63
<210> 34
<211> 717
<212> DNA
<213> 人工序列
<220>
<223> eGFP
<400> 34
gtgagcaagg gcgaggagct gttcaccggg gtggtgccca tcctggtcga gctggacggc 60
gacgtaaacg gccacaagtt cagcgtgtcc ggcgagggcg agggcgatgc cacctacggc 120
aagctgaccc tgaagttcat ctgcaccacc ggcaagctgc ccgtgccctg gcccaccctc 180
gtgaccaccc tgacctacgg cgtgcagtgc ttcagccgct accccgacca catgaagcag 240
cacgacttct tcaagtccgc catgcccgaa ggctacgtcc aggagcgcac catcttcttc 300
aaggacgacg gcaactacaa gacccgcgcc gaggtgaagt tcgagggcga caccctggtg 360
aaccgcatcg agctgaaggg catcgacttc aaggaggacg gcaacatcct ggggcacaag 420
ctggagtaca actacaacag ccacaacgtc tatatcatgg ccgacaagca gaagaacggc 480
atcaaggtga acttcaagat ccgccacaac atcgaggacg gcagcgtgca gctcgccgac 540
cactaccagc agaacacccc catcggcgac ggccccgtgc tgctgcccga caaccactac 600
ctgagcaccc agtccgccct gagcaaagac cccaacgaga agcgcgatca catggtcctg 660
ctggagttcg tgaccgccgc cgggatcact ctcggcatgg acgagctgta caagtga 717
<210> 35
<211> 3438
<212> DNA
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-Fab-CD28ATD-CD28CSD-CD3zSSD-eGFP pETR17097
<400> 35
atgggatgga gctgtatcat cctcttcttg gtagcaacag ctaccggtgt gcattccgat 60
atcgtgatga cccagactcc actctccctg cccgtcaccc ctggagagcc cgccagcatt 120
agctgcaggt ctagcaagag cctcttgcac agcaatggca tcacttattt gtattggtac 180
ctgcaaaagc cagggcagtc tccacagctc ctgatttatc aaatgtccaa ccttgtctct 240
ggcgtccctg accggttctc cggatccggg tcaggcactg atttcacact gaaaatcagc 300
agggtggagg ctgaggatgt tggagtttat tactgcgctc agaatctaga acttccttac 360
accttcggcg gagggaccaa ggtggagatc aaacgtacgg tggctgcacc atctgtcttc 420
atcttcccgc catctgatga gcagttgaaa tctggaactg cctctgttgt gtgcctgctg 480
aataacttct atcccagaga ggccaaagta cagtggaagg tggataacgc cctccaatcg 540
ggtaactccc aggagagtgt cacagagcag gacagcaagg acagcaccta cagcctcagc 600
agcaccctga cgctgagcaa agcagactac gagaaacaca aagtctacgc ctgcgaagtc 660
acccatcagg gcctgagctc gcccgtcaca aagagcttca acaggggaga gtgttagaat 720
agaattcccc gaagtaactt agaagctgta aatcaacgat caatagcagg tgtggcacac 780
cagtcatacc ttgatcaagc acttctgttt ccccggactg agtatcaata ggctgctcgc 840
gcggctgaag gagaaaacgt tcgttacccg accaactact tcgagaagct tagtaccacc 900
atgaacgagg cagggtgttt cgctcagcac aaccccagtg tagatcaggc tgatgagtca 960
ctgcaacccc catgggcgac catggcagtg gctgcgttgg cggcctgccc atggagaaat 1020
ccatgggacg ctctaattct gacatggtgt gaagtgccta ttgagctaac tggtagtcct 1080
ccggcccctg attgcggcta atcctaactg cggagcacat gctcacaaac cagtgggtgg 1140
tgtgtcgtaa cgggcaactc tgcagcggaa ccgactactt tgggtgtccg tgtttccttt 1200
tattcctata ttggctgctt atggtgacaa tcaaaaagtt gttaccatat agctattgga 1260
ttggccatcc ggtgtgcaac agggcaactg tttacctatt tattggtttt gtaccattat 1320
cactgaagtc tgtgatcact ctcaaattca ttttgaccct caacacaatc aaacgccacc 1380
atgggatgga gctgtatcat cctcttcttg gtagcaacag ctaccggtgt gcactcccag 1440
gtgcaattgg tgcagtctgg cgctgaagtt aagaagcctg ggagttcagt gaaggtctcc 1500
tgcaaggctt cgggatacgc cttcagctat tcttggatca attgggtgcg gcaggcgcct 1560
ggacaagggc tcgagtggat gggacggatc tttcccggcg atggggatac tgactacaat 1620
gggaaattca agggcagagt cacaattacc gccgacaaat ccactagcac agcctatatg 1680
gagctgagca gcctgagatc tgaggacacg gccgtgtatt actgtgcaag aaatgtcttt 1740
gatggttact ggcttgttta ctggggccag ggaaccctgg tcaccgtctc cagcgctagc 1800
accaagggcc cctccgtgtt ccccctggcc cccagcagca agagcaccag cggcggcaca 1860
gccgctctgg gctgcctggt caaggactac ttccccgagc ccgtgaccgt gtcctggaac 1920
agcggagccc tgacctccgg cgtgcacacc ttccccgccg tgctgcagag ttctggcctg 1980
tatagcctga gcagcgtggt caccgtgcct tctagcagcc tgggcaccca gacctacatc 2040
tgcaacgtga accacaagcc cagcaacacc aaggtggaca agaaggtgga gcccaagagc 2100
tgcggagggg gcggatcctt ctgggtgctg gtggtggtgg gcggcgtgct ggcctgctac 2160
agcctgctgg tgaccgtggc cttcatcatc ttctgggtga ggagcaagag gagcaggctg 2220
ctgcacagcg actacatgaa catgaccccc aggaggcccg gccccaccag gaagcactac 2280
cagccctacg ccccccccag ggacttcgcc gcctacagga gcagggtgaa gttcagcagg 2340
agcgccgacg cccccgccta ccagcagggc cagaaccagc tgtataacga gctgaacctg 2400
ggcaggaggg aggagtacga cgtgctggac aagaggaggg gcagggaccc cgagatgggc 2460
ggcaagccca ggaggaagaa cccccaggag ggcctgtata acgagctgca gaaggacaag 2520
atggccgagg cctacagcga gatcggcatg aagggcgaga ggaggagggg caagggccac 2580
gacggcctgt accagggcct gagcaccgcc accaaggaca cctacgacgc cctgcacatg 2640
caggccctgc cccccaggtc cggagagggc agaggaagtc ttctaacatg cggtgacgtg 2700
gaggagaatc ccggccctag ggtgagcaag ggcgaggagc tgttcaccgg ggtggtgccc 2760
atcctggtcg agctggacgg cgacgtaaac ggccacaagt tcagcgtgtc cggcgagggc 2820
gagggcgatg ccacctacgg caagctgacc ctgaagttca tctgcaccac cggcaagctg 2880
cccgtgccct ggcccaccct cgtgaccacc ctgacctacg gcgtgcagtg cttcagccgc 2940
taccccgacc acatgaagca gcacgacttc ttcaagtccg ccatgcccga aggctacgtc 3000
caggagcgca ccatcttctt caaggacgac ggcaactaca agacccgcgc cgaggtgaag 3060
ttcgagggcg acaccctggt gaaccgcatc gagctgaagg gcatcgactt caaggaggac 3120
ggcaacatcc tggggcacaa gctggagtac aactacaaca gccacaacgt ctatatcatg 3180
gccgacaagc agaagaacgg catcaaggtg aacttcaaga tccgccacaa catcgaggac 3240
ggcagcgtgc agctcgccga ccactaccag cagaacaccc ccatcggcga cggccccgtg 3300
ctgctgcccg acaaccacta cctgagcacc cagtccgccc tgagcaaaga ccccaacgag 3360
aagcgcgatc acatggtcct gctggagttc gtgaccgccg ccgggatcac tctcggcatg 3420
gacgagctgt acaagtga 3438
<210> 36
<211> 411
<212> PRT
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-crossFab VH-CL轻链-ATD-CD28ATD-CD28CSD-CD3zSSD融合物pETR17098
<400> 36
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser
20 25 30
Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser Ala Ser Val Ala Ala Pro Ser Val Phe
115 120 125
Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val
130 135 140
Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp
145 150 155 160
Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr
165 170 175
Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr
180 185 190
Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val
195 200 205
Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly
210 215 220
Glu Cys Gly Gly Gly Gly Ser Phe Trp Val Leu Val Val Val Gly Gly
225 230 235 240
Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe
245 250 255
Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn
260 265 270
Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr
275 280 285
Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser
290 295 300
Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr
305 310 315 320
Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys
325 330 335
Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn
340 345 350
Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu
355 360 365
Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly
370 375 380
His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr
385 390 395 400
Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
405 410
<210> 37
<211> 226
<212> PRT
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-crossFab VH-CL轻链pETR17098
<400> 37
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser
20 25 30
Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser Ala Ser Val Ala Ala Pro Ser Val Phe
115 120 125
Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val
130 135 140
Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp
145 150 155 160
Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr
165 170 175
Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr
180 185 190
Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val
195 200 205
Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly
210 215 220
Glu Cys
225
<210> 38
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-crossFab VL-CH1重链-pETR17098
<400> 38
Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser
20 25 30
Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Val Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn
85 90 95
Leu Glu Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser
115 120 125
Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys
130 135 140
Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
145 150 155 160
Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu
165 170 175
Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr
180 185 190
Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val
195 200 205
Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215
<210> 39
<211> 107
<212> PRT
<213> 人工序列
<220>
<223> crossFab CL
<400> 39
Ala Ser Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
1 5 10 15
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
20 25 30
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
35 40 45
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
50 55 60
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
65 70 75 80
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
85 90 95
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
100 105
<210> 40
<211> 105
<212> PRT
<213> 人工序列
<220>
<223> crossFab CH1
<400> 40
Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser
1 5 10 15
Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys
20 25 30
Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
35 40 45
Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu
50 55 60
Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr
65 70 75 80
Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val
85 90 95
Asp Lys Lys Val Glu Pro Lys Ser Cys
100 105
<210> 41
<211> 402
<212> PRT
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-crossFab VL-CH1重链-ATD-CD28ATD-CD28CSD-CD3zSSD融合物
<400> 41
Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser
20 25 30
Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Val Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn
85 90 95
Leu Glu Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser
115 120 125
Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys
130 135 140
Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
145 150 155 160
Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu
165 170 175
Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr
180 185 190
Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val
195 200 205
Asp Lys Lys Val Glu Pro Lys Ser Cys Gly Gly Gly Gly Ser Phe Trp
210 215 220
Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val
225 230 235 240
Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu
245 250 255
Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr
260 265 270
Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr
275 280 285
Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln
290 295 300
Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu
305 310 315 320
Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly
325 330 335
Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu
340 345 350
Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly
355 360 365
Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser
370 375 380
Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro
385 390 395 400
Pro Arg
<210> 42
<211> 217
<212> PRT
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-crossFab VL-CH1重链
<400> 42
Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser
20 25 30
Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Val Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn
85 90 95
Leu Glu Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser
115 120 125
Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys
130 135 140
Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
145 150 155 160
Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu
165 170 175
Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr
180 185 190
Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val
195 200 205
Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215
<210> 43
<211> 226
<212> PRT
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-crossFab VH-CL轻链
<400> 43
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser
20 25 30
Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser Ala Ser Val Ala Ala Pro Ser Val Phe
115 120 125
Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val
130 135 140
Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp
145 150 155 160
Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr
165 170 175
Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr
180 185 190
Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val
195 200 205
Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly
210 215 220
Glu Cys
225
<210> 44
<211> 107
<212> PRT
<213> 人工序列
<220>
<223> crossFab CL
<400> 44
Ala Ser Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
1 5 10 15
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
20 25 30
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
35 40 45
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
50 55 60
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
65 70 75 80
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
85 90 95
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
100 105
<210> 45
<211> 105
<212> PRT
<213> 人工序列
<220>
<223> crossFab CH1
<400> 45
Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser
1 5 10 15
Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys
20 25 30
Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
35 40 45
Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu
50 55 60
Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr
65 70 75 80
Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val
85 90 95
Asp Lys Lys Val Glu Pro Lys Ser Cys
100 105
<210> 46
<211> 2664
<212> DNA
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-crossFabVH-CL CD28ATD-CD28CSD-CD3zSSD pETR17098
<400> 46
atgggatgga gctgtatcat cctcttcttg gtagcaacag ctaccggtgt gcattcccag 60
gtgcaattgg tgcagtctgg cgctgaagtt aagaagcctg ggagttcagt gaaggtctcc 120
tgcaaggctt ccggatacgc cttcagctat tcttggatca attgggtgcg gcaggcgcct 180
ggacaagggc tcgagtggat gggacggatc tttcccggcg atggggatac tgactacaat 240
gggaaattca agggcagagt cacaattacc gccgacaaat ccactagcac agcctatatg 300
gagctgagca gcctgagatc tgaggacacg gccgtgtatt actgtgcaag aaatgtcttt 360
gatggttact ggcttgttta ctggggccag ggaaccctgg tcaccgtctc ctcagctagc 420
gtggccgctc cctccgtgtt catcttccca ccttccgacg agcagctgaa gtccggcacc 480
gcttctgtcg tgtgcctgct gaacaacttc tacccccgcg aggccaaggt gcagtggaag 540
gtggacaacg ccctgcagtc cggcaacagc caggaatccg tgaccgagca ggactccaag 600
gacagcacct actccctgtc ctccaccctg accctgtcca aggccgacta cgagaagcac 660
aaggtgtacg cctgcgaagt gacccaccag ggcctgtcta gccccgtgac caagtctttc 720
aaccggggcg agtgctgata aggaattccc cgaagtaact tagaagctgt aaatcaacga 780
tcaatagcag gtgtggcaca ccagtcatac cttgatcaag cacttctgtt tccccggact 840
gagtatcaat aggctgctcg cgcggctgaa ggagaaaacg ttcgttaccc gaccaactac 900
ttcgagaagc ttagtaccac catgaacgag gcagggtgtt tcgctcagca caaccccagt 960
gtagatcagg ctgatgagtc actgcaaccc ccatgggcga ccatggcagt ggctgcgttg 1020
gcggcctgcc catggagaaa tccatgggac gctctaattc tgacatggtg tgaagtgcct 1080
attgagctaa ctggtagtcc tccggcccct gattgcggct aatcctaact gcggagcaca 1140
tgctcacaaa ccagtgggtg gtgtgtcgta acgggcaact ctgcagcgga accgactact 1200
ttgggtgtcc gtgtttcctt ttattcctat attggctgct tatggtgaca atcaaaaagt 1260
tgttaccata tagctattgg attggccatc cggtgtgcaa cagggcaact gtttacctat 1320
ttattggttt tgtaccatta tcactgaagt ctgtgatcac tctcaaattc attttgaccc 1380
tcaacacaat caaacgccac catgggatgg agctgtatca tcctcttctt ggtagcaaca 1440
gctaccggtg tgcactccga catcgtgatg acccagactc cactctccct gcccgtcacc 1500
cctggagagc ccgccagcat tagctgcagg tctagcaaga gcctcttgca cagcaatggc 1560
atcacttatt tgtattggta cctgcaaaag ccagggcagt ctccacagct cctgatttat 1620
caaatgtcca accttgtctc tggcgtccct gatcggttct ccggttccgg gtcaggcact 1680
gatttcacac tgaaaatcag cagggtggag gctgaggatg ttggagttta ttactgcgct 1740
cagaatctag aacttcctta caccttcggc ggagggacca aggtggagat caaatccagc 1800
gctagcacca agggcccctc cgtgttcccc ctggccccca gcagcaagag caccagcggc 1860
ggcacagccg ctctgggctg cctggtcaag gactacttcc ccgagcccgt gaccgtgtcc 1920
tggaacagcg gagccctgac ctccggcgtg cacaccttcc ccgccgtgct gcagagttct 1980
ggcctgtata gcctgagcag cgtggtcacc gtgccttcta gcagcctggg cacccagacc 2040
tacatctgca acgtgaacca caagcccagc aacaccaagg tggacaagaa ggtggagccc 2100
aagagctgcg gagggggcgg atccttctgg gtgctggtgg tggtgggcgg cgtgctggcc 2160
tgctacagcc tgctggtgac cgtggccttc atcatcttct gggtgaggag caagaggagc 2220
aggctgctgc acagcgacta catgaacatg acccccagga ggcccggccc caccaggaag 2280
cactaccagc cctacgcccc ccccagggac ttcgccgcct acaggagcag ggtgaagttc 2340
agcaggagcg ccgacgcccc cgcctaccag cagggccaga accagctgta taacgagctg 2400
aacctgggca ggagggagga gtacgacgtg ctggacaaga ggaggggcag ggaccccgag 2460
atgggcggca agcccaggag gaagaacccc caggagggcc tgtataacga gctgcagaag 2520
gacaagatgg ccgaggccta cagcgagatc ggcatgaagg gcgagaggag gaggggcaag 2580
ggccacgacg gcctgtacca gggcctgagc accgccacca aggacaccta cgacgccctg 2640
cacatgcagg ccctgccccc cagg 2664
<210> 47
<211> 324
<212> DNA
<213> 人工序列
<220>
<223> crossFab CL
<400> 47
gctagcgtgg ccgctccctc cgtgttcatc ttcccacctt ccgacgagca gctgaagtcc 60
ggcaccgctt ctgtcgtgtg cctgctgaac aacttctacc cccgcgaggc caaggtgcag 120
tggaaggtgg acaacgccct gcagtccggc aacagccagg aatccgtgac cgagcaggac 180
tccaaggaca gcacctactc cctgtcctcc accctgaccc tgtccaaggc cgactacgag 240
aagcacaagg tgtacgcctg cgaagtgacc caccagggcc tgtctagccc cgtgaccaag 300
tctttcaacc ggggcgagtg ctga 324
<210> 48
<211> 315
<212> DNA
<213> 人工序列
<220>
<223> crossFab CH1
<400> 48
tccagcgcta gcaccaaggg cccctccgtg ttccccctgg cccccagcag caagagcacc 60
agcggcggca cagccgctct gggctgcctg gtcaaggact acttccccga gcccgtgacc 120
gtgtcctgga acagcggagc cctgacctcc ggcgtgcaca ccttccccgc cgtgctgcag 180
agttctggcc tgtatagcct gagcagcgtg gtcaccgtgc cttctagcag cctgggcacc 240
cagacctaca tctgcaacgt gaaccacaag cccagcaaca ccaaggtgga caagaaggtg 300
gagcccaaga gctgc 315
<210> 49
<211> 3444
<212> DNA
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-crossFabVH-CL CD28ATD-CD28CSD-CD3zSSD-eGFP pETR17098
<400> 49
atgggatgga gctgtatcat cctcttcttg gtagcaacag ctaccggtgt gcattcccag 60
gtgcaattgg tgcagtctgg cgctgaagtt aagaagcctg ggagttcagt gaaggtctcc 120
tgcaaggctt ccggatacgc cttcagctat tcttggatca attgggtgcg gcaggcgcct 180
ggacaagggc tcgagtggat gggacggatc tttcccggcg atggggatac tgactacaat 240
gggaaattca agggcagagt cacaattacc gccgacaaat ccactagcac agcctatatg 300
gagctgagca gcctgagatc tgaggacacg gccgtgtatt actgtgcaag aaatgtcttt 360
gatggttact ggcttgttta ctggggccag ggaaccctgg tcaccgtctc ctcagctagc 420
gtggccgctc cctccgtgtt catcttccca ccttccgacg agcagctgaa gtccggcacc 480
gcttctgtcg tgtgcctgct gaacaacttc tacccccgcg aggccaaggt gcagtggaag 540
gtggacaacg ccctgcagtc cggcaacagc caggaatccg tgaccgagca ggactccaag 600
gacagcacct actccctgtc ctccaccctg accctgtcca aggccgacta cgagaagcac 660
aaggtgtacg cctgcgaagt gacccaccag ggcctgtcta gccccgtgac caagtctttc 720
aaccggggcg agtgctgata aggaattccc cgaagtaact tagaagctgt aaatcaacga 780
tcaatagcag gtgtggcaca ccagtcatac cttgatcaag cacttctgtt tccccggact 840
gagtatcaat aggctgctcg cgcggctgaa ggagaaaacg ttcgttaccc gaccaactac 900
ttcgagaagc ttagtaccac catgaacgag gcagggtgtt tcgctcagca caaccccagt 960
gtagatcagg ctgatgagtc actgcaaccc ccatgggcga ccatggcagt ggctgcgttg 1020
gcggcctgcc catggagaaa tccatgggac gctctaattc tgacatggtg tgaagtgcct 1080
attgagctaa ctggtagtcc tccggcccct gattgcggct aatcctaact gcggagcaca 1140
tgctcacaaa ccagtgggtg gtgtgtcgta acgggcaact ctgcagcgga accgactact 1200
ttgggtgtcc gtgtttcctt ttattcctat attggctgct tatggtgaca atcaaaaagt 1260
tgttaccata tagctattgg attggccatc cggtgtgcaa cagggcaact gtttacctat 1320
ttattggttt tgtaccatta tcactgaagt ctgtgatcac tctcaaattc attttgaccc 1380
tcaacacaat caaacgccac catgggatgg agctgtatca tcctcttctt ggtagcaaca 1440
gctaccggtg tgcactccga catcgtgatg acccagactc cactctccct gcccgtcacc 1500
cctggagagc ccgccagcat tagctgcagg tctagcaaga gcctcttgca cagcaatggc 1560
atcacttatt tgtattggta cctgcaaaag ccagggcagt ctccacagct cctgatttat 1620
caaatgtcca accttgtctc tggcgtccct gatcggttct ccggttccgg gtcaggcact 1680
gatttcacac tgaaaatcag cagggtggag gctgaggatg ttggagttta ttactgcgct 1740
cagaatctag aacttcctta caccttcggc ggagggacca aggtggagat caaatccagc 1800
gctagcacca agggcccctc cgtgttcccc ctggccccca gcagcaagag caccagcggc 1860
ggcacagccg ctctgggctg cctggtcaag gactacttcc ccgagcccgt gaccgtgtcc 1920
tggaacagcg gagccctgac ctccggcgtg cacaccttcc ccgccgtgct gcagagttct 1980
ggcctgtata gcctgagcag cgtggtcacc gtgccttcta gcagcctggg cacccagacc 2040
tacatctgca acgtgaacca caagcccagc aacaccaagg tggacaagaa ggtggagccc 2100
aagagctgcg gagggggcgg atccttctgg gtgctggtgg tggtgggcgg cgtgctggcc 2160
tgctacagcc tgctggtgac cgtggccttc atcatcttct gggtgaggag caagaggagc 2220
aggctgctgc acagcgacta catgaacatg acccccagga ggcccggccc caccaggaag 2280
cactaccagc cctacgcccc ccccagggac ttcgccgcct acaggagcag ggtgaagttc 2340
agcaggagcg ccgacgcccc cgcctaccag cagggccaga accagctgta taacgagctg 2400
aacctgggca ggagggagga gtacgacgtg ctggacaaga ggaggggcag ggaccccgag 2460
atgggcggca agcccaggag gaagaacccc caggagggcc tgtataacga gctgcagaag 2520
gacaagatgg ccgaggccta cagcgagatc ggcatgaagg gcgagaggag gaggggcaag 2580
ggccacgacg gcctgtacca gggcctgagc accgccacca aggacaccta cgacgccctg 2640
cacatgcagg ccctgccccc caggtccgga gagggcagag gaagtcttct aacatgcggt 2700
gacgtggagg agaatcccgg ccctagggtg agcaagggcg aggagctgtt caccggggtg 2760
gtgcccatcc tggtcgagct ggacggcgac gtaaacggcc acaagttcag cgtgtccggc 2820
gagggcgagg gcgatgccac ctacggcaag ctgaccctga agttcatctg caccaccggc 2880
aagctgcccg tgccctggcc caccctcgtg accaccctga cctacggcgt gcagtgcttc 2940
agccgctacc ccgaccacat gaagcagcac gacttcttca agtccgccat gcccgaaggc 3000
tacgtccagg agcgcaccat cttcttcaag gacgacggca actacaagac ccgcgccgag 3060
gtgaagttcg agggcgacac cctggtgaac cgcatcgagc tgaagggcat cgacttcaag 3120
gaggacggca acatcctggg gcacaagctg gagtacaact acaacagcca caacgtctat 3180
atcatggccg acaagcagaa gaacggcatc aaggtgaact tcaagatccg ccacaacatc 3240
gaggacggca gcgtgcagct cgccgaccac taccagcaga acacccccat cggcgacggc 3300
cccgtgctgc tgcccgacaa ccactacctg agcacccagt ccgccctgag caaagacccc 3360
aacgagaagc gcgatcacat ggtcctgctg gagttcgtga ccgccgccgg gatcactctc 3420
ggcatggacg agctgtacaa gtga 3444
<210> 50
<211> 404
<212> PRT
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-Fab VL-CL轻链-CD28ATD-CD28CSD-CD3zSSD融合物
<400> 50
Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser
20 25 30
Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Val Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn
85 90 95
Leu Glu Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130 135 140
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145 150 155 160
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser
210 215 220
Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu
225 230 235 240
Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser
245 250 255
Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly
260 265 270
Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala
275 280 285
Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala
290 295 300
Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg
305 310 315 320
Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu
325 330 335
Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn
340 345 350
Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met
355 360 365
Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly
370 375 380
Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala
385 390 395 400
Leu Pro Pro Arg
<210> 51
<211> 658
<212> PRT
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-scFab-CD28ATD-CD28CSD-CD3zSSD融合物pETR17101
<400> 51
Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser
20 25 30
Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Val Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn
85 90 95
Leu Glu Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130 135 140
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145 150 155 160
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser
210 215 220
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
225 230 235 240
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gln Val Gln Leu Val
245 250 255
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser
260 265 270
Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser Trp Ile Asn Trp Val
275 280 285
Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Phe Pro
290 295 300
Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe Lys Gly Arg Val Thr
305 310 315 320
Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser
325 330 335
Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asn Val Phe
340 345 350
Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
355 360 365
Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser
370 375 380
Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys
385 390 395 400
Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
405 410 415
Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu
420 425 430
Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr
435 440 445
Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val
450 455 460
Asp Lys Lys Val Glu Pro Lys Ser Cys Gly Gly Gly Gly Ser Phe Trp
465 470 475 480
Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val
485 490 495
Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu
500 505 510
Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr
515 520 525
Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr
530 535 540
Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln
545 550 555 560
Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu
565 570 575
Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly
580 585 590
Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu
595 600 605
Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly
610 615 620
Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser
625 630 635 640
Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro
645 650 655
Pro Arg
<210> 52
<211> 473
<212> PRT
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-scFab
<400> 52
Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser
20 25 30
Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Val Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn
85 90 95
Leu Glu Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130 135 140
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145 150 155 160
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser
210 215 220
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
225 230 235 240
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gln Val Gln Leu Val
245 250 255
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser
260 265 270
Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser Trp Ile Asn Trp Val
275 280 285
Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Phe Pro
290 295 300
Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe Lys Gly Arg Val Thr
305 310 315 320
Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser
325 330 335
Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asn Val Phe
340 345 350
Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
355 360 365
Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser
370 375 380
Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys
385 390 395 400
Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
405 410 415
Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu
420 425 430
Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr
435 440 445
Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val
450 455 460
Asp Lys Lys Val Glu Pro Lys Ser Cys
465 470
<210> 53
<211> 106
<212> PRT
<213> 人工序列
<220>
<223> scFab-CL
<400> 53
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
1 5 10 15
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
20 25 30
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
35 40 45
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
50 55 60
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
65 70 75 80
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
85 90 95
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu
100 105
<210> 54
<211> 32
<212> PRT
<213> 人工序列
<220>
<223> (G4S)6G2接头
<400> 54
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5 10 15
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
20 25 30
<210> 55
<211> 2031
<212> DNA
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-scFab-CD28ATD-CD28CSD-CD3zSSD融合物pETR170101
<400> 55
atgggatgga gctgtatcat cctcttcttg gtagcaacag ctacgggtgt gcattccgac 60
atcgtgatga cccagactcc actctccctg cccgtcaccc ctggagagcc cgccagcatt 120
agctgcaggt ctagcaagag cctcttgcac agcaatggca tcacttattt gtattggtac 180
ctgcaaaagc cagggcagtc tccacagctc ctgatttatc aaatgtccaa ccttgtctct 240
ggcgtccctg atcggttctc cggttccggg tcaggcactg atttcacact gaaaatcagc 300
agggtggagg ctgaggatgt tggagtttat tactgcgctc agaatctaga acttccttac 360
accttcggcg gagggaccaa ggtggagatc aaacgtacgg tggctgcacc atctgtcttc 420
atcttcccgc catctgatga gcagttgaaa tctggaactg cctctgttgt gtgcctgctg 480
aataacttct atcccagaga ggccaaagta cagtggaagg tggataacgc cctccaatcg 540
ggtaactccc aggagagtgt cacagagcag gacagcaagg acagcaccta cagcctcagc 600
agcaccctga cgctgagcaa agcagactac gagaaacaca aagtctacgc ctgcgaagtc 660
acccatcagg gcctgagctc gcccgtcaca aagagcttca acaggggaga gtgtggcggc 720
ggaggatctg gtggcggagg tagtggtggt ggtggatctg gcggaggcgg ctccggcgga 780
ggtggaagcg gaggtggtgg ttccggagga caggtgcaat tggtgcagtc tggcgctgaa 840
gttaagaagc ctgggagttc agtgaaggtc tcctgcaagg cttcgggata cgccttcagc 900
tattcttgga tcaattgggt gcggcaggcg cctggacaag ggctcgagtg gatgggacgg 960
atctttcccg gcgatgggga tactgactac aatgggaaat tcaagggcag agtcacaatt 1020
accgccgaca aatccactag cacagcctat atggagctga gcagcctgag atctgaggac 1080
acggccgtgt attactgtgc aagaaatgtc tttgatggtt actggcttgt ttactggggc 1140
cagggaaccc tggtcaccgt ctcctcagct agcaccaagg gcccctccgt gttccccctg 1200
gcccccagca gcaagagcac cagcggcggc acagccgctc tgggctgcct ggtcaaggac 1260
tacttccccg agcccgtgac cgtgtcctgg aacagcggag ccctgacctc cggcgtgcac 1320
accttccccg ccgtgctgca gagttctggc ctgtatagcc tgagcagcgt ggtcaccgtg 1380
ccttctagca gcctgggcac ccagacctac atctgcaacg tgaaccacaa gcccagcaac 1440
accaaggtgg acaagaaggt ggagcccaag agctgcggag ggggcggatc cttctgggtg 1500
ctggtggtgg tgggcggcgt gctggcctgc tacagcctgc tggtgaccgt ggccttcatc 1560
atcttctggg tgaggagcaa gaggagcagg ctgctgcaca gcgactacat gaacatgacc 1620
cccaggaggc ccggccccac caggaagcac taccagccct acgccccccc cagggacttc 1680
gccgcctaca ggagcagggt gaagttcagc aggagcgccg acgcccccgc ctaccagcag 1740
ggccagaacc agctgtataa cgagctgaac ctgggcagga gggaggagta cgacgtgctg 1800
gacaagagga ggggcaggga ccccgagatg ggcggcaagc ccaggaggaa gaacccccag 1860
gagggcctgt ataacgagct gcagaaggac aagatggccg aggcctacag cgagatcggc 1920
atgaagggcg agaggaggag gggcaagggc cacgacggcc tgtaccaggg cctgagcacc 1980
gccaccaagg acacctacga cgccctgcac atgcaggccc tgccccccag g 2031
<210> 56
<211> 336
<212> DNA
<213> 人工序列
<220>
<223> scFab-VL
<400> 56
gacatcgtga tgacccagac tccactctcc ctgcccgtca cccctggaga gcccgccagc 60
attagctgca ggtctagcaa gagcctcttg cacagcaatg gcatcactta tttgtattgg 120
tacctgcaaa agccagggca gtctccacag ctcctgattt atcaaatgtc caaccttgtc 180
tctggcgtcc ctgatcggtt ctccggttcc gggtcaggca ctgatttcac actgaaaatc 240
agcagggtgg aggctgagga tgttggagtt tattactgcg ctcagaatct agaacttcct 300
tacaccttcg gcggagggac caaggtggag atcaaa 336
<210> 57
<211> 321
<212> DNA
<213> 人工序列
<220>
<223> scFab-CL
<400> 57
cgtacggtgg ctgcaccatc tgtcttcatc ttcccgccat ctgatgagca gttgaaatct 60
ggaactgcct ctgttgtgtg cctgctgaat aacttctatc ccagagaggc caaagtacag 120
tggaaggtgg ataacgccct ccaatcgggt aactcccagg agagtgtcac agagcaggac 180
agcaaggaca gcacctacag cctcagcagc accctgacgc tgagcaaagc agactacgag 240
aaacacaaag tctacgcctg cgaagtcacc catcagggcc tgagctcgcc cgtcacaaag 300
agcttcaaca ggggagagtg t 321
<210> 58
<211> 357
<212> DNA
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-scFab-VH
<400> 58
caggtgcaat tggtgcagtc tggcgctgaa gttaagaagc ctgggagttc agtgaaggtc 60
tcctgcaagg cttcgggata cgccttcagc tattcttgga tcaattgggt gcggcaggcg 120
cctggacaag ggctcgagtg gatgggacgg atctttcccg gcgatgggga tactgactac 180
aatgggaaat tcaagggcag agtcacaatt accgccgaca aatccactag cacagcctat 240
atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc aagaaatgtc 300
tttgatggtt actggcttgt ttactggggc cagggaaccc tggtcaccgt ctcctca 357
<210> 59
<211> 2806
<212> DNA
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-scFab-CD28ATD-CD28CSD-CD3zSSD-eGFP融合物pETR170101
<400> 59
atggagctgt atcatcctct tcttggtagc aacagctacg ggtgtgcatt ccgacatcgt 60
gatgacccag actccactct ccctgcccgt cacccctgga gagcccgcca gcattagctg 120
caggtctagc aagagcctct tgcacagcaa tggcatcact tatttgtatt ggtacctgca 180
aaagccaggg cagtctccac agctcctgat ttatcaaatg tccaaccttg tctctggcgt 240
ccctgatcgg ttctccggtt ccgggtcagg cactgatttc acactgaaaa tcagcagggt 300
ggaggctgag gatgttggag tttattactg cgctcagaat ctagaacttc cttacacctt 360
cggcggaggg accaaggtgg agatcaaacg tacggtggct gcaccatctg tcttcatctt 420
cccgccatct gatgagcagt tgaaatctgg aactgcctct gttgtgtgcc tgctgaataa 480
cttctatccc agagaggcca aagtacagtg gaaggtggat aacgccctcc aatcgggtaa 540
ctcccaggag agtgtcacag agcaggacag caaggacagc acctacagcc tcagcagcac 600
cctgacgctg agcaaagcag actacgagaa acacaaagtc tacgcctgcg aagtcaccca 660
tcagggcctg agctcgcccg tcacaaagag cttcaacagg ggagagtgtg gcggcggagg 720
atctggtggc ggaggtagtg gtggtggtgg atctggcgga ggcggctccg gcggaggtgg 780
aagcggaggt ggtggttccg gaggacaggt gcaattggtg cagtctggcg ctgaagttaa 840
gaagcctggg agttcagtga aggtctcctg caaggcttcg ggatacgcct tcagctattc 900
ttggatcaat tgggtgcggc aggcgcctgg acaagggctc gagtggatgg gacggatctt 960
tcccggcgat ggggatactg actacaatgg gaaattcaag ggcagagtca caattaccgc 1020
cgacaaatcc actagcacag cctatatgga gctgagcagc ctgagatctg aggacacggc 1080
cgtgtattac tgtgcaagaa atgtctttga tggttactgg cttgtttact ggggccaggg 1140
aaccctggtc accgtctcct cagctagcac caagggcccc tccgtgttcc ccctggcccc 1200
cagcagcaag agcaccagcg gcggcacagc cgctctgggc tgcctggtca aggactactt 1260
ccccgagccc gtgaccgtgt cctggaacag cggagccctg acctccggcg tgcacacctt 1320
ccccgccgtg ctgcagagtt ctggcctgta tagcctgagc agcgtggtca ccgtgccttc 1380
tagcagcctg ggcacccaga cctacatctg caacgtgaac cacaagccca gcaacaccaa 1440
ggtggacaag aaggtggagc ccaagagctg cggagggggc ggatccttct gggtgctggt 1500
ggtggtgggc ggcgtgctgg cctgctacag cctgctggtg accgtggcct tcatcatctt 1560
ctgggtgagg agcaagagga gcaggctgct gcacagcgac tacatgaaca tgacccccag 1620
gaggcccggc cccaccagga agcactacca gccctacgcc ccccccaggg acttcgccgc 1680
ctacaggagc agggtgaagt tcagcaggag cgccgacgcc cccgcctacc agcagggcca 1740
gaaccagctg tataacgagc tgaacctggg caggagggag gagtacgacg tgctggacaa 1800
gaggaggggc agggaccccg agatgggcgg caagcccagg aggaagaacc cccaggaggg 1860
cctgtataac gagctgcaga aggacaagat ggccgaggcc tacagcgaga tcggcatgaa 1920
gggcgagagg aggaggggca agggccacga cggcctgtac cagggcctga gcaccgccac 1980
caaggacacc tacgacgccc tgcacatgca ggccctgccc cccaggtccg gagagggcag 2040
aggaagtctt ctaacatgcg gtgacgtgga ggagaatccc ggccctaggg tgagcaaggg 2100
cgaggagctg ttcaccgggg tggtgcccat cctggtcgag ctggacggcg acgtaaacgg 2160
ccacaagttc agcgtgtccg gcgagggcga gggcgatgcc acctacggca agctgaccct 2220
gaagttcatc tgcaccaccg gcaagctgcc cgtgccctgg cccaccctcg tgaccaccct 2280
gacctacggc gtgcagtgct tcagccgcta ccccgaccac atgaagcagc acgacttctt 2340
caagtccgcc atgcccgaag gctacgtcca ggagcgcacc atcttcttca aggacgacgg 2400
caactacaag acccgcgccg aggtgaagtt cgagggcgac accctggtga accgcatcga 2460
gctgaagggc atcgacttca aggaggacgg caacatcctg gggcacaagc tggagtacaa 2520
ctacaacagc cacaacgtct atatcatggc cgacaagcag aagaacggca tcaaggtgaa 2580
cttcaagatc cgccacaaca tcgaggacgg cagcgtgcag ctcgccgacc actaccagca 2640
gaacaccccc atcggcgacg gccccgtgct gctgcccgac aaccactacc tgagcaccca 2700
gtccgccctg agcaaagacc ccaacgagaa gcgcgatcac atggtcctgc tggagttcgt 2760
gaccgccgcc gggatcactc tcggcatgga cgagctgtac aagtga 2806
<210> 60
<211> 436
<212> PRT
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-ds-scFv-CD28ATD-CD28CSD-CD3zSSD融合物pETR17162
<400> 60
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser
20 25 30
Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
115 120 125
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr
130 135 140
Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile
145 150 155 160
Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Ile Thr Tyr
165 170 175
Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile
180 185 190
Tyr Gln Met Ser Asn Leu Val Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala
210 215 220
Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn Leu Glu Leu Pro Tyr
225 230 235 240
Thr Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly Ser
245 250 255
Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu
260 265 270
Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser
275 280 285
Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly
290 295 300
Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala
305 310 315 320
Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala
325 330 335
Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg
340 345 350
Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu
355 360 365
Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn
370 375 380
Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met
385 390 395 400
Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly
405 410 415
Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala
420 425 430
Leu Pro Pro Arg
435
<210> 61
<211> 251
<212> PRT
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-ds-scFv
<400> 61
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser
20 25 30
Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
115 120 125
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr
130 135 140
Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile
145 150 155 160
Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Ile Thr Tyr
165 170 175
Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile
180 185 190
Tyr Gln Met Ser Asn Leu Val Ser Gly Val Pro Asp Arg Phe Ser Gly
195 200 205
Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala
210 215 220
Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn Leu Glu Leu Pro Tyr
225 230 235 240
Thr Phe Gly Cys Gly Thr Lys Val Glu Ile Lys
245 250
<210> 62
<211> 119
<212> PRT
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-ds-Fab VH
<400> 62
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser
20 25 30
Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met
35 40 45
Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe
50 55 60
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210> 63
<211> 112
<212> PRT
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-ds-Fab VL
<400> 63
Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser
20 25 30
Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Val Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn
85 90 95
Leu Glu Leu Pro Tyr Thr Phe Gly Cys Gly Thr Lys Val Glu Ile Lys
100 105 110
<210> 64
<211> 1364
<212> DNA
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-ds-Fab-CD28ATD-CD28CSD-CD3zSSD融合物pETR17162
<400> 64
atgggatgga gctgtatcat cctcttcttg gtagcaacag ctaccggtgt gcattcccag 60
gtgcaattgg tgcagtctgg cgctgaagtt aagaagcctg ggagttcagt gaaggtctcc 120
tgcaaggctt ccggttacgc cttcagctat tcttggatca attgggtgcg gcaggcgcct 180
ggacaatgtc tcgagtggat gggacggatc tttcccggcg atggggatac tgactacaat 240
gggaaattca agggcagagt cacaattacc gccgacaaat ccactagcac agcctatatg 300
gagctgagca gcctgagatc tgaggacacg gccgtgtatt actgtgcaag aaatgtcttt 360
gatggttact ggcttgttta ctggggccag ggaaccctgg tcaccgtctc ctcaggaggg 420
ggcggaagtg gtggcggggg aagcggcggg ggtggcagcg gagggggcgg atctgacatc 480
gtgatgaccc agactccact ctccctgccc gtcacccctg gagagcccgc cagcattagc 540
tgcaggtcta gcaagagcct cttgcacagc aatggcatca cttatttgta ttggtacctg 600
caaaagccag ggcagtctcc acagctcctg atttatcaaa tgtccaacct tgtctctggc 660
gtccctgacc gcttctccgg ttccgggtca ggcactgatt tcacactgaa aatcagcagg 720
gtggaggctg aggatgttgg agtttattac tgcgctcaga atctagaact tccttacacc 780
ttcggctgtg ggaccaaggt ggagatcaag gagggggcgg atccttctgg gtgctggtgg 840
tggtgggcgg cgtgctggcc tgctacagcc tgctggtgac cgtggccttc atcatcttct 900
gggtgaggag caagaggagc aggctgctgc acagcgacta catgaacatg acccccagga 960
ggcccggccc caccaggaag cactaccagc cctacgcccc ccccagggac ttcgccgcct 1020
acaggagcag ggtgaagttc agcaggagcg ccgacgcccc cgcctaccag cagggccaga 1080
accagctgta taacgagctg aacctgggca ggagggagga gtacgacgtg ctggacaaga 1140
ggaggggcag ggaccccgag atgggcggca agcccaggag gaagaacccc caggagggcc 1200
tgtataacga gctgcagaag gacaagatgg ccgaggccta cagcgagatc ggcatgaagg 1260
gcgagaggag gaggggcaag ggccacgacg gcctgtacca gggcctgagc accgccacca 1320
aggacaccta cgacgccctg cacatgcagg ccctgccccc cagg 1364
<210> 65
<211> 357
<212> DNA
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-ds-Fab VH
<400> 65
caggtgcaat tggtgcagtc tggcgctgaa gttaagaagc ctgggagttc agtgaaggtc 60
tcctgcaagg cttccggtta cgccttcagc tattcttgga tcaattgggt gcggcaggcg 120
cctggacaat gtctcgagtg gatgggacgg atctttcccg gcgatgggga tactgactac 180
aatgggaaat tcaagggcag agtcacaatt accgccgaca aatccactag cacagcctat 240
atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc aagaaatgtc 300
tttgatggtt actggcttgt ttactggggc cagggaaccc tggtcaccgt ctcctca 357
<210> 66
<211> 336
<212> DNA
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-ds-Fab VL
<400> 66
gacatcgtga tgacccagac tccactctcc ctgcccgtca cccctggaga gcccgccagc 60
attagctgca ggtctagcaa gagcctcttg cacagcaatg gcatcactta tttgtattgg 120
tacctgcaaa agccagggca gtctccacag ctcctgattt atcaaatgtc caaccttgtc 180
tctggcgtcc ctgaccgctt ctccggttcc gggtcaggca ctgatttcac actgaaaatc 240
agcagggtgg aggctgagga tgttggagtt tattactgcg ctcagaatct agaacttcct 300
tacaccttcg gctgtgggac caaggtggag atcaaa 336
<210> 67
<211> 2151
<212> DNA
<213> 人工序列
<220>
<223> 抗CD20-(GA101)-ds-scFv-CD28ATD-CD28CSD-CD3zSSD-eGFP融合物pETR17162
<400> 67
gccaccatgg gatggagctg tatcatcctc ttcttggtag caacagctac cggtgtgcat 60
tcccaggtgc aattggtgca gtctggcgct gaagttaaga agcctgggag ttcagtgaag 120
gtctcctgca aggcttccgg ttacgccttc agctattctt ggatcaattg ggtgcggcag 180
gcgcctggac aatgtctcga gtggatggga cggatctttc ccggcgatgg ggatactgac 240
tacaatggga aattcaaggg cagagtcaca attaccgccg acaaatccac tagcacagcc 300
tatatggagc tgagcagcct gagatctgag gacacggccg tgtattactg tgcaagaaat 360
gtctttgatg gttactggct tgtttactgg ggccagggaa ccctggtcac cgtctcctca 420
ggagggggcg gaagtggtgg cgggggaagc ggcgggggtg gcagcggagg gggcggatct 480
gacatcgtga tgacccagac tccactctcc ctgcccgtca cccctggaga gcccgccagc 540
attagctgca ggtctagcaa gagcctcttg cacagcaatg gcatcactta tttgtattgg 600
tacctgcaaa agccagggca gtctccacag ctcctgattt atcaaatgtc caaccttgtc 660
tctggcgtcc ctgaccgctt ctccggttcc gggtcaggca ctgatttcac actgaaaatc 720
agcagggtgg aggctgagga tgttggagtt tattactgcg ctcagaatct agaacttcct 780
tacaccttcg gctgtgggac caaggtggag atcaaaggag ggggcggatc cttctgggtg 840
ctggtggtgg tgggcggcgt gctggcctgc tacagcctgc tggtgaccgt ggccttcatc 900
atcttctggg tgaggagcaa gaggagcagg ctgctgcaca gcgactacat gaacatgacc 960
cccaggaggc ccggccccac caggaagcac taccagccct acgccccccc cagggacttc 1020
gccgcctaca ggagcagggt gaagttcagc aggagcgccg acgcccccgc ctaccagcag 1080
ggccagaacc agctgtataa cgagctgaac ctgggcagga gggaggagta cgacgtgctg 1140
gacaagagga ggggcaggga ccccgagatg ggcggcaagc ccaggaggaa gaacccccag 1200
gagggcctgt ataacgagct gcagaaggac aagatggccg aggcctacag cgagatcggc 1260
atgaagggcg agaggaggag gggcaagggc cacgacggcc tgtaccaggg cctgagcacc 1320
gccaccaagg acacctacga cgccctgcac atgcaggccc tgccccccag gtccggagag 1380
ggcagaggaa gtcttctaac atgcggtgac gtggaggaga atcccggccc tagggtgagc 1440
aagggcgagg agctgttcac cggggtggtg cccatcctgg tcgagctgga cggcgacgta 1500
aacggccaca agttcagcgt gtccggcgag ggcgagggcg atgccaccta cggcaagctg 1560
accctgaagt tcatctgcac caccggcaag ctgcccgtgc cctggcccac cctcgtgacc 1620
accctgacct acggcgtgca gtgcttcagc cgctaccccg accacatgaa gcagcacgac 1680
ttcttcaagt ccgccatgcc cgaaggctac gtccaggagc gcaccatctt cttcaaggac 1740
gacggcaact acaagacccg cgccgaggtg aagttcgagg gcgacaccct ggtgaaccgc 1800
atcgagctga agggcatcga cttcaaggag gacggcaaca tcctggggca caagctggag 1860
tacaactaca acagccacaa cgtctatatc atggccgaca agcagaagaa cggcatcaag 1920
gtgaacttca agatccgcca caacatcgag gacggcagcg tgcagctcgc cgaccactac 1980
cagcagaaca cccccatcgg cgacggcccc gtgctgctgc ccgacaacca ctacctgagc 2040
acccagtccg ccctgagcaa agaccccaac gagaagcgcg atcacatggt cctgctggag 2100
ttcgtgaccg ccgccgggat cactctcggc atggacgagc tgtacaagtg a 2151
<210> 68
<211> 164
<212> PRT
<213> 人(Homo sapiens)
<400> 68
Met Lys Trp Lys Ala Leu Phe Thr Ala Ala Ile Leu Gln Ala Gln Leu
1 5 10 15
Pro Ile Thr Glu Ala Gln Ser Phe Gly Leu Leu Asp Pro Lys Leu Cys
20 25 30
Tyr Leu Leu Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu Thr Ala
35 40 45
Leu Phe Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
50 55 60
Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
65 70 75 80
Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
85 90 95
Gly Gly Lys Pro Gln Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn
100 105 110
Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met
115 120 125
Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly
130 135 140
Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala
145 150 155 160
Leu Pro Pro Arg
<210> 69
<211> 492
<212> DNA
<213> 人(Homo sapiens)
<400> 69
atgaagtgga aggcgctttt caccgcggcc atcctgcagg cacagttgcc gattacagag 60
gcacagagct ttggcctgct ggatcccaaa ctctgctacc tgctggatgg aatcctcttc 120
atctatggtg tcattctcac tgccttgttc ctgagagtga agttcagcag gagcgcagag 180
ccccccgcgt accagcaggg ccagaaccag ctctataacg agctcaatct aggacgaaga 240
gaggagtacg atgttttgga caagagacgt ggccgggacc ctgagatggg gggaaagccg 300
agaaggaaga accctcagga aggcctgtac aatgaactgc agaaagataa gatggcggag 360
gcctacagtg agattgggat gaaaggcgag cgccggaggg gcaaggggca cgatggcctt 420
taccagggtc tcagtacagc caccaaggac acctacgacg cccttcacat gcaggccctg 480
ccccctcgct aa 492
<210> 70
<211> 164
<212> PRT
<213> 小鼠(Mus musculus)
<400> 70
Met Lys Trp Lys Val Ser Val Leu Ala Cys Ile Leu His Val Arg Phe
1 5 10 15
Pro Gly Ala Glu Ala Gln Ser Phe Gly Leu Leu Asp Pro Lys Leu Cys
20 25 30
Tyr Leu Leu Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Ile Thr Ala
35 40 45
Leu Tyr Leu Arg Ala Lys Phe Ser Arg Ser Ala Glu Thr Ala Ala Asn
50 55 60
Leu Gln Asp Pro Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
65 70 75 80
Glu Glu Tyr Asp Val Leu Glu Lys Lys Arg Ala Arg Asp Pro Glu Met
85 90 95
Gly Gly Lys Gln Gln Arg Arg Arg Asn Pro Gln Glu Gly Val Tyr Asn
100 105 110
Ala Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Thr
115 120 125
Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly
130 135 140
Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Thr
145 150 155 160
Leu Ala Pro Arg
<210> 71
<211> 495
<212> DNA
<213> 小鼠(Mus musculus)
<400> 71
atgaagtgga aagtgtctgt tctcgcctgc atcctccacg tgcggttccc aggagcagag 60
gcacagagct ttggtctgct ggatcccaaa ctctgctact tgctagatgg aatcctcttc 120
atctacggag tcatcatcac agccctgtac ctgagagcaa aattcagcag gagtgcagag 180
actgctgcca acctgcagga ccccaaccag ctctacaatg agctcaatct agggcgaaga 240
gaggaatatg acgtcttgga gaagaagcgg gctcgggatc cagagatggg aggcaaacag 300
cagaggagga ggaaccccca ggaaggcgta tacaatgcac tgcagaaaga caagatggca 360
gaagcctaca gtgagatcgg cacaaaaggc gagaggcgga gaggcaaggg gcacgatggc 420
ctttaccagg gtctcagcac tgccaccaag gacacctatg atgccctgca tatgcagacc 480
ctggcccctc gctaa 495
<210> 72
<211> 660
<212> DNA
<213> 人(Homo sapiens)
<400> 72
atgctgcgcc tgctgctggc gctgaacctg tttccgagca ttcaggtgac cggcaacaaa 60
attctggtga aacagagccc gatgctggtg gcgtatgata acgcggtgaa cctgagctgc 120
aaatatagct ataacctgtt tagccgcgaa tttcgcgcga gcctgcataa aggcctggat 180
agcgcggtgg aagtgtgcgt ggtgtatggc aactatagcc agcagctgca ggtgtatagc 240
aaaaccggct ttaactgcga tggcaaactg ggcaacgaaa gcgtgacctt ttatctgcag 300
aacctgtatg tgaaccagac cgatatttat ttttgcaaaa ttgaagtgat gtatccgccg 360
ccgtatctgg ataacgaaaa aagcaacggc accattattc atgtgaaagg caaacatctg 420
tgcccgagcc cgctgtttcc gggcccgagc aaaccgtttt gggtgctggt ggtggtgggc 480
ggcgtgctgg cgtgctatag cctgctggtg accgtggcgt ttattatttt ttgggtgcgc 540
agcaaacgca gccgcctgct gcatagcgat tatatgaaca tgaccccgcg ccgcccgggc 600
ccgacccgca aacattatca gccgtatgcg ccgccgcgcg attttgcggc gtatcgcagc 660
<210> 73
<211> 220
<212> PRT
<213> 人(Homo sapiens)
<400> 73
Met Leu Arg Leu Leu Leu Ala Leu Asn Leu Phe Pro Ser Ile Gln Val
1 5 10 15
Thr Gly Asn Lys Ile Leu Val Lys Gln Ser Pro Met Leu Val Ala Tyr
20 25 30
Asp Asn Ala Val Asn Leu Ser Cys Lys Tyr Ser Tyr Asn Leu Phe Ser
35 40 45
Arg Glu Phe Arg Ala Ser Leu His Lys Gly Leu Asp Ser Ala Val Glu
50 55 60
Val Cys Val Val Tyr Gly Asn Tyr Ser Gln Gln Leu Gln Val Tyr Ser
65 70 75 80
Lys Thr Gly Phe Asn Cys Asp Gly Lys Leu Gly Asn Glu Ser Val Thr
85 90 95
Phe Tyr Leu Gln Asn Leu Tyr Val Asn Gln Thr Asp Ile Tyr Phe Cys
100 105 110
Lys Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser
115 120 125
Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro
130 135 140
Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly
145 150 155 160
Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile
165 170 175
Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met
180 185 190
Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro
195 200 205
Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser
210 215 220
<210> 74
<211> 654
<212> DNA
<213> 小鼠(Mus musculus)
<400> 74
atgaccctgc gcctgctgtt tctggcgctg aactttttta gcgtgcaggt gaccgaaaac 60
aaaattctgg tgaaacagag cccgctgctg gtggtggata gcaacgaagt gagcctgagc 120
tgccgctata gctataacct gctggcgaaa gaatttcgcg cgagcctgta taaaggcgtg 180
aacagcgatg tggaagtgtg cgtgggcaac ggcaacttta cctatcagcc gcagtttcgc 240
agcaacgcgg aatttaactg cgatggcgat tttgataacg aaaccgtgac ctttcgcctg 300
tggaacctgc atgtgaacca taccgatatt tatttttgca aaattgaatt tatgtatccg 360
ccgccgtatc tggataacga acgcagcaac ggcaccatta ttcatattaa agaaaaacat 420
ctgtgccata cccagagcag cccgaaactg ttttgggcgc tggtggtggt ggcgggcgtg 480
ctgttttgct atggcctgct ggtgaccgtg gcgctgtgcg tgatttggac caacagccgc 540
cgcaaccgcc tgctgcagag cgattatatg aacatgaccc cgcgccgccc gggcctgacc 600
cgcaaaccgt atcagccgta tgcgccggcg cgcgattttg cggcgtatcg cccg 654
<210> 75
<211> 218
<212> PRT
<213> 小鼠(Mus musculus)
<400> 75
Met Thr Leu Arg Leu Leu Phe Leu Ala Leu Asn Phe Phe Ser Val Gln
1 5 10 15
Val Thr Glu Asn Lys Ile Leu Val Lys Gln Ser Pro Leu Leu Val Val
20 25 30
Asp Ser Asn Glu Val Ser Leu Ser Cys Arg Tyr Ser Tyr Asn Leu Leu
35 40 45
Ala Lys Glu Phe Arg Ala Ser Leu Tyr Lys Gly Val Asn Ser Asp Val
50 55 60
Glu Val Cys Val Gly Asn Gly Asn Phe Thr Tyr Gln Pro Gln Phe Arg
65 70 75 80
Ser Asn Ala Glu Phe Asn Cys Asp Gly Asp Phe Asp Asn Glu Thr Val
85 90 95
Thr Phe Arg Leu Trp Asn Leu His Val Asn His Thr Asp Ile Tyr Phe
100 105 110
Cys Lys Ile Glu Phe Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Arg
115 120 125
Ser Asn Gly Thr Ile Ile His Ile Lys Glu Lys His Leu Cys His Thr
130 135 140
Gln Ser Ser Pro Lys Leu Phe Trp Ala Leu Val Val Val Ala Gly Val
145 150 155 160
Leu Phe Cys Tyr Gly Leu Leu Val Thr Val Ala Leu Cys Val Ile Trp
165 170 175
Thr Asn Ser Arg Arg Asn Arg Leu Leu Gln Ser Asp Tyr Met Asn Met
180 185 190
Thr Pro Arg Arg Pro Gly Leu Thr Arg Lys Pro Tyr Gln Pro Tyr Ala
195 200 205
Pro Ala Arg Asp Phe Ala Ala Tyr Arg Pro
210 215
<210> 76
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> CD28 YMNM
<400> 76
Tyr Met Asn Met
1
<210> 77
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> CD28 PYAP
<400> 77
Pro Tyr Ala Pro
1
<210> 78
<211> 21
<212> PRT
<213> 人工序列
<220>
<223> 信号肽
<400> 78
Ala Thr Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala
1 5 10 15
Thr Gly Val His Ser
20
<210> 79
<211> 57
<212> DNA
<213> 人工序列
<220>
<223> 信号肽DNA序列
<400> 79
atgggatgga gctgtatcat cctcttcttg gtagcaacag ctaccggtgt gcactcc 57
<210> 80
<211> 116
<212> PRT
<213> 人工序列
<220>
<223> 抗WT1 (33F05) VH
<400> 80
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Asn Ser Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ser Tyr Tyr Glu Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110
Thr Val Ser Ser
115
<210> 81
<211> 107
<212> PRT
<213> 人工序列
<220>
<223> 抗WT1 (33F05) VL
<400> 81
Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln
1 5 10 15
Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala
20 25 30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr
35 40 45
Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser
50 55 60
Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu
65 70 75 80
Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Pro Asp Met Asn Gly Asn Ala
85 90 95
Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105
<210> 82
<211> 120
<212> PRT
<213> 人工序列
<220>
<223> 抗WT1 (11D06) VH
<400> 82
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ile Glu Leu Trp Trp Gly Gly Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 83
<211> 106
<212> PRT
<213> 人工序列
<220>
<223> 抗WT1 (11D06) VL
<400> 83
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Gly Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Glu Asp Tyr Thr Thr
85 90 95
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
<210> 84
<211> 119
<212> PRT
<213> 人工序列
<220>
<223> 抗WT1 (33H09) VH
<400> 84
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Ser Tyr Asp Leu Phe Ser Leu Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Thr Val Thr Val Ser Ser
115
<210> 85
<211> 106
<212> PRT
<213> 人工序列
<220>
<223> 抗WT1 (33H09) VL
<400> 85
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Asp Gly Ile Thr
85 90 95
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
<210> 86
<211> 119
<212> PRT
<213> 人工序列
<220>
<223> 抗WT1 (5E11) VH
<400> 86
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Ser Tyr Asp Leu Tyr Ser Phe Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Thr Val Thr Val Ser Ser
115
<210> 87
<211> 108
<212> PRT
<213> 人工序列
<220>
<223> 抗WT1 (5E11) VL
<400> 87
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Phe Pro Pro Met
85 90 95
Ile Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
<210> 88
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 抗CD3 HCDR1 Kabat
<400> 88
Thr Tyr Ala Met Asn
1 5
<210> 89
<211> 19
<212> PRT
<213> 人工序列
<220>
<223> 抗CD3 HCDR2 Kabat
<400> 89
Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser
1 5 10 15
Val Lys Gly
<210> 90
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗CD3 HCDR3 Kabat
<400> 90
His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe Ala Tyr
1 5 10
<210> 91
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 抗CD3 LCDR1 Kabat
<400> 91
Gly Ser Ser Thr Gly Ala Val Thr Thr Ser Asn Tyr Ala Asn
1 5 10
<210> 92
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 抗CD3 LCDR2 Kabat
<400> 92
Gly Thr Asn Lys Arg Ala Pro
1 5
<210> 93
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 抗CD3 LCDR3 Kabat
<400> 93
Ala Leu Trp Tyr Ser Asn Leu Trp Val
1 5
Claims (16)
1.一种用于评估抗原结合模块的特异性的方法,其包含下述步骤:
a)提供对靶抗原特异性的抗原结合模块;
b)生成嵌合抗原受体(CAR)表达性报告T(CAR-T)细胞,其通过:
i.将该抗原结合模块转移入与应答元件可操作偶联的CAR载体系统;和
ii.将该CAR载体系统转染入包含在该应答元件控制下的报告基因的报告T细胞;
c)使该报告CAR-T细胞与在表面上包含该靶抗原的靶细胞接触,特别是其中该靶细胞是癌细胞;和
d)通过测定该报告基因的表达来测定T细胞激活以建立该抗原结合模块的特异性。
2.权利要求1的方法,其中该抗原结合模块是Fab片段,特别是自噬菌体展示文库筛选衍生的Fab片段。
3.权利要求1或2的方法,其中该抗原结合模块包含可变重链域(VH)和可变轻链域(VL)且其中将该抗原结合模块的VH和VL域的编码多核苷酸序列转移至该CAR载体系统。
4.权利要求1至3任一项的方法,其中该CAR载体系统编码包含Fab或交叉Fab片段,锚定跨膜域和至少一个细胞内信号传导和/或共信号传导域的CAR。
5.权利要求4的方法,其中该靶抗原对该报告CAR-T细胞的结合导致该细胞内信号传导和/或共信号传导域的激活。
6.权利要求4或5任一项的方法,其中该细胞内信号传导域的激活导致该应答元件的激活。
7.依照权利要求1至6任一项的方法,其中该应答元件的激活导致该报告基因的表达。
8.依照权利要求1至7任一项的方法,其中该报告基因编码发光蛋白,特别是荧光蛋白。
9.依照权利要求1至8任一项的方法,其中该靶抗原是细胞表面受体。
10.依照权利要求1至9任一项的方法,其中该靶抗原是与人主要组织相容性复合物(MHC)的分子结合的肽。
11.依照权利要求10的方法,其中该抗原结合模块是T细胞受体样(TCRL)抗原结合模块。
12.依照权利要求1至11任一项的方法,其中在该靶细胞存在下高水平的该报告基因的表达和在该靶细胞缺失下低水平的该报告基因的表达指示该抗原结合模块的高特异性。
13.依照权利要求1至12任一项的方法,其中在该靶细胞存在下高水平的该报告基因的表达和在该靶细胞缺失下低水平的该报告基因的表达指示包含该抗原结合模块的T细胞双特异性(TCB)抗体的高特异性。
14.依照权利要求1至13任一项的方法,其中该方法是体外方法。
15.一种用于生成TCB抗体的方法,其中该TCB抗体型式包含对靶抗原特异性的第一抗原结合模块和能够特异性结合T细胞激活性受体的第二抗原结合模块,其中该第一抗原结合模块是依照权利要求1至14任一项的方法选择的。
16.权利要求15的方法,其中该T细胞激活性受体是CD3。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17209198.5 | 2017-12-21 | ||
EP17209198 | 2017-12-21 | ||
PCT/EP2018/086067 WO2019122060A1 (en) | 2017-12-21 | 2018-12-20 | Car-t cell assay for specificity test of novel antigen binding moieties |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111492243A true CN111492243A (zh) | 2020-08-04 |
CN111492243B CN111492243B (zh) | 2024-11-01 |
Family
ID=60935666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880081668.XA Active CN111492243B (zh) | 2017-12-21 | 2018-12-20 | 用于新颖抗原结合模块的特异性测试的car-t细胞测定法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11788205B2 (zh) |
EP (1) | EP3729081A1 (zh) |
JP (1) | JP2021508246A (zh) |
CN (1) | CN111492243B (zh) |
WO (1) | WO2019122060A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111247429A (zh) * | 2017-12-21 | 2020-06-05 | 豪夫迈·罗氏有限公司 | 用于新颖抗原结合模块的特异性测试的通用报告细胞测定法 |
CN113252894A (zh) * | 2021-07-07 | 2021-08-13 | 北京艺妙神州医药科技有限公司 | 一种检测CAR-T细胞scFv亲和力的方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4110829A4 (en) * | 2020-02-27 | 2024-06-05 | Sorrento Therapeutics, Inc. | DIMERE ANTIGEN RECEPTORS (DAR) THAT BIND CD20 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105358576A (zh) * | 2013-02-20 | 2016-02-24 | 诺华股份有限公司 | 使用人源化抗EGFRvIII嵌合抗原受体治疗癌症 |
WO2016164731A2 (en) * | 2015-04-08 | 2016-10-13 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
CN106687483A (zh) * | 2014-07-21 | 2017-05-17 | 诺华股份有限公司 | 使用人源化抗‑bcma嵌合抗原受体治疗癌症 |
CN107109420A (zh) * | 2014-07-21 | 2017-08-29 | 诺华股份有限公司 | 使用cll-1嵌合抗原受体的癌症治疗 |
CN107109419A (zh) * | 2014-07-21 | 2017-08-29 | 诺华股份有限公司 | 使用cd33嵌合抗原受体治疗癌症 |
CN107108744A (zh) * | 2014-08-19 | 2017-08-29 | 诺华股份有限公司 | 抗cd123嵌合抗原受体(car)用于癌症治疗 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
EP1240319A1 (en) | 1999-12-15 | 2002-09-18 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
WO2003102157A2 (en) | 2002-06-03 | 2003-12-11 | Genentech, Inc. | Synthetic antibody phage libraries |
AU2004205631A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
WO2007056441A2 (en) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
US20070292936A1 (en) | 2006-05-09 | 2007-12-20 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
EP2318434A1 (en) | 2008-07-31 | 2011-05-11 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Her2/neu specific t cell receptors |
-
2018
- 2018-12-20 WO PCT/EP2018/086067 patent/WO2019122060A1/en unknown
- 2018-12-20 EP EP18822071.9A patent/EP3729081A1/en active Pending
- 2018-12-20 CN CN201880081668.XA patent/CN111492243B/zh active Active
- 2018-12-20 JP JP2020533234A patent/JP2021508246A/ja active Pending
-
2020
- 2020-06-19 US US16/906,931 patent/US11788205B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105358576A (zh) * | 2013-02-20 | 2016-02-24 | 诺华股份有限公司 | 使用人源化抗EGFRvIII嵌合抗原受体治疗癌症 |
CN106687483A (zh) * | 2014-07-21 | 2017-05-17 | 诺华股份有限公司 | 使用人源化抗‑bcma嵌合抗原受体治疗癌症 |
CN107109420A (zh) * | 2014-07-21 | 2017-08-29 | 诺华股份有限公司 | 使用cll-1嵌合抗原受体的癌症治疗 |
CN107109419A (zh) * | 2014-07-21 | 2017-08-29 | 诺华股份有限公司 | 使用cd33嵌合抗原受体治疗癌症 |
CN107108744A (zh) * | 2014-08-19 | 2017-08-29 | 诺华股份有限公司 | 抗cd123嵌合抗原受体(car)用于癌症治疗 |
WO2016164731A2 (en) * | 2015-04-08 | 2016-10-13 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111247429A (zh) * | 2017-12-21 | 2020-06-05 | 豪夫迈·罗氏有限公司 | 用于新颖抗原结合模块的特异性测试的通用报告细胞测定法 |
CN113252894A (zh) * | 2021-07-07 | 2021-08-13 | 北京艺妙神州医药科技有限公司 | 一种检测CAR-T细胞scFv亲和力的方法 |
CN113252894B (zh) * | 2021-07-07 | 2021-11-09 | 北京艺妙神州医药科技有限公司 | 一种检测CAR-T细胞scFv亲和力的方法 |
Also Published As
Publication number | Publication date |
---|---|
US11788205B2 (en) | 2023-10-17 |
EP3729081A1 (en) | 2020-10-28 |
US20200318105A1 (en) | 2020-10-08 |
JP2021508246A (ja) | 2021-03-04 |
CN111492243B (zh) | 2024-11-01 |
WO2019122060A1 (en) | 2019-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6903188B2 (ja) | Bcmaに対するモノクローナル抗体 | |
KR102712254B1 (ko) | 개선된 항원 결합 수용체 | |
KR20190133017A (ko) | 개선된 항원 결합 수용체 구성 | |
KR101870555B1 (ko) | T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법 | |
Gorman et al. | Humanisation of monoclonal antibodies for therapy | |
KR101886983B1 (ko) | 2 개의 fab 단편을 포함하는 fc-부재 항체 및 이용 방법 | |
US9758594B2 (en) | Stable multivalent antibody | |
JP4553584B2 (ja) | タンパク質ライブラリーの作製方法およびそこからタンパク質を選択する方法 | |
KR20150004856A (ko) | Cd3 결합 폴리펩타이드 | |
JP2020503015A (ja) | 抗cd19のヒト化抗体及びcd19を標的とする免疫エフェクター細胞 | |
CN112424601A (zh) | 检测癌症患者中肿瘤抗原的诊断性测定法 | |
KR102367658B1 (ko) | 항원 특이적 t 세포 및 그의 용도 | |
KR20230024984A (ko) | Cd70-지시 암 면역요법용 유전적으로 변형된 자연 살해 세포 | |
US12000064B2 (en) | Universal reporter cell assay for specificity test of novel antigen binding moieties | |
CN112118892A (zh) | Cd79特异性嵌合抗原受体 | |
CN111742219A (zh) | 用于新颖靶抗原结合模块的特异性测定法 | |
CN111492243B (zh) | 用于新颖抗原结合模块的特异性测试的car-t细胞测定法 | |
KR20210143096A (ko) | Cd22에 특이적인 항체 및 이의 용도 | |
Isaacs | Antibody engineering to develop new antirheumatic therapies | |
US12038441B2 (en) | CAR-T reporter based diagnostic assays to detect tumor antigens in cancer patients | |
KR20230005952A (ko) | 전구체 삼중-특이적 항체 구조체 및 그의 이용 방법 | |
RU2820683C2 (ru) | Двухвалентное биспецифическое химерное антитело, включающее гетеродимер на основе MHC или MHC-подобных белков | |
Vellalore Maruthachalam | NEXT-GENERATION SEQUENCING AND MOTIF GRAFTING APPLICATIONS IN SYNTHETIC ANTIBODY DISCOVERY | |
Parekh | Novel CD123 Binders for CAR-T Cell Therapy | |
CA3234046A1 (en) | Anti-bcma single domain antibodies and therapeutic constructs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40035031 Country of ref document: HK |
|
GR01 | Patent grant |